BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. British Journal of Surgery 1998;85:1457-9. [DOI: 10.1046/j.1365-2168.1998.00940.x] [Cited by in Crossref: 761] [Cited by in F6Publishing: 698] [Article Influence: 40.1] [Reference Citation Analysis]
Number Citing Articles
1 Jiang Y, Chen Y, Chen T, Wu L, Ou J, Li R, Zhang X, Yang J, Cao J. Is there association of gross tumor volume of adenocarcinoma of oesophagogastric junction measured on magnetic resonance imaging with N stage? European Journal of Radiology 2019;110:181-6. [DOI: 10.1016/j.ejrad.2018.05.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
2 Viklund P, Wengström Y, Rouvelas I, Lindblad M, Lagergren J. Quality of life and persisting symptoms after oesophageal cancer surgery. European Journal of Cancer 2006;42:1407-14. [DOI: 10.1016/j.ejca.2006.02.005] [Cited by in Crossref: 77] [Cited by in F6Publishing: 72] [Article Influence: 4.8] [Reference Citation Analysis]
3 Brücher B. Plattenepithelkarzinom des Ösophagus: Präoperative kombinierte Radiochemotherapie aus chirurgisch-onkologischer Sicht. Chirurg 2009;80:1011-8. [DOI: 10.1007/s00104-009-1733-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
4 Tao K, Dong JH. Phase I Clinical Research of Jejunal Interposition in Adenocarcinoma of the Esophagogastric Junction II/III Proximal Gastrectomy. Gastroenterol Res Pract 2016;2016:1639654. [PMID: 27840635 DOI: 10.1155/2016/1639654] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Feng Q, Long D, Du MS, Wang XS, Li ZS, Zhao YL, Qian F, Wen Y, Yu PW, Shi Y. Short-Term Clinical Efficacy of Neoadjuvant Chemotherapy Combined With Laparoscopic Gastrectomy for Locally Advanced Siewert Type II and III Adenocarcinoma of the Esophagogastric Junction: A Retrospective, Propensity Score-Matched Study. Front Oncol 2021;11:690662. [PMID: 34660265 DOI: 10.3389/fonc.2021.690662] [Reference Citation Analysis]
6 Ceroni M, Norero E, Henríquez JP, Viñuela E, Briceño E, Martínez C, Aguayo G, Araos F, González P, Díaz A, Caracci M. Total esophagogastrectomy plus extended lymphadenectomy with transverse colon interposition: A treatment for extensive esophagogastric junction cancer. World J Hepatol 2015; 7(22): 2411-2417 [PMID: 26464757 DOI: 10.4254/wjh.v7.i22.2411] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
7 Deans DA, Wigmore SJ, Gilmour H, Tisdale MJ, Fearon KC, Ross JA. Expression of the proteolysis-inducing factor core peptide mRNA is upregulated in both tumour and adjacent normal tissue in gastro-oesophageal malignancy. Br J Cancer 2006;94:731-6. [PMID: 16495932 DOI: 10.1038/sj.bjc.6602989] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
8 Warschkow R, Tarantino I, Ukegjini K, Beutner U, Müller SA, Schmied BM, Steffen T. Diagnostic study and meta-analysis of C-reactive protein as a predictor of postoperative inflammatory complications after gastroesophageal cancer surgery. Langenbecks Arch Surg 2012;397:727-36. [DOI: 10.1007/s00423-012-0944-6] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 4.9] [Reference Citation Analysis]
9 Paireder M, Jomrich G, Kristo I, Asari R, Rieder E, Beer A, Ilhan-Mutlu A, Preusser M, Schmid R, Schoppmann SF. Modification of preoperative radiochemotherapy for esophageal cancer (CROSS protocol) is safe and efficient with no impact on surgical morbidity. Strahlenther Onkol 2020;196:779-86. [PMID: 32055873 DOI: 10.1007/s00066-020-01594-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
10 Tseng J, Posner MC. For Gastroesophageal Junction Cancers, Does an "Esophageal" or "Gastric" Surgical Approach Offer Better Perioperative and Oncologic Outcomes? Ann Surg Oncol 2020;27:511-7. [PMID: 31571057 DOI: 10.1245/s10434-019-07732-x] [Reference Citation Analysis]
11 Gaur P, Hofstetter WL, Bekele BN, Correa AM, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Rice TW, Swisher SG. Comparison Between Established and the Worldwide Esophageal Cancer Collaboration Staging Systems. The Annals of Thoracic Surgery 2010;89:1797-1804.e3. [DOI: 10.1016/j.athoracsur.2010.02.048] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
12 Patel M, Ferry K, Franceschi D, Kaklamanos I, Livingstone A, Ardalan B. Esophageal Carcinoma: Current Controversial Topics. Cancer Investigation 2004;22:897-912. [DOI: 10.1081/cnv-200039672] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
13 Beales IL, Vardi I, Dearman L, Broughton T. Statin use is associated with a reduction in the incidence of esophageal adenocarcinoma: a case control study. Dis Esophagus. 2012;Sep 18; Epub ahead of print. [PMID: 22989236 DOI: 10.1111/j.1442-2050.2012.01412.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
14 Zhu T, Hu Z, Wang Z, Ding H, Li R, Sun J, Wang G. Epigenetically silenced PD-L1 confers drug resistance to anti-PD1 therapy in gastric cardia adenocarcinoma. Int Immunopharmacol 2020;82:106245. [PMID: 32088639 DOI: 10.1016/j.intimp.2020.106245] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
15 Hu B, El Hajj N, Sittler S, Lammert N, Barnes R, Meloni-Ehrig A. Gastric cancer: Classification, histology and application of molecular pathology. J Gastrointest Oncol. 2012;3:251-261. [PMID: 22943016 DOI: 10.3978/j.issn.2078-6891.2012.021] [Cited by in F6Publishing: 160] [Reference Citation Analysis]
16 Patriti A, Ceccarelli G, Ceribelli C, Bartoli A, Spaziani A, Cisano C, Cigliano S, Casciola L. Robot-assisted laparoscopic management of cardia carcinoma according to Siewert recommendations. Int J Med Robotics Comput Assist Surg 2011;7:170-7. [DOI: 10.1002/rcs.385] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
17 Guo W, Dong Z, Chen Z, Yang Z, Wen D, Kuang G, Guo Y, Shan B. Aberrant CpG island hypermethylation of RASSF1A in gastric cardia adenocarcinoma. Cancer Invest. 2009;27:459-465. [PMID: 19160099 DOI: 10.1080/07357900802620828] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
18 Sawas T, Killcoyne S, Iyer PG, Wang KK, Smyrk TC, Kisiel JB, Qin Y, Ahlquist DA, Rustgi AK, Costa RJ, Gerstung M, Fitzgerald RC, Katzka DA; OCCAMS Consortium. Identification of Prognostic Phenotypes of Esophageal Adenocarcinoma in 2 Independent Cohorts. Gastroenterology 2018;155:1720-1728.e4. [PMID: 30165050 DOI: 10.1053/j.gastro.2018.08.036] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 8.5] [Reference Citation Analysis]
19 Martin L, Lagergren J, Lindblad M, Rouvelas I, Lagergren P. Malnutrition after oesophageal cancer surgery in Sweden. Br J Surg. 2007;94:1496-1500. [PMID: 17668914 DOI: 10.1002/bjs.5881] [Cited by in Crossref: 83] [Cited by in F6Publishing: 80] [Article Influence: 5.5] [Reference Citation Analysis]
20 Abbrederis K, Lorenzen S, von Weikersthal LF, Vehling-Kaiser U, Schuster T, Rothling N, Peschel C, Lordick F. Weekly docetaxel monotherapy for advanced gastric or esophagogastric junction cancer. Results of a phase II study in elderly patients or patients with impaired performance status. Crit Rev Oncol Hematol. 2008;66:84-90. [PMID: 18243012 DOI: 10.1016/j.critrevonc.2007.12.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
21 Imamura Y, Watanabe M, Oki E, Morita M, Baba H. Esophagogastric junction adenocarcinoma shares characteristics with gastric adenocarcinoma: Literature review and retrospective multicenter cohort study. Ann Gastroenterol Surg 2021;5:46-59. [PMID: 33532680 DOI: 10.1002/ags3.12406] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Beales IL, Vardi I, Dearman L. Regular statin and aspirin use in patients with Barrett’s oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma. Eur J Gastroenterol Hepatol. 2012;24:917-923. [PMID: 22569083 DOI: 10.1097/meg.0b013e3283543f01] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
23 Shen C, Yang H, Zhang B, Chen H, Chen Z, Chen J. Changes of quality of life after gastric tube reconstruction in adenocarcinoma of the esophagogastric junction. Pak J Med Sci 2013;29:1193-8. [PMID: 24353718 DOI: 10.12669/pjms.295.3879] [Reference Citation Analysis]
24 Blank S, Schmidt T, Heger P, Strowitzki MJ, Sisic L, Heger U, Nienhueser H, Haag GM, Bruckner T, Mihaljevic AL, Ott K, Büchler MW, Ulrich A. Surgical strategies in true adenocarcinoma of the esophagogastric junction (AEG II): thoracoabdominal or abdominal approach? Gastric Cancer 2018;21:303-14. [DOI: 10.1007/s10120-017-0746-1] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
25 Allum WH; European Union Network of Excellence (EUNE) for Gastric Cancer Steering Group. Gastric cancer in Europe. British Journal of Surgery 2008;95:406-8. [DOI: 10.1002/bjs.6197] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
26 Duan XF, Tang P, Yu ZT. Neoadjuvant chemoradiotherapy for resectable esophageal cancer: an in-depth study of randomized controlled trials and literature review. Cancer Biol Med. 2014;11:191-201. [PMID: 25364580 DOI: 10.7497/j.issn.2095-3941.2014.03.005] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
27 Leers JM, Knepper L, van der Veen A, Schröder W, Fuchs H, Schiller P, Hellmich M, Zettelmeyer U, Brosens LAA, Quaas A, Ruurda JP, van Hillegersberg R, Bruns CJ. The CARDIA-trial protocol: a multinational, prospective, randomized, clinical trial comparing transthoracic esophagectomy with transhiatal extended gastrectomy in adenocarcinoma of the gastroesophageal junction (GEJ) type II. BMC Cancer 2020;20:781. [PMID: 32819399 DOI: 10.1186/s12885-020-07152-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Theisen J, Stein HJ, Feith M, Kauer WKH, Dittler HJ, Pirchi D, Siewert JR. Preferred location for the development of esophageal adenocarcinoma within a segment of intestinal metaplasia. Surg Endosc 2006;20:235-8. [DOI: 10.1007/s00464-005-0187-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
29 Giganti F, Ambrosi A, Petrone MC, Canevari C, Chiari D, Salerno A, Arcidiacono PG, Nicoletti R, Albarello L, Mazza E, Gallivanone F, Gianolli L, Orsenigo E, Esposito A, Staudacher C, Del Maschio A, De Cobelli F. Prospective comparison of MR with diffusion-weighted imaging, endoscopic ultrasound, MDCT and positron emission tomography-CT in the pre-operative staging of oesophageal cancer: results from a pilot study. Br J Radiol 2016;89:20160087. [PMID: 27767330 DOI: 10.1259/bjr.20160087] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
30 Mullen JT, Kwak EL, Hong TS. What's the Best Way to Treat GE Junction Tumors? Approach Like Gastric Cancer. Ann Surg Oncol 2016;23:3780-5. [PMID: 27459983 DOI: 10.1245/s10434-016-5426-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
31 Omae M, Fujisaki J, Horiuchi Y, Yoshizawa N, Matsuo Y, Kubota M, Suganuma T, Okada K, Ishiyama A, Hirasawa T, Yamamoto Y, Tsuchida T, Hoshino E, Igarashi M. Safety, efficacy, and long-term outcomes for endoscopic submucosal dissection of early esophagogastric junction cancer. Gastric Cancer 2013;16:147-54. [PMID: 22692465 DOI: 10.1007/s10120-012-0162-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
32 Feussner H, Feith M. [Oesophageal tumours--what does the surgeon need from the radiologist?]. Radiologe 2007;47:97-100. [PMID: 17277966 DOI: 10.1007/s00117-006-1465-5] [Reference Citation Analysis]
33 Bornschein J, Dingwerth A, Selgrad M, Venerito M, Stuebs P, Frauenschlaeger K, Achilleos A, Roessner A, Malfertheiner P. Adenocarcinomas at different positions at the gastro-oesophageal junction show distinct association with gastritis and gastric preneoplastic conditions. Eur J Gastroenterol Hepatol 2015;27:492-500. [PMID: 25822856 DOI: 10.1097/MEG.0000000000000299] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
34 Crumley AB, Stuart RC, McKernan M, McMillan DC. Is hypoalbuminemia an independent prognostic factor in patients with gastric cancer? World J Surg. 2010;34:2393-2398. [PMID: 20602101 DOI: 10.1007/s00268-010-0641-y] [Cited by in Crossref: 75] [Cited by in F6Publishing: 72] [Article Influence: 6.8] [Reference Citation Analysis]
35 Chong IY, Cunningham D, Barber LJ, Campbell J, Chen L, Kozarewa I, Fenwick K, Assiotis I, Guettler S, Garcia-murillas I, Awan S, Lambros M, Starling N, Wotherspoon A, Stamp G, Gonzalez-de-castro D, Benson M, Chau I, Hulkki S, Nohadani M, Eltahir Z, Lemnrau A, Orr N, Rao S, Lord CJ, Ashworth A. The genomic landscape of oesophagogastric junctional adenocarcinoma: Exome sequencing of OGJ. J Pathol 2013;231:301-10. [DOI: 10.1002/path.4247] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
36 Tan MC, Mansour N, White DL, Sisson A, El-Serag HB, Thrift AP. Systematic review with meta-analysis: prevalence of prior and concurrent Barrett's oesophagus in oesophageal adenocarcinoma patients. Aliment Pharmacol Ther 2020;52:20-36. [PMID: 32452599 DOI: 10.1111/apt.15760] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
37 Pasini F, de Manzoni G, Pedrazzani C, Grandinetti A, Durante E, Gabbani M, Tomezzoli A, Griso C, Guglielmi A, Pelosi G. High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy. Ann Oncol. 2005;16:1133-1139. [PMID: 15946974 DOI: 10.1093/annonc/mdi207] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
38 van der Sluis PC, van der Horst S, May AM, Schippers C, Brosens LAA, Joore HCA, Kroese CC, Haj Mohammad N, Mook S, Vleggaar FP, Borel Rinkes IHM, Ruurda JP, van Hillegersberg R. Robot-assisted Minimally Invasive Thoracolaparoscopic Esophagectomy Versus Open Transthoracic Esophagectomy for Resectable Esophageal Cancer: A Randomized Controlled Trial. Ann Surg. 2019;269:621-630. [PMID: 30308612 DOI: 10.1097/sla.0000000000003031] [Cited by in Crossref: 152] [Cited by in F6Publishing: 71] [Article Influence: 76.0] [Reference Citation Analysis]
39 Valentí V, Hernández-Lizoain JL, Marínez-Regueira F, Bellver M, Rodríguez J, Díaz González JA, Torres W, Sola JJ, Alvarez-Cienfuegos J. Transthoracic oesophagectomy with lymphadenectomy in 100 oesophageal cancer patients: multidisciplinary approach. Clin Transl Oncol 2011;13:899-903. [PMID: 22126734 DOI: 10.1007/s12094-011-0752-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
40 Button MR, Morgan CA, Croydon ES, Roberts SA, Crosby TD. Study to determine adequate margins in radiotherapy planning for esophageal carcinoma by detailing patterns of recurrence after definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009;73:818-823. [PMID: 18718726 DOI: 10.1016/j.ijrobp.2008.04.062] [Cited by in Crossref: 58] [Cited by in F6Publishing: 62] [Article Influence: 4.1] [Reference Citation Analysis]
41 Cai Q, Zhu C, Yuan Y, Feng Q, Feng Y, Hao Y, Li J, Zhang K, Ye G, Ye L, Lv N, Zhang S, Liu C, Li M, Liu Q, Li R, Pan J, Yang X, Zhu X, Li Y, Lao B, Ling A, Chen H, Li X, Xu P, Zhou J, Liu B, Du Z, Du Y, Li Z; Gastrointestinal Early Cancer Prevention & Treatment Alliance of China (GECA). Development and validation of a prediction rule for estimating gastric cancer risk in the Chinese high-risk population: a nationwide multicentre study. Gut 2019;68:1576-87. [PMID: 30926654 DOI: 10.1136/gutjnl-2018-317556] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
42 Shen J, Zhu X, Du Y, Zhu Y, Yu P, Yang L, Xu Z, Huang L, Zhang Y, Zhang Y, Liu L, Cheng X. Adjuvant SOX chemotherapy versus concurrent chemoradiotherapy after D2 radical resection of locally advanced esophagogastric junction (EGJ) adenocarcinoma: study protocol for a randomized phase III trial (ARTEG). Trials 2021;22:753. [PMID: 34717717 DOI: 10.1186/s13063-021-05617-7] [Reference Citation Analysis]
43 Zhang H, Wang W, Cheng Y, Song Y, Zhu K, Dang C. Adenocarcinomas of the esophagogastric junction: experiences at a single institution in China. World J Surg Oncol 2013;11:155. [PMID: 23849250 DOI: 10.1186/1477-7819-11-155] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
44 Paireder M, Asari R, Radlspöck W, Fabbri A, Tschoner A, Függer R, Zacherl J, Schoppmann SF. Esophageal resection in Austria—preparing a national registry. Eur Surg 2021;53:206-14. [DOI: 10.1007/s10353-021-00734-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Duan XF, Yue J, Tang P, Shang XB, Jiang HJ, Yu ZT. Lymph node dissection for Siewert II esophagogastric junction adenocarcinoma: A retrospective study of 3 surgical procedures. Medicine (Baltimore) 2017;96:e6120. [PMID: 28207537 DOI: 10.1097/MD.0000000000006120] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
46 Nishiwaki N, Noma K, Matsuda T, Maeda N, Tanabe S, Sakurama K, Shirakawa Y, Fujiwara T. Risk factor of mediastinal lymph node metastasis of Siewert type I and II esophagogastric junction carcinomas. Langenbecks Arch Surg 2020;405:1101-9. [PMID: 33155069 DOI: 10.1007/s00423-020-02017-4] [Reference Citation Analysis]
47 Lahiff C, Schilling C, Cathcart M, Mulligan N, Doran P, Muldoon C, Murray D, Pidgeon GP, Reynolds JV, Macmathuna P. Prognostic significance of neuroepithelial transforming gene 1 in adenocarcinoma of the oesophagogastric junction. British Journal of Surgery 2014;101:55-62. [DOI: 10.1002/bjs.9373] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
48 Rizk N. Gastroesophageal Junction Tumors. Ann Surg Oncol 2016;23:3798-800. [DOI: 10.1245/s10434-016-5427-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
49 Zingg U, McQuinn A, DiValentino D, Esterman AJ, Bessell JR, Thompson SK, Jamieson GG, Watson DI. Minimally invasive vs open esophagectomy for patients with esophageal cancer. Ann Thorac Surg. 2009;87:911-919. [PMID: 19231418 DOI: 10.1016/j.athoracsur.2008.11.060] [Cited by in Crossref: 97] [Cited by in F6Publishing: 85] [Article Influence: 7.5] [Reference Citation Analysis]
50 Abnet CC, Freedman ND, Hollenbeck AR, Fraumeni JF Jr, Leitzmann M, Schatzkin A. A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma. Eur J Cancer 2008;44:465-71. [PMID: 18221867 DOI: 10.1016/j.ejca.2007.12.009] [Cited by in Crossref: 112] [Cited by in F6Publishing: 93] [Article Influence: 8.0] [Reference Citation Analysis]
51 Kneuertz PJ, Hofstetter WL, Chiang Y, Das P, Blum M, Elimova E, Mansfield P, Ajani J, Badgwell B. Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy: Do Thoracic and Abdominal Approaches Differ? Ann Surg Oncol 2016;23:626-32. [DOI: 10.1245/s10434-015-4898-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
52 Ashktorab H, Nouri Z, Nouraie M, Razjouyan H, Lee EE, Dowlati E, El-Seyed el-W, Laiyemo A, Brim H, Smoot DT. Esophageal carcinoma in African Americans: a five-decade experience. Dig Dis Sci 2011;56:3577-82. [PMID: 21847566 DOI: 10.1007/s10620-011-1853-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
53 Gwynne S, Hurt C, Evans M, Holden C, Vout L, Crosby T. Definitive chemoradiation for oesophageal cancer--a standard of care in patients with non-metastatic oesophageal cancer. Clin Oncol (R Coll Radiol). 2011;23:182-188. [PMID: 21232928 DOI: 10.1016/j.clon.2010.12.001] [Cited by in Crossref: 72] [Cited by in F6Publishing: 67] [Article Influence: 6.5] [Reference Citation Analysis]
54 Faber J, Uitdehaag MJ, Spaander M, van Steenbergen-Langeveld S, Vos P, Berkhout M, Lamers C, Rümke H, Tilanus H, Siersema P, van Helvoort A, van der Gaast A. Improved body weight and performance status and reduced serum PGE2 levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro-esophageal junction. J Cachexia Sarcopenia Muscle 2015;6:32-44. [PMID: 26136410 DOI: 10.1002/jcsm.12009] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
55 Reynolds JV, Ravi N, Muldoon C, Larkin JO, Rowley S, O'Byrne K, Hollywood D, O'Toole D. Differential pathologic variables and outcomes across the spectrum of adenocarcinoma of the esophagogastric junction. World J Surg 2010;34:2821-9. [PMID: 20827475 DOI: 10.1007/s00268-010-0783-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
56 Stockeld D, Backman L, Fagerberg J, Granström L. Esophageal cancer in Stockholm county 1978–1995. Acta Oncologica 2009;46:1075-84. [DOI: 10.1080/02841860701426807] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
57 Hayes T, Smyth E, Riddell A, Allum W. Staging in Esophageal and Gastric Cancers. Hematology/Oncology Clinics of North America 2017;31:427-40. [DOI: 10.1016/j.hoc.2017.02.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
58 Polkowski WP, Skomra DG, Mielko J, Wallner GT, Szumiło J, Zinkiewicz K, Korobowicz EM, van Lanschot JJ. E-cadherin expression as predictive marker of proximal resection line involvement for advanced carcinoma of the gastric cardia. Eur J Surg Oncol 2004;30:1084-92. [PMID: 15522555 DOI: 10.1016/j.ejso.2004.07.022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
59 Bettstetter M, Berezowska S, Keller G, Walch A, Feuchtinger A, Slotta-Huspenina J, Feith M, Drecoll E, Höfler H, Langer R. Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome. Hum Pathol 2013;44:829-36. [PMID: 23158210 DOI: 10.1016/j.humpath.2012.08.005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
60 Reim D, Gertler R, Novotny A, Becker K, zum Büschenfelde CM, Ebert M, Dobritz M, Langer R, Hoefler H, Friess H. Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer. Ann Surg Oncol. 2012;19:2108-2118. [PMID: 22130620 DOI: 10.1245/s10434-011-2147-8] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 4.5] [Reference Citation Analysis]
61 Cao J, Yang T, Wang G, Zhang H, You Y, Chen J, Yang J, Yang W. Analysis of the clinicopathological features and prognostic factors in 734 cases of Chinese Hui and Han patients with adenocarcinoma of the esophagogastric junction. Surg Oncol 2018;27:556-62. [PMID: 30217319 DOI: 10.1016/j.suronc.2018.07.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
62 Kano Y, Ohashi M, Ida S, Kumagai K, Makuuchi R, Sano T, Hiki N, Nunobe S. Therapeutic value of splenectomy to dissect splenic hilar lymph nodes for type 4 gastric cancer involving the greater curvature, compared with other types. Gastric Cancer 2020;23:927-36. [PMID: 32307689 DOI: 10.1007/s10120-020-01072-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
63 Law S. Surgical Protocol for Esophageal Adenocarcinoma. Methods Mol Biol 2018;1756:35-50. [PMID: 29600358 DOI: 10.1007/978-1-4939-7734-5_4] [Reference Citation Analysis]
64 Godoy MCB, Bruzzi JF, Viswanathan C, Truong MT, Guimarães MD, Hofstetter WL, Erasmus JJ, Marom EM. Multimodality imaging evaluation of esophageal cancer: staging, therapy assessment, and complications. Abdom Imaging 2013;38:974-93. [DOI: 10.1007/s00261-013-9986-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
65 Schiesser M, Schneider PM. Surgical strategies for adenocarcinoma of the esophagogastric junction. Recent Results Cancer Res. 2010;182:93-106. [PMID: 20676874 DOI: 10.1007/978-3-540-70579-6_8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
66 Hosoda K, Azuma M, Katada C, Ishido K, Niihara M, Ushiku H, Sakuraya M, Washio M, Wada T, Watanabe A, Harada H, Tanabe S, Koizumi W, Yamashita K, Hiki N. A phase I study of docetaxel/oxaliplatin/S-1 (DOS) combination neoadjuvant chemotherapy for patients with locally advanced adenocarcinoma of the esophagogastric junction. Int J Clin Oncol 2020;25:1090-7. [PMID: 32124094 DOI: 10.1007/s10147-020-01638-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
67 Han L, Dong Z, Wang C, Guo Y, Shen S, Kuang G, Guo W. Decreased expression and aberrant methylation of RASSF5A correlates with malignant progression of gastric cardia adenocarcinoma. Mol Carcinog. 2014;Epub ahead of print. [PMID: 25420558 DOI: 10.1002/mc.22245] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
68 Oono Y, Kuwata T, Takashima K, Shinmura K, Hori K, Yoda Y, Ikematsu H, Shitara K, Kinoshita T, Yano T. Human epidermal growth factor receptor 2-, epidermal growth factor receptor-, and mesenchymal epithelial transition factor-positive sites of gastric cancer using surgical samples. Gastric Cancer 2019;22:335-43. [PMID: 29951752 DOI: 10.1007/s10120-018-0853-7] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
69 Benoit V, de Moraes E, Dar NA, Taranchon E, Bours V, Hautefeuille A, Tanière P, Chariot A, Scoazec JY, de Moura Gallo CV, Merville MP, Hainaut P. Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappaB. Oncogene 2006;25:5708-18. [PMID: 16682957 DOI: 10.1038/sj.onc.1209579] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 2.8] [Reference Citation Analysis]
70 Javeri H, Xiao L, Rohren E, Lee JH, Liao Z, Hofstetter W, Maru D, Bhutani MS, Swisher SG, Macapinlac H. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer. 2009;115:5184-5192. [PMID: 19685531 DOI: 10.1002/cncr.24604] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 3.4] [Reference Citation Analysis]
71 Ma XL, Gu JY, Qiu JF. Controversy over classifications and surgical approaches for esophagogastric junction carcinomas. Shijie Huaren Xiaohua Zazhi 2021; 29(2): 53-57 [DOI: 10.11569/wcjd.v29.i2.53] [Reference Citation Analysis]
72 Dikken JL, Coit DG, Klimstra DS, Rizk NP, van Grieken N, Ilson D, Tang LH. Prospective impact of tumor grade assessment in biopsies on tumor stage and prognostic grouping in gastroesophageal adenocarcinoma: Relevance of the seventh edition American Joint Committee on Cancer Staging Manual revision. Cancer 2012;118:349-57. [DOI: 10.1002/cncr.26301] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
73 Bachmann R, Bachmann J, Hungbauer A, Schmehl J, Sitzmann G, Königsrainer A, Ladurner R. Impact of response evaluation for resectable esophageal adenocarcinoma – A retrospective cohort study. International Journal of Surgery 2014;12:1025-30. [DOI: 10.1016/j.ijsu.2014.08.400] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
74 Scheepers JJ, Veenhof AA, van der Peet DL, van Groeningen C, Mulder C, Meijer S, Cuesta MA. Laparoscopic transhiatal resection for malignancies of the distal esophagus: Outcome of the first 50 resected patients. Surgery 2008;143:278-85. [DOI: 10.1016/j.surg.2007.08.019] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
75 Jagadesham VP, Lagarde SM, Immanuel A, Griffin SM. Systemic inflammatory markers and outcome in patients with locally advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. British Journal of Surgery 2017;104:401-7. [DOI: 10.1002/bjs.10425] [Cited by in Crossref: 13] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
76 Siewert JR, Feith M. Adenocarcinoma of the esophagogastric junction: competition between Barrett and gastric cancer. J Am Coll Surg. 2007;205:S49-S53. [PMID: 17916519 DOI: 10.1016/j.jamcollsurg.2007.06.324] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
77 Otani K, Kitayama J, Kaisaki S, Ishigami H, Hidemura A, Fujishiro M, Omata M, Nagawa H. Early gastric cancer shows different associations with adipose tissue volume depending on histological type. Gastric Cancer 2008;11:86-95. [DOI: 10.1007/s10120-008-0459-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
78 Kurokawa Y, Hiki N, Yoshikawa T, Kishi K, Ito Y, Ohi M, Wada N, Takiguchi S, Mine S, Hasegawa S, Matsuda T, Takeuchi H. Mediastinal lymph node metastasis and recurrence in adenocarcinoma of the esophagogastric junction. Surgery. 2015;157:551-555. [PMID: 25532434 DOI: 10.1016/j.surg.2014.08.099] [Cited by in Crossref: 54] [Cited by in F6Publishing: 43] [Article Influence: 6.8] [Reference Citation Analysis]
79 Rutegård M, Lagergren P, Rouvelas I, Lagergren J. Intrathoracic anastomotic leakage and mortality after esophageal cancer resection: a population-based study. Ann Surg Oncol 2012;19:99-103. [PMID: 21769467 DOI: 10.1245/s10434-011-1926-6] [Cited by in Crossref: 97] [Cited by in F6Publishing: 98] [Article Influence: 8.8] [Reference Citation Analysis]
80 Maru DM, Khurana H, Rashid A, Correa AM, Anandasabapathy S, Krishnan S, Komaki R, Ajani JA, Swisher SG, Hofstetter WL. Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus. Am J Surg Pathol 2008;32:1404-11. [PMID: 18670347 DOI: 10.1097/PAS.0b013e31816bf41f] [Cited by in Crossref: 75] [Cited by in F6Publishing: 37] [Article Influence: 5.4] [Reference Citation Analysis]
81 Braiteh F, Correa AM, Hofstetter WL, Rice DC, Vaporciyan AA, Walsh GL, Roth JA, Mehran RJ, Swisher SG, Ajani JA. Association of age and survival in patients with gastroesophageal cancer undergoing surgery with or without preoperative therapy. Cancer 2009;115:4450-8. [PMID: 19562780 DOI: 10.1002/cncr.24488] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
82 Gokon Y, Fujishima F, Taniyama Y, Ishida H, Yamagata T, Sawai T, Uzuki M, Ichikawa H, Itakura Y, Takahashi K, Yajima N, Hagiwara M, Nishida A, Ozawa Y, Sakuma T, Kanba R, Sakamoto K, Zuguchi M, Saito M, Kamei T, Sasano H. Immune microenvironment in Barrett's esophagus adjacent to esophageal adenocarcinoma: possible influence of adjacent mucosa on cancer development and progression. Virchows Arch 2020;477:825-34. [PMID: 32533341 DOI: 10.1007/s00428-020-02854-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
83 Jayaprakash N, O'Kelly F, Lim KT, Reynolds JV. Management of synchronous adenocarcinoma of the esophago-gastric junction and ampulla of Vater: Case report of a surgically challenging condition. Patient Saf Surg. 2009;3:23. [PMID: 19785744 DOI: 10.1186/1754-9493-3-23] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
84 Matzinger O, Gerber E, Bernstein Z, Maingon P, Haustermans K, Bosset JF, Gulyban A, Poortmans P, Collette L, Kuten A. EORTC-ROG expert opinion: radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach. Radiother Oncol 2009;92:164-75. [PMID: 19375186 DOI: 10.1016/j.radonc.2009.03.018] [Cited by in Crossref: 86] [Cited by in F6Publishing: 68] [Article Influence: 6.6] [Reference Citation Analysis]
85 Geddert H, Kiel S, Zotz RB, Zhang J, Willers R, Gabbert HE, Sarbia M. Polymorphism of p16 INK4A and cyclin D1 in adenocarcinomas of the upper gastrointestinal tract. J Cancer Res Clin Oncol 2005;131:803-8. [PMID: 16163549 DOI: 10.1007/s00432-005-0021-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
86 Pacelli F, Bossola M, Rosa F, Tortorelli AP, Papa V, Doglietto GB. Is malnutrition still a risk factor of postoperative complications in gastric cancer surgery? Clin Nutr. 2008;27:398-407. [PMID: 18436350 DOI: 10.1016/j.clnu.2008.03.002] [Cited by in Crossref: 68] [Cited by in F6Publishing: 61] [Article Influence: 4.9] [Reference Citation Analysis]
87 Xiao JW, Liu ZL, Ye PC, Luo YJ, Fu ZM, Zou Q, Wei SJ. Clinical comparison of antrum-preserving double tract reconstruction vs roux-en-Y reconstruction after gastrectomy for Siewert types II and III adenocarcinoma of the esophagogastric junction. World J Gastroenterol 2015; 21(34): 9999-10007 [PMID: 26379405 DOI: 10.3748/wjg.v21.i34.9999] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
88 Suttie SA, Li AG, Quinn M, Park KG. The impact of operative approach on outcome of surgery for gastro-oesophageal tumours. World J Surg Oncol 2007;5:95. [PMID: 17708773 DOI: 10.1186/1477-7819-5-95] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
89 Zheng QK, Yin Q, Zhang N, Sun ZG. Clinical and prognostic features of MMP-2 and VEGF in AEG patients. Open Med (Wars) 2021;16:786-94. [PMID: 34027107 DOI: 10.1515/med-2021-0252] [Reference Citation Analysis]
90 Khan O, Goh S, Byrne B, Somers S, Mercer S, Toh S. Long-term outcomes of extended proximal gastrectomy for oesophagogastric junctional tumours. World J Surg. 2011;35:2245-2251. [PMID: 21850599 DOI: 10.1007/s00268-011-1235-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
91 Cai Z, Rui W, Li S, Fingerhut A, Sun J, Ma J, Zang L, Zhu Z, Zheng M. Microsatellite Status Affects Tumor Response and Survival in Patients Undergoing Neoadjuvant Chemotherapy for Clinical Stage III Gastric Cancer. Front Oncol 2020;10:614785. [PMID: 33384963 DOI: 10.3389/fonc.2020.614785] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Ajani JA, Walsh G, Komaki R, Morris J, Swisher SG, Putnam JB Jr, Lynch PM, Wu TT, Smythe R, Vaporciyan A. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer. 2004;100:2347-2354. [PMID: 15160337 DOI: 10.1002/cncr.20284] [Cited by in Crossref: 60] [Cited by in F6Publishing: 50] [Article Influence: 3.3] [Reference Citation Analysis]
93 Bornschein J, Wernisch L, Secrier M, Miremadi A, Perner J, MacRae S, O'Donovan M, Newton R, Menon S, Bower L, Eldridge MD, Devonshire G, Cheah C, Turkington R, Hardwick RH, Selgrad M, Venerito M, Malfertheiner P, Fitzgerald RC; OCCAMS Consortium. Transcriptomic profiling reveals three molecular phenotypes of adenocarcinoma at the gastroesophageal junction. Int J Cancer 2019;145:3389-401. [PMID: 31050820 DOI: 10.1002/ijc.32384] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
94 Xiong J, Kang W, Ma F, Liu H, Ma S, Li Y, Jin P, Hu H, Tian Y. Modified Systemic Inflammation Score Is an Independent Predictor of Long-Term Outcome in Patients Undergoing Surgery for Adenocarcinoma of the Esophagogastric Junction. Front Surg 2021;8:622821. [PMID: 34820414 DOI: 10.3389/fsurg.2021.622821] [Reference Citation Analysis]
95 Bystricky B, Okines AF, Cunningham D. Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs. 2011;71:541-555. [PMID: 21443280 DOI: 10.2165/11585460-000000000-000003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
96 Feng H, Zheng J, Zheng C, Deng Z, Liao Q, Wang J, Li Y. The probability of Lymph node metastasis with a tumor size larger than and smaller than 4 cm is different in stages T1-T3 of Siewert type II adenocarcinoma of esophagogastric junction: A Population-Based Study. J Cancer 2021;12:6873-82. [PMID: 34659575 DOI: 10.7150/jca.63392] [Reference Citation Analysis]
97 Hasegawa S, Yoshikawa T, Rino Y, Oshima T, Aoyama T, Hayashi T, Sato T, Yukawa N, Kameda Y, Sasaki T, Ono H, Tsuchida K, Cho H, Kunisaki C, Masuda M, Tsuburaya A. Priority of lymph node dissection for Siewert type II/III adenocarcinoma of the esophagogastric junction. Ann Surg Oncol. 2013;20:4252-4259. [PMID: 23943020 DOI: 10.1245/s10434-013-3036-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
98 Neri A, Marrelli D, Voglino C, Di Mare G, Ferrara F, Marini M, Roviello F. Recurrence after surgery in esophago-gastric junction adenocarcinoma: Current management and future perspectives. Surg Oncol. 2016;25:355-363. [PMID: 27916166 DOI: 10.1016/j.suronc.2016.08.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
99 Glückstein MI, Dintner S, Arndt TT, Vlasenko D, Schenkirsch G, Agaimy A, Müller G, Märkl B, Grosser B. Comprehensive Immunohistochemical Study of the SWI/SNF Complex Expression Status in Gastric Cancer Reveals an Adverse Prognosis of SWI/SNF Deficiency in Genomically Stable Gastric Carcinomas. Cancers (Basel) 2021;13:3894. [PMID: 34359794 DOI: 10.3390/cancers13153894] [Reference Citation Analysis]
100 Weitz J, Jaques DP, Brennan M, Karpeh M. Association of splenectomy with postoperative complications in patients with proximal gastric and gastroesophageal junction cancer. Ann Surg Oncol. 2004;11:682-689. [PMID: 15231523 DOI: 10.1245/aso.2004.03.048] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
101 May KS, Yang GY, Khushalani NI. The Role of Radiation in the Perioperative Treatment of Esophagogastric Cancer. Curr Treat Options in Oncol 2011;12:61-71. [DOI: 10.1007/s11864-011-0139-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
102 von Döbeln GA, Klevebro F, Jacobsen AB, Johannessen HO, Nielsen NH, Johnsen G, Hatlevoll I, Glenjen NI, Friesland S, Lundell L, Yu J, Nilsson M. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial. Dis Esophagus 2019;32. [PMID: 30137281 DOI: 10.1093/dote/doy078] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
103 Canale M, Casadei-Gardini A, Ulivi P, Arechederra M, Berasain C, Lollini PL, Fernández-Barrena MG, Avila MA. Epigenetic Mechanisms in Gastric Cancer: Potential New Therapeutic Opportunities. Int J Mol Sci 2020;21:E5500. [PMID: 32752096 DOI: 10.3390/ijms21155500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
104 Fontana MG, La Pinta M, Moneghini D, Villanacci V, Donato F, Rindi G, Paparini S, Baronchelli C, Bertoli G, Alquati P. Prognostic value of Goseki histological classification in adenocarcinoma of the cardia. Br J Cancer. 2003;88:401-405. [PMID: 12569383 DOI: 10.1038/sj.bjc.6600663] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
105 Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu FS, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019;393:1948-57. [PMID: 30982686 DOI: 10.1016/S0140-6736(18)32557-1] [Cited by in Crossref: 458] [Cited by in F6Publishing: 236] [Article Influence: 152.7] [Reference Citation Analysis]
106 Rosenberg R, Nekarda H, Bauer P, Schenck U, Hoefler H, Siewert JR. Free peritoneal tumour cells are an independent prognostic factor in curatively resected stage IB gastric carcinoma. British Journal of Surgery 2006;93:325-31. [DOI: 10.1002/bjs.5196] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
107 Zhang J, Su XQ, Wu XJ, Liu YH, Wang H, Zong XN, Wang Y, Ji JF. Effect of body mass index on adenocarcinoma of gastric cardia. World J Gastroenterol 2003; 9(12): 2658-2661 [PMID: 14669307 DOI: 10.3748/wjg.v9.i12.2658] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
108 Genitsch V, Novotny A, Seiler CA, Kröll D, Walch A, Langer R. Epstein-barr virus in gastro-esophageal adenocarcinomas - single center experiences in the context of current literature. Front Oncol 2015;5:73. [PMID: 25859432 DOI: 10.3389/fonc.2015.00073] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
109 MacDonald WC, Owen DA, Le N. Chronic advanced gastric cancer: clinicopathologic analysis of survival data. Hum Pathol 2008;39:641-9. [PMID: 18439937 DOI: 10.1016/j.humpath.2007.10.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
110 Gao P, Cai N, Yang X, Yuan Z, Zhang T, Lu M, Jin L, Ye W, Suo C, Chen X. Association of Helicobacter pylori and gastric atrophy with adenocarcinoma of the esophagogastric junction in Taixing, China. Int J Cancer 2021. [PMID: 34498732 DOI: 10.1002/ijc.33801] [Reference Citation Analysis]
111 Dong Z, Guo W, Zhou R, Wan L, Li Y, Wang N, Kuang G, Wang S. Polymorphisms of the DNA repair gene XPA and XPC and its correlation with gastric cardiac adenocarcinoma in a high incidence population in North China. J Clin Gastroenterol. 2008;42:910-915. [PMID: 18645534 DOI: 10.1097/mcg.0b013e3180f6262c] [Cited by in Crossref: 32] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
112 Shen KR, Cassivi SD, Deschamps C, Allen MS, Nichols FC 3rd, Harmsen WS, Pairolero PC. Surgical treatment of tumors of the proximal stomach with involvement of the distal esophagus: a 26-year experience with Siewert type III tumors. J Thorac Cardiovasc Surg 2006;132:755-62. [PMID: 17000284 DOI: 10.1016/j.jtcvs.2006.05.064] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
113 Zhang J, Li Y, Wang R, Wen D, Sarbia M, Kuang G, Wu M, Wei L, He M, Zhang L. Association of cyclin D1 (G870A) polymorphism with susceptibility to esophageal and gastric cardiac carcinoma in a northern Chinese population. Int J Cancer. 2003;105:281-284. [PMID: 12673692 DOI: 10.1002/ijc.11067] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 2.6] [Reference Citation Analysis]
114 Villwock Mde M, Meurer L, Cavazzola LT, Gurski RR, Edelweiss MI, Schirmer CC. Prevalence of p21 immunohistochemical expression in esophageal adenocarcinoma. Arq Gastroenterol 2006;43:212-8. [PMID: 17160237 DOI: 10.1590/s0004-28032006000300011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
115 Gu J, Wang YS, Wang M, Li YM, Wang YJ. Treatment of gastric cardia cancer with capecitabine and oxaliplatin: an analysis of 46 cases. Shijie Huaren Xiaohua Zazhi 2008; 16(30): 3443-3447 [DOI: 10.11569/wcjd.v16.i30.3443] [Reference Citation Analysis]
116 Bonavina L, Soligo D, Quirici N, Bossolasco P, Cesana B, Lembertenghi Deliliers G, Peracchia A. Bone marrow-disseminated tumor cells in patients with carcinoma of the esophagus or cardia. Surgery. 2001;129:15-22. [PMID: 11150029 DOI: 10.1067/msy.2001.109503] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 2.3] [Reference Citation Analysis]
117 Cordin J, Lehmann K, Schneider PM. Clinical Staging of Adenocarcinoma of the Esophagogastric Junction. In: Schneider PM, editor. Adenocarcinoma of the Esophagogastric Junction. Berlin: Springer Berlin Heidelberg; 2010. pp. 73-83. [DOI: 10.1007/978-3-540-70579-6_6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
118 Han WH, Eom BW, Yoon HM, Reim D, Kim YW, Kim MS, Lee JM, Ryu KW. The optimal extent of lymph node dissection in gastroesophageal junctional cancer: retrospective case control study. BMC Cancer 2019;19:719. [PMID: 31331305 DOI: 10.1186/s12885-019-5922-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
119 Davoodvandi A, Shabani Varkani M, Clark CCT, Jafarnejad S. Quercetin as an anticancer agent: Focus on esophageal cancer. J Food Biochem 2020;44:e13374. [PMID: 32686158 DOI: 10.1111/jfbc.13374] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
120 Davies AR, Deans DAC, Penman I, Plevris JN, Fletcher J, Wall L, Phillips H, Gilmour H, Patel D, De Beaux A, Paterson-brown S. The multidisciplinary team meeting improves staging accuracy and treatment selection for gastro-esophageal cancer. Diseases of the Esophagus 2006;19:496-503. [DOI: 10.1111/j.1442-2050.2006.00629.x] [Cited by in Crossref: 99] [Cited by in F6Publishing: 92] [Article Influence: 6.2] [Reference Citation Analysis]
121 Hu Y, Yoon SS. Extent of gastrectomy and lymphadenectomy for gastric adenocarcinoma. Surg Oncol 2021;40:101689. [PMID: 34839198 DOI: 10.1016/j.suronc.2021.101689] [Reference Citation Analysis]
122 Fuster D, Mayoral M, Rubello D, Pineda E, Fernández-Esparrach G, Pagès M, Colletti PM, Pons F. Is there a role for PET/CT with esophagogastric junction adenocarcinoma? Clin Nucl Med. 2015;40:e201-e207. [PMID: 25546207 DOI: 10.1097/RLU.0000000000000661] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
123 Siewert JR, Stein HJ, Lordick F. Ösophaguskarzinom. In: Siewert JR, Rothmund M, Schumpelick V, editors. Praxis der Viszeralchirurgie. Berlin/Heidelberg: Springer-Verlag; 2006. pp. 403-33. [DOI: 10.1007/3-540-30036-8_35] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
124 Gertler R, Stein HJ, Loos M, Langer R, Friess H, Feith M. How to classify adenocarcinomas of the esophagogastric junction: as esophageal or gastric cancer? Am J Surg Pathol. 2011;35:1512-1522. [PMID: 21934477 DOI: 10.1097/pas.0b013e3182294764] [Cited by in Crossref: 38] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
125 Chiappa A, Andreoni B, Dionigi R, Spaggiari L, Foschi D, Polvani G, Orecchia R, Fazio N, Pravettoni G, Cossu ML, Galetta D, Venturino M, Ferrari C, Macone L, Crosta C, Bonanni B, Biffi R. A rationale multidisciplinary approach for treatment of esophageal and gastroesophageal junction cancer: Accurate review of management and perspectives. Crit Rev Oncol Hematol. 2018;132:161-168. [PMID: 30447922 DOI: 10.1016/j.critrevonc.2018.10.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
126 Ren G, Chen YW, Cai R, Zhang WJ, Wu XR, Jin YN. Lymph node metastasis in gastric cardiac adenocarcinoma in male patients. World J Gastroenterol 2013; 19(37): 6245-6257 [PMID: 24115823 DOI: 10.3748/wjg.v19.i37.6245] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
127 Hu P, Pang Z, Shen H, Wang G, Sun H, Du J. Tumor-infiltrating neutrophils predict poor outcome in adenocarcinoma of the esophagogastric junction. Tumour Biol 2015;36:2965-71. [PMID: 25487619 DOI: 10.1007/s13277-014-2927-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
128 Zanoni A, Verlato G, Baiocchi GL, Casella F, Cossu A, d'Ignazio A, De Pascale S, Giacopuzzi S. Siewert III esophagogastric junction adenocarcinoma: does TNM 8th save us? Updates Surg 2018;70:241-9. [PMID: 29808375 DOI: 10.1007/s13304-018-0537-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
129 Huang C, Lv C, Lin J, Chen Q, Zheng C, Li P, Xie J, Wang J, Lu J, Cao L, Lin M, Tu R. Laparoscopic-assisted versus open total gastrectomy for Siewert type II and III esophagogastric junction carcinoma: a propensity score-matched case-control study. Surg Endosc 2017;31:3495-503. [DOI: 10.1007/s00464-016-5375-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
130 Ichihara S, Uedo N, Gotoda T. Considering the esophagogastric junction as a ‘zone’. Digestive Endoscopy 2017;29:3-10. [DOI: 10.1111/den.12792] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
131 Allum W, Garofalo A, Degiuli M, Schuhmacher C. The first European Union Network of Excellence for Gastric Cancer conference, Rome, Italy, April 2008. Gastric Cancer 2009;12:56-65. [PMID: 19390934 DOI: 10.1007/s10120-009-0499-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
132 Aratani K, Komatsu S, Ichikawa D, Ohashi T, Miyamae M, Okajima W, Imamura T, Kiuchi J, Nishibeppu K, Kosuga T, Konishi H, Shiozaki A, Fujiwara H, Okamoto K, Tsuda H, Otsuji E. Overexpression of CTEN relates to tumor malignant potential and poor outcomes of adenocarcinoma of the esophagogastric junction. Oncotarget 2017;8:84112-22. [PMID: 29137409 DOI: 10.18632/oncotarget.21109] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
133 Kauppila JH, Lagergren J. The surgical management of esophago-gastric junctional cancer. Surg Oncol. 2016;25:394-400. [PMID: 27916171 DOI: 10.1016/j.suronc.2016.09.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
134 Paireder M, Asari R, Kristo I, Rieder E, Zacherl J, Kabon B, Fleischmann E, Schoppmann SF. Morbidity in open versus minimally invasive hybrid esophagectomy (MIOMIE): Long-term results of a randomized controlled clinical study. Eur Surg. 2018;50:249-255. [PMID: 30546384 DOI: 10.1007/s10353-018-0552-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
135 Bozzetti F, Bignami P, Bertario L, Fissi S, Eboli M. Surgical treatment of gastric cancer invading the oesophagus. Eur J Surg Oncol. 2000;26:810-814. [PMID: 11087650 DOI: 10.1053/ejso.2000.1009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
136 Jin X, Kuang G, Wei LZ, Li Y, Wang R, Guo W, Wang N, Fang SM, Wen DG, Chen ZF, Zhang JH. No association of the matrix metalloproteinase 1 promoter polymorphism with susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in northern China. World J Gastroenterol 2005; 11(16): 2385-2389 [PMID: 15832405 DOI: 10.3748/wjg.v11.i16.2385] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
137 van Zoonen M, van Oijen MG, van Leeuwen MS, van Hillegersberg R, Siersema PD, Vleggaar FP. Low impact of staging EUS for determining surgical resectability in esophageal cancer. Surg Endosc. 2012;26:2828-2834. [PMID: 22692460 DOI: 10.1007/s00464-012-2254-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
138 Jackson C, Starling N, Chua YJ, Cunningham D. Pharmacotherapy for oesophagogastric cancer. Drugs 2007;67:2539-56. [PMID: 18034590 DOI: 10.2165/00003495-200767170-00006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
139 Kerroucha R, Hervieu V, Chambonnière M, Mège-lechevallier F, Poncet G, Boulez J, Tanière P, Scoazec J. Adénocarcinomes de l’estomac et de l’œsophage distal. Annales de Pathologie 2004;24:228-35. [DOI: 10.1016/s0242-6498(04)93957-0] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
140 Carneiro F, Moutinho C, Pera G, Caldas C, Fenger C, Offerhaus J, Save V, Stenling R, Nesi G, Mahlke U, Bläker H, Torrado J, Roukos DH, Sabourin J, Boeing H, Palli D, Bueno-de-mesquita HB, Overvad K, Bingham S, Clavel-chapelon F, Lund E, Trichopoulou A, Manjer J, Riboli E, Gonzalez CA. Pathology findings and validation of gastric and esophageal cancer cases in a European cohort (EPIC/EUR-GAST). Scandinavian Journal of Gastroenterology 2009;42:618-27. [DOI: 10.1080/00365520601101641] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
141 Monges G. Adénocarcinomes du bas œsophage. Adénocarcinomes du cardia. Cancer/Radiothérapie 2001;5:80s-3s. [DOI: 10.1016/s1278-3218(01)80011-1] [Reference Citation Analysis]
142 Hayakawa Y, Sethi N, Sepulveda AR, Bass AJ, Wang TC. Oesophageal adenocarcinoma and gastric cancer: should we mind the gap? Nat Rev Cancer. 2016;16:305-318. [PMID: 27112208 DOI: 10.1038/nrc.2016.24] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 13.6] [Reference Citation Analysis]
143 Tang LH, Klimstra DS. Barrett's esophagus and adenocarcinoma of the gastroesophageal junction: a pathologic perspective. Surg Oncol Clin N Am 2006;15:715-32. [PMID: 17030269 DOI: 10.1016/j.soc.2006.07.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
144 Tanière P, Martel-Planche G, Maurici D, Lombard-Bohas C, Scoazec JY, Montesano R, Berger F, Hainaut P. Molecular and clinical differences between adenocarcinomas of the esophagus and of the gastric cardia. Am J Pathol. 2001;158:33-40. [PMID: 11141476 DOI: 10.1016/s0002-9440(10)63941-7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
145 Liu CT, Hong CQ, Huang XC, Li EM, Xu YW, Peng YH. Blood-based Markers in the Prognostic Prediction of Esophagogastric Junction Cancer. J Cancer 2020;11:4332-42. [PMID: 32489452 DOI: 10.7150/jca.44545] [Reference Citation Analysis]
146 Geh JI, Crellin AM, Glynne-Jones R. Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer. Br J Surg. 2001;88:338-356. [PMID: 11260097 DOI: 10.1046/j.1365-2168.2001.01670.x] [Cited by in Crossref: 145] [Cited by in F6Publishing: 130] [Article Influence: 6.9] [Reference Citation Analysis]
147 Schulz C, Kullmann F, Kunzmann V, Fuchs M, Geissler M, Vehling-Kaiser U, Stauder H, Wein A, Al-Batran SE, Kubin T. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors. Int J Cancer. 2015;137:678-685. [PMID: 25530271 DOI: 10.1002/ijc.29403] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 7.1] [Reference Citation Analysis]
148 Guo W, Dong Z, Guo Y, Shen S, Guo X, Kuang G, Yang Z. Decreased expression and frequent promoter hypermethylation of RASSF2 and RASSF6 correlate with malignant progression and poor prognosis of gastric cardia adenocarcinoma. Mol Carcinog 2016;55:1655-66. [PMID: 26456015 DOI: 10.1002/mc.22416] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
149 Fukuchi M, Mochiki E, Ishiguro T, Saito K, Naitoh H, Kumagai Y, Ishibashi K, Ishida H. Prognostic Impact of Splenectomy in Patients with Esophagogastric Junction Carcinoma. In Vivo 2018;32:145-9. [PMID: 29275312 DOI: 10.21873/invivo.11217] [Reference Citation Analysis]
150 Jain S, Dhingra S. Pathology of esophageal cancer and Barrett's esophagus. Ann Cardiothorac Surg. 2017;6:99-109. [PMID: 28446998 DOI: 10.21037/acs.2017.03.06] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
151 Wagh MS, Mathew AP, Veerabhadran B, Muralee M, Rahuman SA, George PS, Chandramohan K. Validation of Malayalam Translation of the European Organization for the Research and Treatment of Cancer Quality of Life Instrument OG25 for Esophagogastric Junction Cancers. Indian J Palliat Care 2020;26:295-301. [PMID: 33311869 DOI: 10.4103/IJPC.IJPC_135_19] [Reference Citation Analysis]
152 Guo W, Dong Z, Guo Y, Kuang G, Yang Z, Chen Z. Detection of promoter hypermethylation of the CpG island of E-cadherin in gastric cardiac adenocarcinoma. Eur J Med Res 2009;14:453-8. [PMID: 19748854 DOI: 10.1186/2047-783x-14-10-453] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
153 Dolan K, Sutton R, Walker SJ, Morris AI, Campbell F, Williams EM. New classification of oesophageal and gastric carcinomas derived from changing patterns in epidemiology. Br J Cancer. 1999;80:834-842. [PMID: 10360663 DOI: 10.1038/sj.bjc.6690429] [Cited by in Crossref: 90] [Cited by in F6Publishing: 88] [Article Influence: 3.9] [Reference Citation Analysis]
154 Ouattara M, D'journo XB, Loundou A, Trousse D, Dahan L, Doddoli C, Seitz JF, Thomas P. Body mass index kinetics and risk factors of malnutrition one year after radical oesophagectomy for cancer. European Journal of Cardio-Thoracic Surgery 2012;41:1088-93. [DOI: 10.1093/ejcts/ezr182] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
155 Zhang WH, Chen XZ, Liu K, Anil K, Yang K, Chen JP, Zhou ZG, Hu JK. Comparison of the clinicopathological characteristics and the survival outcomes between the Siewert type II/III adenocarcinomas. Med Oncol. 2014;31:116. [PMID: 25023054 DOI: 10.1007/s12032-014-0116-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
156 Giacopuzzi S, Bencivenga M, Weindelmayer J, Verlato G, de Manzoni G. Western strategy for EGJ carcinoma. Gastric Cancer. 2017;20:60-68. [PMID: 28039533 DOI: 10.1007/s10120-016-0685-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.7] [Reference Citation Analysis]
157 Kutup A, Yekebas EF, Izbicki JR. Current diagnosis and future impact of micrometastases for therapeutic strategies in adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results Cancer Res 2010;182:115-25. [PMID: 20676876 DOI: 10.1007/978-3-540-70579-6_10] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
158 Sendler A. Metabolic response evaluation by PET during neoadjuvant treatment for adenocarcinoma of the esophagus and esophagogastric junction. Recent Results Cancer Res 2010;182:167-77. [PMID: 20676880 DOI: 10.1007/978-3-540-70579-6_14] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
159 Nakamura M, Iwahashi M, Nakamori M, Naka T, Ojima T, Iida T, Katsuda M, Tsuji T, Hayata K, Mastumura S, Yamaue H. Lower Mediastinal Lymph Node Metastasis is an Independent Survival Factor of Siewert Type II and III Adenocarcinomas in the Gastroesophageal Junction. The American Surgeon 2012;78:567-73. [DOI: 10.1177/000313481207800539] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
160 Rosa F, Alfieri S, Tortorelli AP, Fiorillo C, Costamagna G, Doglietto GB. Trends in clinical features, postoperative outcomes, and long-term survival for gastric cancer: a Western experience with 1,278 patients over 30 years. World J Surg Oncol. 2014;12:217. [PMID: 25030691 DOI: 10.1186/1477-7819-12-217] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
161 Lagarde SM, Cense HA, Hulscher JB, Tilanus HW, Ten Kate FJ, Obertop H, van Lanschot JJ. Prospective analysis of patients with adenocarcinoma of the gastric cardia and lymph node metastasis in the proximal field of the chest. Br J Surg 2005;92:1404-8. [PMID: 16127682 DOI: 10.1002/bjs.5138] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
162 Dassen AE, Dikken JL, van de Velde CJ, Wouters MW, Bosscha K, Lemmens VE. Changes in treatment patterns and their influence on long-term survival in patients with stages I-III gastric cancer in The Netherlands. Int J Cancer. 2013;133:1859-1866. [PMID: 23564267 DOI: 10.1002/ijc.28192] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
163 Wijetunge S, Ma Y, DeMeester S, Hagen J, DeMeester T, Chandrasoma P. Association of adenocarcinomas of the distal esophagus, “gastroesophageal junction,” and “gastric cardia” with gastric pathology. Am J Surg Pathol. 2010;34:1521-1527. [PMID: 20871225 DOI: 10.1097/pas.0b013e3181eff133] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
164 Piso P, Werner U, Lang H, Mirena P, Klempnauer J. Proximal versus distal gastric carcinoma--what are the differences? Ann Surg Oncol 2000;7:520-5. [PMID: 10947021 DOI: 10.1007/s10434-000-0520-0] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 1.9] [Reference Citation Analysis]
165 Liu K, Zhang W, Chen X, Chen X, Yang K, Zhang B, Chen Z, Zhou Z, Hu J. Comparison on Clinicopathological Features and Prognosis Between Esophagogastric Junctional Adenocarcinoma (Siewert II/III Types) and Distal Gastric Adenocarcinoma: Retrospective Cohort Study, a Single Institution, High Volume Experience in China. Medicine (Baltimore). 2015;94:e1386. [PMID: 26313779 DOI: 10.1097/md.0000000000001386] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
166 Rutegård M, Lagergren P, Rouvelas I, Mason R, Lagergren J. Surgical complications and long-term survival after esophagectomy for cancer in a nationwide Swedish cohort study. Eur J Surg Oncol 2012;38:555-61. [PMID: 22483704 DOI: 10.1016/j.ejso.2012.02.177] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 6.8] [Reference Citation Analysis]
167 Chandrasoma P, Wickramasinghe K, Ma Y, DeMeester T. Adenocarcinomas of the distal esophagus and "gastric cardia" are predominantly esophageal carcinomas. Am J Surg Pathol. 2007;31:569-575. [PMID: 17414104 DOI: 10.1097/01.pas.0000213394.34451.d2] [Cited by in Crossref: 71] [Cited by in F6Publishing: 51] [Article Influence: 4.7] [Reference Citation Analysis]
168 Stein HJ, Siewert J. Surgical approach to adenocarcinoma of the gastric cardia. Operative Techniques in General Surgery 2003;5:14-22. [DOI: 10.1053/otgn.2003.35355] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
169 Zhang HD, Tang P, Duan XF, Chen CG, Ma Z, Gao YY, Zhang H, Yu ZT. Extranodal metastasis is a powerful prognostic factor in patients with adenocarcinoma of the esophagogastric junction. J Surg Oncol 2013;108:542-9. [PMID: 24018956 DOI: 10.1002/jso.23430] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
170 Pühringer-Oppermann F, Stahl M, Keller G, Sarbia M. Lack of prognostic impact of p53 gene mutation and p53 phosphorylation at serine 15 in multimodally treated adenocarcinomas of the gastroesophageal junction. J Cancer Res Clin Oncol 2006;132:433-8. [PMID: 16538517 DOI: 10.1007/s00432-006-0085-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
171 Matsumoto S, Takayama T, Wakatsuki K, Enomoto K, Tanaka T, Migita K, Ito M, Nakajima Y. Surgical Outcomes for Cancer at the Gastroesophageal Junction. The American Surgeon 2012;78:1285-91. [DOI: 10.1177/000313481207801140] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
172 von Rahden BH, Kircher S, Lazariotou M, Reiber C, Stuermer L, Otto C, Germer CT, Grimm M. LgR5 expression and cancer stem cell hypothesis: clue to define the true origin of esophageal adenocarcinomas with and without Barrett's esophagus? J Exp Clin Cancer Res. 2011;30:23. [PMID: 21345220 DOI: 10.1186/1756-9966-30-23] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 3.5] [Reference Citation Analysis]
173 Maru DM, Luthra R, Correa AM, White-Cross J, Anandasabapathy S, Krishnan S, Guha S, Komaki R, Swisher SG, Ajani JA, Hofstetter WL, Rashid A. Frequent loss of heterozygosity of chromosome 1q in esophageal adenocarcinoma: loss of chromosome 1q21.3 is associated with shorter overall survival. Cancer 2009;115:1576-85. [PMID: 19156915 DOI: 10.1002/cncr.24122] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
174 Shim HJ, Yun JY, Hwang JE, Bae WK, Cho SH, Chung IJ. Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer. Gastric Cancer 2011;14:249-56. [PMID: 21431297 DOI: 10.1007/s10120-011-0032-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
175 Jovanović I, Todorović V, Milosavljević T, Micev M, Pesko P, Bjelović M, Mouzas Y, Tzardi M. Expression of p53 protein in Barrett's adenocarcinoma and adenocarcinoma of the gastric cardia and antrum. Vojnosanit Pregl 2005;62:879-85. [PMID: 16375215 DOI: 10.2298/vsp0512879j] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
176 von Rahden BH, Feith M, Stein HJ. Carcinoma of the cardia: classification as esophageal or gastric cancer? Int J Colorectal Dis. 2005;20:89-93. [PMID: 15688098 DOI: 10.1007/s00384-004-0646-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.2] [Reference Citation Analysis]
177 Westerterp M, Koppert LB, Buskens CJ, Tilanus HW, ten Kate FJ, Bergman JJ, Siersema PD, van Dekken H, van Lanschot JJ. Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction. Virchows Arch. 2005;446:497-504. [PMID: 15838647 DOI: 10.1007/s00428-005-1243-1] [Cited by in Crossref: 234] [Cited by in F6Publishing: 195] [Article Influence: 13.8] [Reference Citation Analysis]
178 Chen L, Tang K, Wang S, Chen D, Ding K. Predictors of Lymph Node Metastasis in Siewert Type II T1 Adenocarcinoma of the Esophagogastric Junction: A Population-Based Study. Cancer Control 2021;28:10732748211026668. [PMID: 34155922 DOI: 10.1177/10732748211026668] [Reference Citation Analysis]
179 Pastina M, Menna C, Andreetti C, Ibrahim M. The esophagogastric junctional adenocarcinoma an increasing disease. J Thorac Dis 2017;9:1455-8. [PMID: 28740657 DOI: 10.21037/jtd.2017.05.70] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
180 Parry K, Haverkamp L, Bruijnen RC, Siersema PD, Offerhaus GJ, Ruurda JP, van Hillegersberg R. Staging of adenocarcinoma of the gastroesophageal junction. Eur J Surg Oncol. 2016;42:400-406. [PMID: 26777127 DOI: 10.1016/j.ejso.2015.11.014] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
181 Lee LH, MacLean AR, Falck VG, Gui X. Ileocaecal junction carcinoma: a clinicopathological study of 199 cases. Colorectal Dis 2015;17:O1-9. [PMID: 25160770 DOI: 10.1111/codi.12760] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
182 Heye T, Kuntz C, Düx M, Encke J, Palmowski M, Autschbach F, Volke F, Kauffmann GW, Grenacher L. New coil concept for endoluminal MR imaging: initial results in staging of gastric carcinoma in correlation with histopathology. Eur Radiol 2006;16:2401-9. [PMID: 16733675 DOI: 10.1007/s00330-006-0318-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
183 Parry K, Haverkamp L, Bruijnen RC, Siersema PD, Ruurda JP, van Hillegersberg R. Surgical treatment of adenocarcinomas of the gastro-esophageal junction. Ann Surg Oncol. 2015;22:597-603. [PMID: 25190126 DOI: 10.1245/s10434-014-4047-1] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
184 Enzinger PC, Burtness BA, Niedzwiecki D, Ye X, Douglas K, Ilson DH, Villaflor VM, Cohen SJ, Mayer RJ, Venook A, Benson AB, Goldberg RM. CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. J Clin Oncol. 2016;34:2736-2742. [PMID: 27382098 DOI: 10.1200/jco.2015.65.5092] [Cited by in Crossref: 49] [Cited by in F6Publishing: 31] [Article Influence: 8.2] [Reference Citation Analysis]
185 Yang K, Chen HN, Chen XZ, Lu QC, Pan L, Liu J, Dai B, Zhang B, Chen ZX, Chen JP, Hu JK. Transthoracic resection versus non-transthoracic resection for gastroesophageal junction cancer: a meta-analysis. PLoS One 2012;7:e37698. [PMID: 22675487 DOI: 10.1371/journal.pone.0037698] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
186 Ze-Long Y, Guo-Hui M, Lin Z, Wei-Hong Y, Ke-Cheng Z, Yan-Wen J. Survival Trends of Patients With Surgically Resected Gastric Cardia Cancer From 1988 to 2015: A Population-based Study in the United States. Am J Clin Oncol. 2019;42:581-587. [PMID: 31157623 DOI: 10.1097/coc.0000000000000558] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
187 Schröder W, Lambertz R, van Hillegesberger R, Bruns C. [Differentiated surgical approach for adenocarcinoma of the gastroesophageal junction]. Chirurg 2017;88:1010-6. [PMID: 29098306 DOI: 10.1007/s00104-017-0544-7] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
188 Chen K, Deng X, Yang Z, Yu D, Zhang X, Zhang J, Xie D, He Z, Cheng D. Survival nomogram for patients with metastatic siewert type II adenocarcinoma of the esophagogastric junction: a population-based study. Expert Rev Gastroenterol Hepatol 2020;14:757-64. [PMID: 32552040 DOI: 10.1080/17474124.2020.1784726] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
189 Peng J, Wang W, Yuan Y, Hu Y, Wang Y, Chen L. Optimal Extent of Lymph Node Dissection for Siewert Type II Esophagogastric Junction Adenocarcinoma. The Annals of Thoracic Surgery 2015;100:263-9. [DOI: 10.1016/j.athoracsur.2015.02.075] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
190 Kyriazanos I, Tachibana M, Yoshimura H, Kinugasa S, Dhar D, Nagasue N. Impact of splenectomy on the early outcome after oesophagectomy for squamous cell carcinoma of the oesophagus. European Journal of Surgical Oncology (EJSO) 2002;28:113-9. [DOI: 10.1053/ejso.2001.1235] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
191 Schuhmacher CP, Fink U, Becker K, Busch R, Dittler H, Mueller J, Siewert JR. Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxirubicin, and cisplatinum: Closing results after 5 years of follow-up. Cancer 2001;91:918-27. [DOI: 10.1002/1097-0142(20010301)91:5<918::aid-cncr1081>3.0.co;2-w] [Reference Citation Analysis]
192 Wang KL, Wu TT, Choi IS, Wang H, Resetkova E, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Albarracin CT. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer 2007;109:658-67. [PMID: 17211865 DOI: 10.1002/cncr.22445] [Cited by in Crossref: 135] [Cited by in F6Publishing: 133] [Article Influence: 9.0] [Reference Citation Analysis]
193 Stein HJ, Sendler A, Fink U, Siewert JR. Multidisciplinary approach to esophageal and gastric cancer. Surg Clin North Am. 2000;80:659-682; discussions 683-686. [PMID: 10836011 DOI: 10.1016/s0039-6109(05)70205-x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
194 Hauser C, Patett C, von Schoenfels W, Heits N, Schafmayer C, Malchow B, Hampe J, Schniewind B, Becker T, Egberts J. Does neoadjuvant treatment before oncologic esophagectomy affect the postoperative quality of life? A prospective, longitudinal outcome study: Postoperative quality of life. Dis Esophagus 2015;28:652-9. [DOI: 10.1111/dote.12257] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
195 van Blankenstein M, Looman CW, Hop WC, Bytzer P. The incidence of adenocarcinoma and squam-ous cell carcinoma of the esophagus: Barrett's esopha-gus makes a difference. Am J Gastroenterol. 2005;100:766-774. [PMID: 15784017 DOI: 10.1111/j.1572-0241.2005.40790.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
196 Okabayashi T, Gotoda T, Kondo H, Inui T, Ono H, Saito D, Yoshida S, Sasako M, Shimoda T. Early carcinoma of the gastric cardia in Japan: Is it different from that in the West? Cancer 2000;89:2555-9. [DOI: 10.1002/1097-0142(20001215)89:12<2555::aid-cncr6>3.0.co;2-r] [Cited by in Crossref: 70] [Article Influence: 3.2] [Reference Citation Analysis]
197 Rutegård M, Lagergren J, Rouvelas I, Lagergren P. Surgeon Volume is a Poor Proxy for Skill in Esophageal Cancer Surgery. Annals of Surgery 2009;249:256-61. [DOI: 10.1097/sla.0b013e318194d1a5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
198 Zhang X, Patil D, Odze RD, Zhao L, Lisovsky M, Guindi M, Riddell R, Bellizzi A, Yantiss RK, Nalbantoglu I, Appelman HD. The microscopic anatomy of the esophagus including the individual layers, specialized tissues, and unique components and their responses to injury. Ann N Y Acad Sci 2018;1434:304-18. [DOI: 10.1111/nyas.13705] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
199 Dresner SM, Wayman J, Griffin SM. Authors' reply. British Journal of Surgery 1999;86:1589-90. [DOI: 10.1046/j.1365-2168.1999.01309-6.x] [Reference Citation Analysis]
200 Suzuki A, Xiao L, Hayashi Y, Macapinlac HA, Welsh J, Lin SH, Lee JH, Bhutani MS, Maru DM, Hofstetter WL, Swisher SG, Ajani JA. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer 2011;117:4823-33. [PMID: 21456015 DOI: 10.1002/cncr.26122] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 5.5] [Reference Citation Analysis]
201 Davies AR, Zylstra J, Baker CR, Gossage JA, Dellaportas D, Lagergren J, Findlay JM, Puccetti F, El Lakis M, Drummond RJ, Dutta S, Mera A, Van Hemelrijck M, Forshaw MJ, Maynard ND, Allum WH, Low D, Mason RC. A comparison of the left thoracoabdominal and Ivor–Lewis esophagectomy. Diseases of the Esophagus 2018;31:dox129. [DOI: 10.1093/dote/dox129] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
202 Grosser B, Glückstein MI, Dhillon C, Schiele S, Dintner S, VanSchoiack A, Kroeppler D, Martin B, Probst A, Vlasenko D, Schenkirsch G, Märkl B. Stroma AReactive Invasion Front Areas (SARIFA) - a new prognostic biomarker in gastric cancer related to tumor-promoting adipocytes. J Pathol 2021. [PMID: 34580877 DOI: 10.1002/path.5810] [Reference Citation Analysis]
203 Wayman J, Bennett MK, Raimes SA, Griffin SM. The pattern of recurrence of adenocarcinoma of the oesophago-gastric junction. Br J Cancer. 2002;86:1223-1229. [PMID: 11953876 DOI: 10.1038/sj.bjc.6600252] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 3.1] [Reference Citation Analysis]
204 Mirza A, Naveed A, Hayes S, Formela L, Welch I, West CM, Pritchard S. Assessment of Histopathological Response in Gastric and Gastro-Oesophageal Junction Adenocarcinoma following Neoadjuvant Chemotherapy: Which Scoring System to Use? ISRN Pathology 2012;2012:1-8. [DOI: 10.5402/2012/519351] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
205 Xu Y, Man X, Lv Z, Li D, Sun Z, Chen H, Wang Z, Luo Y, Xu H. Loss of heterozygosity at chromosomes 1p35-pter, 4q, and 18q and protein expression differences between adenocarcinomas of the distal stomach and gastric cardia. Human Pathology 2012;43:2308-17. [DOI: 10.1016/j.humpath.2012.01.024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
206 Gretschel S, Schlag PM. Current Status of Sentinel Lymph Node Biopsy in Adenocarcinoma of the Distal Esophagus, Gastric Cardia, and Proximal Stomach. In: Schneider PM, editor. Adenocarcinoma of the Esophagogastric Junction. Berlin: Springer Berlin Heidelberg; 2010. pp. 107-14. [DOI: 10.1007/978-3-540-70579-6_9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
207 Monti M, Massa I, Foca F, Morgagni P, Framarini M, Passardi A, Falcini F, Frassineti GL. Retrospective analysis of gastric cancer management in a real-world setting: a single-institution experience. Tumori 2020;106:165-71. [PMID: 32167020 DOI: 10.1177/0300891620910488] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
208 van den Boorn HG, Stroes CI, Zwinderman AH, Eshuis WJ, Hulshof MCCM, van Etten-Jamaludin FS, Sprangers MAG, van Laarhoven HWM. Health-related quality of life in curatively-treated patients with esophageal or gastric cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2020;154:103069. [PMID: 32818901 DOI: 10.1016/j.critrevonc.2020.103069] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
209 Law S, Wong J. Esophageal cancer: . Current Opinion in Gastroenterology 2001;17:393-9. [DOI: 10.1097/00001574-200107000-00016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
210 Morgan E, Soerjomataram I, Gavin AT, Rutherford MJ, Gatenby P, Bardot A, Ferlay J, Bucher O, De P, Engholm G, Jackson C, Kozie S, Little A, Møller B, Shack L, Tervonen H, Thursfield V, Vernon S, Walsh PM, Woods RR, Finley C, Merrett N, O'Connell DL, Reynolds JV, Bray F, Arnold M. International trends in oesophageal cancer survival by histological subtype between 1995 and 2014. Gut 2021;70:234-42. [PMID: 32554620 DOI: 10.1136/gutjnl-2020-321089] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
211 van der Werf LR, Cords C, Arntz I, Belt EJT, Cherepanin IM, Coene PLO, van der Harst E, Heisterkamp J, Langenhoff BS, Lamme B, van Berge Henegouwen MI, Lagarde SM, Wijnhoven BPL. Population-Based Study on Risk Factors for Tumor-Positive Resection Margins in Patients with Gastric Cancer. Ann Surg Oncol 2019;26:2222-33. [PMID: 31011900 DOI: 10.1245/s10434-019-07381-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
212 Griffin SM, Burt AD, Jennings NA. Lymph node metastasis in early esophageal adenocarcinoma. Ann Surg. 2011;254:731-776; discussion 731-776. [PMID: 21997815 DOI: 10.1097/sla.0b013e318236048b] [Cited by in Crossref: 46] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
213 Shearer CJ, Going JJ, Neilson LJ, Stuart RC. MODIFIED CLASSIFICATION FOR ADENOCARCINOMA OF THE GASTRO-OESOPHAGEAL JUNCTION. ANZ J Surg 2007;77:544-9. [DOI: 10.1111/j.1445-2197.2007.04147.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
214 Pedrazzani C, de Manzoni G, Marrelli D, Giacopuzzi S, Corso G, Minicozzi AM, Rampone B, Roviello F. Lymph node involvement in advanced gastroesophageal junction adenocarcinoma. J Thorac Cardiovasc Surg. 2007;134:378-385. [PMID: 17662776 DOI: 10.1016/j.jtcvs.2007.03.034] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 3.1] [Reference Citation Analysis]
215 Lord RVN. Genetic Basis of the Barrett???s Metaplasia, Dysplasia, Adenocarcinoma Sequence: . Problems in General Surgery 2001;18:53-70. [DOI: 10.1097/00013452-200106000-00008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
216 Zhang L, Du C, Guo X, Yuan L, Niu W, Yu W, Er L, Wang S. Interleukin-8-251A/T polymorphism and Helicobacter pylori infection influence risk for the development of gastric cardiac adenocarcinoma in a high-incidence area of China. Mol Biol Rep 2010;37:3983-9. [DOI: 10.1007/s11033-010-0057-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
217 Giganti F, Orsenigo E, Esposito A, Chiari D, Salerno A, Ambrosi A, Albarello L, Mazza E, Staudacher C, Del Maschio A. Prognostic role of diffusion-weighted MR imaging for resectable gastric cancer. Radiology. 2015;276:444-452. [PMID: 25816106 DOI: 10.1148/radiol.15141900] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
218 Lin X, Li Z, Tan C, Ye X, Xiong J, Liu J, Mo A, Shi Y, Qian F, Yu P, Zhao Y. Survival Benefit of Pyloric Lymph Node Dissection for Siewert Type II/III Adenocarcinoma of the Esophagogastric Junction Based on Tumor Diameter: A Large Cohort Study. Front Oncol 2021;11:748694. [PMID: 34926257 DOI: 10.3389/fonc.2021.748694] [Reference Citation Analysis]
219 Reim D, Novotny A, Friess H, Slotta-Huspenina J, Weichert W, Ott K, Dislich B, Lorenzen S, Becker K, Langer R. Significance of tumour regression in lymph node metastases of gastric and gastro-oesophageal junction adenocarcinomas. J Pathol Clin Res 2020;6:263-72. [PMID: 32401432 DOI: 10.1002/cjp2.169] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
220 Wang S, Chen L, Chen D, Chao J, Shao Y, Tang K, Chen W. Effect of Marital Status on the Survival of Patients With Adenocarcinoma of the Esophagogastric Junction: A Population-Based, Propensity-Matched Study. Cancer Control 2021;28:10732748211066309. [PMID: 34910613 DOI: 10.1177/10732748211066309] [Reference Citation Analysis]
221 Mawhinney MR, Glasgow RE. Current treatment options for the management of esophageal cancer. Cancer Manag Res 2012;4:367-77. [PMID: 23152702 DOI: 10.2147/CMAR.S27593] [Cited by in Crossref: 4] [Cited by in F6Publishing: 13] [Article Influence: 0.4] [Reference Citation Analysis]
222 Derogar M, Lagergren P. Health-related quality of life among 5-year survivors of esophageal cancer surgery: a prospective population-based study. J Clin Oncol 2012;30:413-8. [PMID: 22215745 DOI: 10.1200/JCO.2011.38.9791] [Cited by in Crossref: 75] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
223 Berger B, Belka C. Evidence-based radiation oncology: oesophagus. Radiother Oncol 2009;92:276-90. [PMID: 19375187 DOI: 10.1016/j.radonc.2009.02.019] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 3.6] [Reference Citation Analysis]
224 Ajani JA, Lee J, Sano T, Janjigian YY, Fan D, Song S. Gastric adenocarcinoma. Nat Rev Dis Primers. 2017;3:17036. [PMID: 28569272 DOI: 10.1038/nrdp.2017.36] [Cited by in Crossref: 178] [Cited by in F6Publishing: 184] [Article Influence: 35.6] [Reference Citation Analysis]
225 Hasegawa S, Yoshikawa T. Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies. Gastric Cancer 2010;13:63-73. [DOI: 10.1007/s10120-010-0555-2] [Cited by in Crossref: 76] [Cited by in F6Publishing: 78] [Article Influence: 6.3] [Reference Citation Analysis]
226 Akashi Y, Noguchi T, Nagai K, Kawahara K, Shimada T. Cytoarchitecture of the lamina muscularis mucosae and distribution of the lymphatic vessels in the human stomach. Med Mol Morphol. 2011;44:39-45. [PMID: 21424936 DOI: 10.1007/s00795-010-0503-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
227 Siewert J, Stein H, Sendler A, Fink U. Surgical resection for cancer of the cardia. Semin Surg Oncol 1999;17:125-31. [DOI: 10.1002/(sici)1098-2388(199909)17:2<125::aid-ssu7>3.0.co;2-9] [Cited by in Crossref: 54] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
228 Gockel I, Lorenz D. [Oncologic esophageal resection and reconstruction : Open, hybrid, minimally invasive or robotic?]. Chirurg 2017;88:496-502. [PMID: 28058494 DOI: 10.1007/s00104-016-0364-1] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
229 Tan BH, Brammer K, Randhawa N, Welch NT, Parsons SL, James EJ, Catton JA. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. Eur J Surg Oncol. 2015;41:333-338. [PMID: 25498359 DOI: 10.1016/j.ejso.2014.11.040] [Cited by in Crossref: 140] [Cited by in F6Publishing: 139] [Article Influence: 17.5] [Reference Citation Analysis]
230 Stein HJ, Sendler A, Siewert JR. Site-dependent resection techniques for gastric cancer. Surg Oncol Clin N Am. 2002;11:405-414. [PMID: 12424859 DOI: 10.1016/s1055-3207(02)00017-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
231 Deans DA, Wigmore SJ, Gilmour H, Paterson-Brown S, Ross JA, Fearon KC. Elevated tumour interleukin-1beta is associated with systemic inflammation: A marker of reduced survival in gastro-oesophageal cancer. Br J Cancer. 2006;95:1568-1575. [PMID: 17088911 DOI: 10.1038/sj.bjc.6603446] [Cited by in Crossref: 77] [Cited by in F6Publishing: 75] [Article Influence: 4.8] [Reference Citation Analysis]
232 Tang A, Sohal D, McNamara M, Murthy SC, Raja S. Siewert III Adenocarcinoma: Still Searching for the Right Treatment Combination. Surg Oncol Clin N Am 2020;29:647-53. [PMID: 32883464 DOI: 10.1016/j.soc.2020.07.002] [Reference Citation Analysis]
233 Mariette C, Castel B, Toursel H, Fabre S, Balon JM, Triboulet JP. Surgical management of and long-term survival after adenocarcinoma of the cardia. Br J Surg. 2002;89:1156-1163. [PMID: 12190682 DOI: 10.1046/j.1365-2168.2002.02185.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 65] [Article Influence: 3.7] [Reference Citation Analysis]
234 Rausei S, Ruspi L, Galli F, Pappalardo V, Di Rocco G, Martignoni F, Frattini F, Rovera F, Boni L, Dionigi G. Seventh tumor-node-metastasis staging of gastric cancer: Five-year follow-up. World J Gastroenterol 2016; 22(34): 7748-7753 [PMID: 27678357 DOI: 10.3748/wjg.v22.i34.7748] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
235 Voron T, Gronnier C, Pasquer A, Thereaux J, Gagniere J, Lebreton G, Meunier B, Collet D, Piessen G, Paye F; FREGAT working group - FRENCH. Adenocarcinoma of the oesophagogastric junction Siewert II: An oesophageal cancer better cured with total gastrectomy. Eur J Surg Oncol 2019;45:2473-81. [PMID: 31350076 DOI: 10.1016/j.ejso.2019.07.022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
236 Dassen AE, Bernards N, Lemmens VE, Wouw YAV, Bosscha K, Creemers GJ, Pruijt HJ. Phase II study of docetaxel, cisplatin and capecitabine as preoperative chemotherapy in resectable gastric cancer. World J Gastrointest Surg 2016; 8(10): 706-712 [PMID: 27830043 DOI: 10.4240/wjgs.v8.i10.706] [Reference Citation Analysis]
237 Busquets S, Deans C, Figueras M, Moore-Carrasco R, López-Soriano FJ, Fearon KC, Argilés JM. Apoptosis is present in skeletal muscle of cachectic gastro-intestinal cancer patients. Clin Nutr 2007;26:614-8. [PMID: 17688974 DOI: 10.1016/j.clnu.2007.06.005] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 3.1] [Reference Citation Analysis]
238 Bugiantella W, Rondelli F, Mariani L, Mariani E. Laparoscopic circular stapled longitudinal extramucosal pyloroplasty: an alternative technique for pyloric disruption. Interact Cardiovasc Thorac Surg 2015;21:143-6. [PMID: 25977132 DOI: 10.1093/icvts/ivv116] [Cited by in Crossref: 4] [Article Influence: 0.6] [Reference Citation Analysis]
239 Karstens KF, Stüben BO, Reeh M. Oesophageal Adenocarcinomas: Where Do We Stand Today? Cancers (Basel) 2020;13:E109. [PMID: 33396388 DOI: 10.3390/cancers13010109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
240 Roedl JB, Prabhakar HB, Mueller PR, Colen RR, Blake MA. Prediction of Metastatic Disease and Survival in Patients with Gastric and Gastroesophageal Junction Tumors. Academic Radiology 2009;16:218-26. [DOI: 10.1016/j.acra.2008.06.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
241 Guo W, Dong Z, Liu S, Qiao Y, Kuang G, Guo Y, Shen S, Liang J. Promoter hypermethylation-mediated downregulation of miR-770 and its host gene MEG3, a long non-coding RNA, in the development of gastric cardia adenocarcinoma. Mol Carcinog. 2017;56:1924-1934. [PMID: 28345805 DOI: 10.1002/mc.22650] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 5.6] [Reference Citation Analysis]
242 Hohenberger P, Gretschel S. Gastric cancer. Lancet. 2003;362:305-315. [PMID: 12892963 DOI: 10.1016/s0140-6736(03)13975-x] [Cited by in Crossref: 430] [Cited by in F6Publishing: 215] [Article Influence: 22.6] [Reference Citation Analysis]
243 Jézéquel J, Bessaguet C, Verveur C, Faycal J, Richert Z, Metges JP, Volant A, Nousbaum JB, Robaszkiewicz M. Trends in incidence, management, and survival of gastric and cardia carcinomas in the area of Finistere (France) between 1984 and 2003. Eur J Gastroenterol Hepatol 2010;22:1412-9. [PMID: 21389792 DOI: 10.1097/MEG.0b013e3283408865] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
244 Lehmann K, Eshmuminov D, Bauerfeind P, Gubler C, Veit-haibach P, Weber A, Abdul-rahman H, Fischer M, Reiner C, Schneider P. 18FDG-PET-CT improves specificity of preoperative lymph-node staging in patients with intestinal but not diffuse-type esophagogastric adenocarcinoma. European Journal of Surgical Oncology (EJSO) 2017;43:196-202. [DOI: 10.1016/j.ejso.2016.08.020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
245 Schuchert MJ, Luketich JD, Landreneau RJ. Management of esophageal cancer. Curr Probl Surg 2010;47:845-946. [PMID: 20937424 DOI: 10.1067/j.cpsurg.2010.07.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
246 Casson AG, Porter GA, Veugelers PJ. Evolution and critical appraisal of anastomotic technique following resection of esophageal adenocarcinoma. Dis Esophagus. 2002;15:296-302. [PMID: 12472475 DOI: 10.1046/j.1442-2050.2002.00277.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
247 Berlth F, Hoelscher AH. History of Esophagogastric Junction Cancer Treatment and Current Surgical Management in Western Countries. J Gastric Cancer 2019;19:139-47. [PMID: 31245158 DOI: 10.5230/jgc.2019.19.e18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
248 Yang HK. Issues in the management of the upper third gastric cancer. Cancer Res Treat 2004;36:4-5. [PMID: 20396559 DOI: 10.4143/crt.2004.36.1.4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
249 Mueller JD, Stein HJ, Oyang T, Natsugoe S, Feith M, Werner M, Rüdiger Siewert J. Frequency and clinical impact of lymph node micrometastasis and tumor cell microinvolvement in patients with adenocarcinoma of the esophagogastric junction: Lymph Node Esophagogastric Junction. Cancer 2000;89:1874-82. [DOI: 10.1002/1097-0142(20001101)89:9<1874::aid-cncr2>3.0.co;2-m] [Cited by in Crossref: 9] [Article Influence: 0.4] [Reference Citation Analysis]
250 Labenz J, Koop H, Tannapfel A, Kiesslich R, Hölscher AH. The epidemiology, diagnosis, and treatment of Barrett's carcinoma. Dtsch Arztebl Int 2015;112:224-33; quiz 234. [PMID: 25869347 DOI: 10.3238/arztebl.2015.0224] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
251 Costi R, Himpens J, Bruyns J, Cadière GB. Totally laparoscopic transhiatal esophago-gastrectomy without thoracic or cervical access. The least invasive surgery for adenocarcinoma of the cardia? Surg Endosc. 2004;18:629-632. [PMID: 15026898 DOI: 10.1007/s00464-003-9053-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
252 Djärv T, Lagergren J, Blazeby JM, Lagergren P. Long-term health-related quality of life following surgery for oesophageal cancer. Br J Surg. 2008;95:1121-1126. [PMID: 18581441 DOI: 10.1002/bjs.6293] [Cited by in Crossref: 115] [Cited by in F6Publishing: 104] [Article Influence: 8.2] [Reference Citation Analysis]
253 Geddert H, Kiel S, Iskender E, Florl AR, Krieg T, Vossen S, Gabbert HE, Sarbia M. Correlation of hMLH1 and HPP1 hypermethylation in gastric, but not in esophageal and cardiac adenocarcinoma. Int J Cancer 2004;110:208-11. [PMID: 15069683 DOI: 10.1002/ijc.20058] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
254 Xu Y, Chen YN, Wang ZN, Luo Y, Xu HM. Change of Smad4 expression in gastric carcinogenesis and its clinicopathological significance. Shijie Huaren Xiaohua Zazhi 2007; 15(13): 1510-1515 [DOI: 10.11569/wcjd.v15.i13.1510] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
255 Forman D. Review article: oesophago-gastric adenocarcinoma -- an epidemiological perspective. Aliment Pharmacol Ther. 2004;20 Suppl 5:55-60; discussion 61-62. [PMID: 15456465 DOI: 10.1111/j.1365-2036.2004.02133.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
256 Al-haddad S, Chang AC, De Hertogh G, Grin A, Langer R, Sagaert X, Salemme M, Streutker CJ, Soucy G, Tripathi M, Upton MP, Vieth M, Villanacci V. Adenocarcinoma at the gastroesophageal junction: Adenocarcinoma at the gastroesophageal junction. Ann N Y Acad Sci 2014;1325:211-25. [DOI: 10.1111/nyas.12535] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
257 Zhang XF, Wang YM, Ge H, Cao YY, Chen ZF, Wen DG, Guo W, Wang N, Li Y, Zhang JH. Association of CDH1 single nucleotide polymorphisms with susceptibility to esophageal squamous cell carcinomas and gastric cardia carcinomas. Dis Esophagus. 2008;21:21-29. [PMID: 18197935 DOI: 10.1111/j.1442-2050.2007.00724.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
258 Donlon NE, Elliott JA, Donohoe CL, Murphy CF, Nugent T, Moran B, King S, Ravi N, Reynolds JV. Adverse Biology in Adenocarcinoma of the Esophagus and Esophagogastric Junction Impacts Survival and Response to Neoadjuvant Therapy Independent of Anatomic Subtype. Ann Surg 2020;272:814-9. [PMID: 32657924 DOI: 10.1097/SLA.0000000000004184] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
259 Liakakos T, Katsios C, Roukos DH. Gastroesophageal junction carcinoma multimodal treatment: standards, debate and new therapeutic options. Expert Rev Gastroenterol Hepatol 2011;5:1-4. [PMID: 21309665 DOI: 10.1586/egh.11.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
260 Kumamoto T, Kurahashi Y, Niwa H, Nakanishi Y, Okumura K, Ozawa R, Ishida Y, Shinohara H. True esophagogastric junction adenocarcinoma: background of its definition and current surgical trends. Surg Today 2020;50:809-14. [PMID: 31278583 DOI: 10.1007/s00595-019-01843-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
261 Rutegård M, Lagergren J, Rouvelas I, Lindblad M, Blazeby JM, Lagergren P. Population-based study of surgical factors in relation to health-related quality of life after oesophageal cancer resection. Br J Surg 2008;95:592-601. [PMID: 18300270 DOI: 10.1002/bjs.6021] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 3.1] [Reference Citation Analysis]
262 Bakhti SZ, Latifi-Navid S, Mohammadi S, Zahri S, Bakhti FS, Feizi F, Yazdanbod A, Siavoshi F. Relevance of Helicobacter pylori vacA 3'-end Region Polymorphism to Gastric Cancer. Helicobacter 2016;21:305-16. [PMID: 26612250 DOI: 10.1111/hel.12284] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
263 Wang J, Wang J, Song B, Dai X, Zhang X. Comparative study of laparoscopic‐assisted and open total gastrectomy for Siewert Types II and III adenocarcinoma of the esophagogastric junction. J Cell Physiol 2019;234:11235-9. [DOI: 10.1002/jcp.27777] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
264 Barbour AP, Rizk NP, Gonen M, Tang L, Bains MS, Rusch VW, Coit DG, Brennan MF. Lymphadenectomy for Adenocarcinoma of the Gastroesophageal Junction (GEJ): Impact of Adequate Staging on Outcome. Ann Surg Oncol 2007;14:306-16. [DOI: 10.1245/s10434-006-9166-x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 3.4] [Reference Citation Analysis]
265 Guo W, Dong Z, Guo Y, Lin X, Chen Z, Kuang G, Yang Z. Aberrant methylation and loss expression of RKIP is associated with tumor progression and poor prognosis in gastric cardia adenocarcinoma. Clin Exp Metastasis. 2013;30:265-275. [PMID: 22983529 DOI: 10.1007/s10585-012-9533-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
266 Amonkar SJ, Irving M, Wayman J, Sriram T, Griffin SM, Nicoll JJ, Raimes SA. The changing use of palliative chemotherapy for recurrent esophagogastric cancer: a single center retrospective 15-year review. J Gastrointest Cancer 2008;39:51-7. [PMID: 19238591 DOI: 10.1007/s12029-009-9051-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
267 Fuchs H, Hölscher AH, Leers J, Bludau M, Brinkmann S, Schröder W, Alakus H, Mönig S, Gutschow CA. Long-term quality of life after surgery for adenocarcinoma of the esophagogastric junction: extended gastrectomy or transthoracic esophagectomy? Gastric Cancer 2016;19:312-7. [PMID: 25627475 DOI: 10.1007/s10120-015-0466-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
268 Langer R, Von Rahden BH, Nahrig J, Von Weyhern C, Reiter R, Feith M, Stein HJ, Siewert JR, Höfler H, Sarbia M. Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study. J Clin Pathol 2006;59:631-4. [PMID: 16731604 DOI: 10.1136/jcp.2005.034298] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 4.3] [Reference Citation Analysis]
269 Haverkamp L, Ruurda JP, van Leeuwen MS, Siersema PD, van Hillegersberg R. Systematic review of the surgical strategies of adenocarcinomas of the gastroesophageal junction. Surg Oncol. 2014;23:222-228. [PMID: 25466852 DOI: 10.1016/j.suronc.2014.10.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
270 Moehler M, Schimanski CC, Gockel I, Junginger T, Galle PR. (Neo)adjuvant strategies of advanced gastric carcinoma: time for a change? Dig Dis 2004;22:345-50. [PMID: 15812158 DOI: 10.1159/000083597] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
271 Talsma K, van Hagen P, Grotenhuis BA, Steyerberg EW, Tilanus HW, van Lanschot JJ, Wijnhoven BP. Comparison of the 6th and 7th Editions of the UICC-AJCC TNM Classification for Esophageal Cancer. Ann Surg Oncol. 2012;19:2142-2148. [PMID: 22395974 DOI: 10.1245/s10434-012-2218-5] [Cited by in Crossref: 109] [Cited by in F6Publishing: 107] [Article Influence: 10.9] [Reference Citation Analysis]
272 Stein HJ, Feith M, Bruecher BL, Naehrig J, Sarbia M, Siewert JR. Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. Ann Surg. 2005;242:566-573; discussion 573-575. [PMID: 16192817 DOI: 10.1097/01.sla.0000184211.75970.85] [Cited by in Crossref: 67] [Cited by in F6Publishing: 156] [Article Influence: 3.9] [Reference Citation Analysis]
273 Demicco EG, Farris AB, Baba Y, Agbor-etang B, Bergethon K, Mandal R, Daives D, Fukuoka J, Shimizu M, Dias-santagata D, Ogino S, Iafrate AJ, Gaissert HA, Mino-kenudson M. The dichotomy in carcinogenesis of the distal esophagus and esophagogastric junction: intestinal-type vs cardiac-type mucosa-associated adenocarcinoma. Mod Pathol 2011;24:1177-90. [DOI: 10.1038/modpathol.2011.77] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
274 Gerbaudo VH, Killoran JH, Kim CK, Hornick JL, Nowak JA, Enzinger PC, Mamon HJ. Pilot study of serial FLT and FDG-PET/CT imaging to monitor response to neoadjuvant chemoradiotherapy of esophageal adenocarcinoma: correlation with histopathologic response. Ann Nucl Med 2018;32:165-74. [PMID: 29332233 DOI: 10.1007/s12149-018-1229-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
275 Fox MP, van Berkel V. Management of gastroesophageal junction tumors. Surg Clin North Am. 2012;92:1199-1212. [PMID: 23026278 DOI: 10.1016/j.suc.2012.07.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
276 Däster S, Soysal SD, Stoll L, Peterli R, von Flüe M, Ackermann C. Long-term quality of life after Ivor Lewis esophagectomy for esophageal cancer. World J Surg. 2014;38:2345-2351. [PMID: 24756548 DOI: 10.1007/s00268-014-2576-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
277 Yuan D, Zhu K, Li K, Yan R, Jia Y, Dang C. The preoperative neutrophil-lymphocyte ratio predicts recurrence and survival among patients undergoing R0 resections of adenocarcinomas of the esophagogastric junction. J Surg Oncol 2014;110:333-40. [PMID: 24889121 DOI: 10.1002/jso.23651] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 4.5] [Reference Citation Analysis]
278 Djärv T, Lagergren P. Six-month postoperative quality of life predicts long-term survival after oesophageal cancer surgery. Eur J Cancer 2011;47:530-5. [PMID: 21074989 DOI: 10.1016/j.ejca.2010.10.014] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 4.0] [Reference Citation Analysis]
279 Ito H, Clancy TE, Osteen RT, Swanson RS, Bueno R, Sugarbaker DJ, Ashley SW, Zinner MJ, Whang EE. Adenocarcinoma of the gastric cardia: what is the optimal surgical approach? J Am Coll Surg. 2004;199:880-886. [PMID: 15555971 DOI: 10.1016/j.jamcollsurg.2004.08.015] [Cited by in Crossref: 94] [Cited by in F6Publishing: 82] [Article Influence: 5.5] [Reference Citation Analysis]
280 Liu JF, Jiang T, Shi ZH, Liu XB. Prognostic significance of the location of metastatic lymph nodes in patients with adenocarcinoma of the oesophagogastric junction. ANZ J Surg 2018;88:218-22. [PMID: 27444989 DOI: 10.1111/ans.13663] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
281 Reynolds JV, McLaughlin R, Moore J, Rowley S, Ravi N, Byrne PJ. Prospective evaluation of quality of life in patients with localized oesophageal cancer treated by multimodality therapy or surgery alone. Br J Surg. 2006;93:1084-1090. [PMID: 16779881 DOI: 10.1002/bjs.5373] [Cited by in Crossref: 85] [Cited by in F6Publishing: 79] [Article Influence: 5.3] [Reference Citation Analysis]
282 Hong SJ, Kim TJ, Nam KB, Lee IS, Yang HC, Cho S, Kim K, Jheon S, Lee KW. New TNM staging system for esophageal cancer: what chest radiologists need to know. Radiographics 2014;34:1722-40. [PMID: 25310426 DOI: 10.1148/rg.346130079] [Cited by in Crossref: 48] [Cited by in F6Publishing: 32] [Article Influence: 6.9] [Reference Citation Analysis]
283 Davies AR, Forshaw MJ, Khan AA, Noorani AS, Patel VM, Strauss DC, Mason RC. Transhiatal esophagectomy in a high volume institution. World J Surg Oncol 2008;6:88. [PMID: 18715498 DOI: 10.1186/1477-7819-6-88] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
284 Jena S, Bhattacharya S, Gupta A, Roy S, Sinha NK. Breast metastasis from esophagogastric junction cancer: a case report. Case Rep Surg 2014;2014:489427. [PMID: 25013737 DOI: 10.1155/2014/489427] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
285 Isinger-Ekstrand A, Johansson J, Ohlsson M, Francis P, Staaf J, Jönsson M, Borg A, Nilbert M. Genetic profiles of gastroesophageal cancer: combined analysis using expression array and tiling array--comparative genomic hybridization. Cancer Genet Cytogenet. 2010;200:120-126. [PMID: 20620594 DOI: 10.1016/j.cancergencyto.2010.03.013] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
286 Siersema PD. Esophageal Cancer. Gastroenterology Clinics of North America 2008;37:943-64. [DOI: 10.1016/j.gtc.2008.09.012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
287 Wang Y, Wang S, Zhu C, Cao H, Zhang Z, Zhao E. The Association Between Immune Characteristic and Clinical Pathology in Chinese Patients with Adenocarcinoma of Esophagogastric Junction. Cancer Manag Res 2020;12:3259-69. [PMID: 32494190 DOI: 10.2147/CMAR.S235722] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
288 Chen YC, Lu L, Fan KH, Wang DH, Fu WH. Proximal gastrectomy versus total gastrectomy for adenocarcinoma of the esophagogastric junction: a meta-analysis. J Comp Eff Res 2019;8:753-66. [PMID: 31361160 DOI: 10.2217/cer-2019-0016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
289 Zhang S, Orita H, Fukunaga T. Current surgical treatment of esophagogastric junction adenocarcinoma. World J Gastrointest Oncol 2019; 11(8): 567-578 [PMID: 31435459 DOI: 10.4251/wjgo.v11.i8.567] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
290 Huguier M. [Application of a new classification of cancers of the cardia]. Chirurgie 1999;124:96-7. [PMID: 10193039 DOI: 10.1016/s0001-4001(99)80050-6] [Reference Citation Analysis]
291 Chu LY, Peng YH, Yang T, Fang WK, Hong CQ, Huang LS, Xu LY, Li EM, Xu YW, Xie JJ. Circulating Levels of L1-cell Adhesion Molecule as a Serum Biomarker for Early Detection of Gastric Cancer and Esophagogastric Junction Adenocarcinoma. J Cancer 2020;11:5395-402. [PMID: 32742486 DOI: 10.7150/jca.41100] [Reference Citation Analysis]
292 Mine S, Kurokawa Y, Takeuchi H, Kishi K, Ito Y, Ohi M, Matsuda T, Hamakawa T, Hasegawa S, Yoshikawa T, Hiki N. Distribution of involved abdominal lymph nodes is correlated with the distance from the esophagogastric junction to the distal end of the tumor in Siewert type II tumors. Eur J Surg Oncol. 2015;41:1348-1353. [PMID: 26087995 DOI: 10.1016/j.ejso.2015.05.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
293 Keeney S, Bauer TL. Epidemiology of adenocarcinoma of the esophagogastric junction. Surg Oncol Clin N Am. 2006;15:687-696. [PMID: 17030267 DOI: 10.1016/j.soc.2006.07.014] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
294 Zhang X, He XD, Zhang YC, Yang KH, Tian JH, Chen YL. Characteristics of lymph node (No.5 and No.6) metastasis and significance of lymph node dissection in Siewert type II esophagogastric junction adenocarcinoma (AEG): No.5 and No.6 lymph node metastases of AEG and clearance. Medicine (Baltimore) 2021;100:e27106. [PMID: 34477150 DOI: 10.1097/MD.0000000000027106] [Reference Citation Analysis]
295 Tamandl D, Ta J, Schmid R, Preusser M, Paireder M, Schoppmann SF, Haug A, Ba-ssalamah A. Prognostic value of volumetric PET parameters in unresectable and metastatic esophageal cancer. European Journal of Radiology 2016;85:540-5. [DOI: 10.1016/j.ejrad.2016.01.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
296 Ryan AM, Reynolds JV, Healy L, Byrne M, Moore J, Brannelly N, McHugh A, McCormack D, Flood P. Enteral nutrition enriched with eicosapentaenoic acid (EPA) preserves lean body mass following esophageal cancer surgery: results of a double-blinded randomized controlled trial. Ann Surg. 2009;249:355-363. [PMID: 19247018 DOI: 10.1097/sla.0b013e31819a4789] [Cited by in Crossref: 184] [Cited by in F6Publishing: 46] [Article Influence: 14.2] [Reference Citation Analysis]
297 Duan X, Shang X, Tang P, Jiang H, Yu Z. Lymph node dissection for Siewert II esophagogastric junction adenocarcinoma: a retrospective study of 136 cases. ANZ J Surg 2018;88:E264-7. [PMID: 28503799 DOI: 10.1111/ans.13980] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
298 Blazeby JM, Metcalfe C, Nicklin J, Barham CP, Donovan J, Alderson D. Association between quality of life scores and short-term outcome after surgery for cancer of the oesophagus or gastric cardia. Br J Surg. 2005;92:1502-1507. [PMID: 16252311 DOI: 10.1002/bjs.5175] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 3.0] [Reference Citation Analysis]
299 Zhao XK, Xing P, Song X, Zhao M, Zhao L, Dang Y, Lei LL, Xu RH, Han WL, Wang PP, Yang MM, Hu JF, Zhong K, Zhou FY, Han XN, Meng CL, Ji JJ, Chen X, Wang LD. Focal amplifications are associated with chromothripsis events and diverse prognoses in gastric cardia adenocarcinoma. Nat Commun 2021;12:6489. [PMID: 34764264 DOI: 10.1038/s41467-021-26745-3] [Reference Citation Analysis]
300 Badgwell B, Blum M, Elimova E, Estrella J, Chiang Y, Das P, Mansfield P, Ajani J. Frequency of Resection After Preoperative Chemotherapy or Chemoradiotherapy for Gastric Adenocarcinoma. Ann Surg Oncol 2016;23:1948-55. [DOI: 10.1245/s10434-016-5112-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
301 Nath J, Moorthy K, Taniere P, Hallissey M, Alderson D. Peritoneal lavage cytology in patients with oesophagogastric adenocarcinoma. Br J Surg. 2008;95:721-726. [PMID: 18412292 DOI: 10.1002/bjs.6107] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 2.6] [Reference Citation Analysis]
302 Mönig SP, Hölscher AH. Clinical classification systems of adenocarcinoma of the esophagogastric junction. Recent Results Cancer Res 2010;182:19-28. [PMID: 20676868 DOI: 10.1007/978-3-540-70579-6_2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
303 Matsuno K, Ishihara R, Ohmori M, Iwagami H, Shichijyo S, Maekawa A, Kanesaka T, Yamamoto S, Takeuchi Y, Higashino K, Uedo N, Matsunaga T, Morishima T, Miyashiro I. Time trends in the incidence of esophageal adenocarcinoma, gastric adenocarcinoma, and superficial esophagogastric junction adenocarcinoma.J Gastroenterol. 2019;54:784-791. [PMID: 30927083 DOI: 10.1007/s00535-019-01577-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
304 Yoshikawa T, Takeuchi H, Hasegawa S, Nozaki I, Kishi K, Ito S, Ohi M, Mine S, Hara J, Matsuda T, Hiki N, Kurokawa Y. Theoretical therapeutic impact of lymph node dissection on adenocarcinoma and squamous cell carcinoma of the esophagogastric junction. Gastric Cancer. 2016;19:143-149. [PMID: 25414051 DOI: 10.1007/s10120-014-0439-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
305 Jomrich G, Hollenstein M, John M, Baierl A, Paireder M, Kristo I, Ilhan-Mutlu A, Asari R, Preusser M, Schoppmann SF. The modified glasgow prognostic score is an independent prognostic indicator in neoadjuvantly treated adenocarcinoma of the esophagogastric junction. Oncotarget 2018;9:6968-76. [PMID: 29467943 DOI: 10.18632/oncotarget.24087] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
306 Mohammadi M, IJzerman NS, Hohenberger P, Rutkowski P, Jones RL, Martin-Broto J, Gronchi A, Schöffski P, Vassos N, Farag S, Baia M, Oosten AW, Steeghs N, Desar IME, Reyners AKL, van Sandick JW, Bastiaannet E, Gelderblom H, Schrage Y. Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study. Eur J Surg Oncol 2021;47:2173-81. [PMID: 33895019 DOI: 10.1016/j.ejso.2021.03.234] [Reference Citation Analysis]
307 Wang YM, Wang R, Wen DG, Li Y, Guo W, Wang N, Wei LZ, He YT, Chen ZF, Zhang XF, Zhang JH. Single nucleotide polymorphism in DNA methyltransferase 3B promoter and its association with gastric cardiac adenocarcinoma in North China. World J Gastroenterol 2005; 11(23): 3623-3627 [PMID: 15962389 DOI: 10.3748/wjg.v11.i23.3623] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
308 Liu S, Chai N, Lu Z, Li H, Xiong Y, Zhai Y, Linghu E. Long-term outcomes of superficial neoplasia at the esophagogastric junction treated via endoscopic submucosal dissection and endoscopic submucosal tunnel dissection: a cohort study of a single center from China. Surg Endosc 2020;34:216-25. [DOI: 10.1007/s00464-019-06753-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
309 Whitfield GA, Jackson A, Moore C, Price P. Radical chemoradiotherapy for adenocarcinoma of the distal oesophagus and oesophagogastric junction: what planning margins should we use? BJR 2008;81:921-34. [DOI: 10.1259/bjr/23903754] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
310 Mccullough J, Evoy D, Sweeney K, Meyers C, Ravi N, Keeling N, Byrne P, Reynolds J. D2 lymphadenectomy in the management of gastric cancer. Ir J Med Sci 2003;172:132-5. [DOI: 10.1007/bf02914498] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
311 Guo W, Liang X, Liu L, Guo Y, Shen S, Liang J, Dong Z. MiR-6872 host gene SEMA3B and its antisense lncRNA SEMA3B-AS1 function synergistically to suppress gastric cardia adenocarcinoma progression. Gastric Cancer 2019;22:705-22. [DOI: 10.1007/s10120-019-00924-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
312 Guo W, Wang N, Wang YM, Li Y, Wen DG, Chen ZF, He YT, Zhang JH. Interleukin-10 -1082 promoter polymorphism is not associated with susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in a population of high-incidence region of north China. World J Gastroenterol 2005; 11(6): 858-862 [PMID: 15682481 DOI: 10.3748/wjg.v11.i6.858] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
313 Howard JM, Beddy P, Ennis D, Keogan M, Pidgeon GP, Reynolds JV. Associations between leptin and adiponectin receptor upregulation, visceral obesity and tumour stage in oesophageal and junctional adenocarcinoma. Br J Surg. 2010;97:1020-1027. [PMID: 20632267 DOI: 10.1002/bjs.7072] [Cited by in Crossref: 59] [Cited by in F6Publishing: 67] [Article Influence: 4.9] [Reference Citation Analysis]
314 Oñate-ocaña LF, Milán-revollo G, Aiello-crocifoglio V, Carrillo JF, Gallardo-rincón D, Brom-valladares R, Herrera-goepfert R, Dueñas-gonzález A. Treatment of the Adenocarcinoma of the Esophagogastric Junction at a Single Institution in Mexico. Ann Surg Oncol 2007;14:1439-48. [DOI: 10.1245/s10434-006-9216-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
315 De Pasqual CA, van der Sluis PC, Weindelmayer J, Lagarde SM, Giacopuzzi S, De Manzoni G, Wijnhoven BPL. Transthoracic esophagectomy compared to transhiatal extended gastrectomy for adenocarcinoma of the esophagogastric junction: a multicenter retrospective cohort study. Dis Esophagus 2021:doab090. [PMID: 34969080 DOI: 10.1093/dote/doab090] [Reference Citation Analysis]
316 Giganti F, Salerno A, Ambrosi A, Chiari D, Orsenigo E, Esposito A, Albarello L, Mazza E, Staudacher C, Del Maschio A, De Cobelli F. Prognostic utility of diffusion-weighted MRI in oesophageal cancer: Is apparent diffusion coefficient a potential marker of tumour aggressiveness? Radiol Med. 2016;121:173-180. [PMID: 26392393 DOI: 10.1007/s11547-015-0585-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
317 Martin L, Lagergren J, Jia C, Lindblad M, Rouvelas I, Viklund P. The influence of needle catheter jejunostomy on weight development after oesophageal cancer surgery in a population-based study. European Journal of Surgical Oncology (EJSO) 2007;33:713-7. [DOI: 10.1016/j.ejso.2007.01.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
318 Lordick F, Stein HJ, Peschel C, Siewert JR. Neoadjuvant therapy for oesophagogastric cancer. Br J Surg. 2004;91:540-551. [PMID: 15122603 DOI: 10.1002/bjs.4575] [Cited by in Crossref: 78] [Cited by in F6Publishing: 55] [Article Influence: 4.3] [Reference Citation Analysis]
319 Cao R, Chen Y, Wang J, Chen M, Chen S, Tang W. Association of Long Noncoding RNAs Polymorphisms with the Risk of Esophagogastric Junction Adenocarcinoma: A Three-Center Study of 1063 Cases and 1677 Controls. DNA Cell Biol 2020;39:828-35. [PMID: 32181690 DOI: 10.1089/dna.2020.5368] [Reference Citation Analysis]
320 Liu W, Dong Z, Liang J, Guo X, Guo Y, Shen S, Kuang G, Guo W. Downregulation of Potential Tumor Suppressor miR-203a by Promoter Methylation Contributes to the Invasiveness of Gastric Cardia Adenocarcinoma. Cancer Invest 2016;34:506-16. [PMID: 27791400 DOI: 10.1080/07357907.2016.1242010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
321 Ielpo B, Pernaute AS, Elia S, Buonomo OC, Valladares LD, Aguirre EP, Petrella G, Garcia AT. Impact of number and site of lymph node invasion on survival of adenocarcinoma of esophagogastric junction. Interact Cardiovasc Thorac Surg. 2010;10:704-708. [PMID: 20154347 DOI: 10.1510/icvts.2009.222778] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
322 Jomrich G, Hollenstein M, John M, Ristl R, Paireder M, Kristo I, Asari R, Schoppmann SF. High Mean Corpuscular Volume Predicts Poor Outcome for Patients With Gastroesophageal Adenocarcinoma. Ann Surg Oncol 2019;26:976-85. [PMID: 30706229 DOI: 10.1245/s10434-019-07186-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
323 Kofoed SC, Calatayud D, Jensen LS, Jensen MV, Svendsen LB. Intrathoracic anastomotic leakage after gastroesophageal cancer resection is associated with reduced long-term survival. World J Surg 2014;38:114-9. [PMID: 24129798 DOI: 10.1007/s00268-013-2245-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
324 Lin X, Wan J, Li Z, Yan M, Liu J, Shi Y, Qian F, Zhao Y. Surgical and survival outcomes after laparoscopic and open gastrectomy for serosa-invasive Siewert type II/III esophagogastric junction carcinoma: a propensity score matching analysis. Surg Endosc 2021. [PMID: 34761283 DOI: 10.1007/s00464-021-08867-3] [Reference Citation Analysis]
325 Macdonald WC, Owen DA. Gastric carcinoma after surgical treatment of peptic ulcer: An analysis of morphologic features and a comparison with cancer in the nonoperated stomach. Cancer 2001;91:1732-8. [DOI: 10.1002/1097-0142(20010501)91:9<1732::aid-cncr1191>3.0.co;2-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
326 Saito H, Fukumoto Y, Osaki T, Fukuda K, Tatebe S, Tsujitani S, Ikeguchi M. Distinct recurrence pattern and outcome of adenocarcinoma of the gastric cardia in comparison with carcinoma of other regions of the stomach. World J Surg. 2006;30:1864-1869. [PMID: 16983479 DOI: 10.1007/s00268-005-0582-z] [Cited by in Crossref: 58] [Cited by in F6Publishing: 62] [Article Influence: 3.6] [Reference Citation Analysis]
327 Li H, Bai E, Zhang Y, Jia Z, He S, Fu J. Role of Nampt and Visceral Adiposity in Esophagogastric Junction Adenocarcinoma. J Immunol Res 2017;2017:3970605. [PMID: 28168205 DOI: 10.1155/2017/3970605] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
328 Egberts JH, Schniewind B, Bestmann B, Schafmayer C, Egberts F, Faendrich F, Kuechler T, Tepel J. Impact of the site of anastomosis after oncologic esophagectomy on quality of life--a prospective, longitudinal outcome study. Ann Surg Oncol. 2008;15:566-575. [PMID: 17929101 DOI: 10.1245/s10434-007-9615-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
329 Rahma OE, Greten TF, Duffy A. Locally advanced cancer of the esophagus, current treatment strategies, and future directions. Front Oncol 2012;2:52. [PMID: 22655277 DOI: 10.3389/fonc.2012.00052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
330 Schuhmacher C, Novotny A, Feith M, Friess H. Die neue TNM-Klassifikation der Tumoren des ösophagogastralen Übergangs: Chirurgische Konsequenzen. Chirurg 2012;83:23-30. [DOI: 10.1007/s00104-011-2146-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
331 Zhang J, Jin X, Fang S, Wang R, Li Y, Wang N, Guo W, Wang Y, Wen D, Wei L. The functional polymorphism in the matrix metalloproteinase-7 promoter increases susceptibility to esophageal squamous cell carcinoma, gastric cardiac adenocarcinoma and non-small cell lung carcinoma. Carcinogenesis. 2005;26:1748-1753. [PMID: 15930031 DOI: 10.1093/carcin/bgi144] [Cited by in Crossref: 67] [Cited by in F6Publishing: 70] [Article Influence: 3.9] [Reference Citation Analysis]
332 Zhang JW, Huang L, Xu AM. Preoperative monocyte-lymphocyte and neutrophil-lymphocyte but not platelet-lymphocyte ratios are predictive of clinical outcomes in resected patients with non-metastatic Siewert type II/III adenocarcinoma of esophagogastric junction: a prospective cohort study (the AMONP corhort). Oncotarget 2017;8:57516-27. [PMID: 28915691 DOI: 10.18632/oncotarget.15497] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
333 Heeren P, Kelder W, Blondeel I, van Westreenen H, Hollema H, Plukker J. Prognostic value of nodal micrometastases in patients with cancer of the gastro-oesophageal junction. European Journal of Surgical Oncology (EJSO) 2005;31:270-6. [DOI: 10.1016/j.ejso.2004.12.001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
334 Bumm R, Feith M, Lordick F, Herschbach P, Siewert JR. Impact of multidisciplinary tumor boards on diagnosis and treatment of esophageal cancer. Eur Surg 2007;39:136-40. [DOI: 10.1007/s10353-007-0333-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
335 Dinneen K, Baird AM, Ryan C, Sheils O. The Role of Cancer Stem Cells in Drug Resistance in Gastroesophageal Junction Adenocarcinoma. Front Mol Biosci 2021;8:600373. [PMID: 33628765 DOI: 10.3389/fmolb.2021.600373] [Reference Citation Analysis]
336 Park JC, Lee YC, Kim JH, Kim YJ, Lee SK, Shin SK, Hyung WJ, Noh SH, Kim CB. Clinicopathological features and prognostic factors of proximal gastric carcinoma in a population with high Helicobacter pylori prevalence: a single-center, large-volume study in Korea. Ann Surg Oncol. 2010;17:829-837. [PMID: 19882188 DOI: 10.1245/s10434-009-0785-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
337 Whitson BA, Groth SS, Li Z, Kratzke RA, Maddaus MA. Survival of patients with distal esophageal and gastric cardia tumors: a population-based analysis of gastroesophageal junction carcinomas. J Thorac Cardiovasc Surg. 2010;139:43-48. [PMID: 19660401 DOI: 10.1016/j.jtcvs.2009.04.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
338 Lenglinger J, Ringhofer C, Riegler M. AEG I and II: is it one tumor entity? Ann Surg 2008;247:1080-1; author reply 1081. [PMID: 18520245 DOI: 10.1097/SLA.0b013e3181758d4b] [Reference Citation Analysis]
339 Kohlruss M, Grosser B, Krenauer M, Slotta-Huspenina J, Jesinghaus M, Blank S, Novotny A, Reiche M, Schmidt T, Ismani L, Hapfelmeier A, Mathias D, Meyer P, Gaida MM, Bauer L, Ott K, Weichert W, Keller G. Prognostic implication of molecular subtypes and response to neoadjuvant chemotherapy in 760 gastric carcinomas: role of Epstein-Barr virus infection and high- and low-microsatellite instability. J Pathol Clin Res 2019;5:227-39. [PMID: 31206244 DOI: 10.1002/cjp2.137] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
340 Hosoda K, Yamashita K, Katada N, Watanabe M. Overview of multimodal therapy for adenocarcinoma of the esophagogastric junction. Gen Thorac Cardiovasc Surg 2015;63:549-56. [DOI: 10.1007/s11748-015-0575-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
341 Davies AR, Gossage JA, Zylstra J, Mattsson F, Lagergren J, Maisey N, Smyth EC, Cunningham D, Allum WH, Mason RC. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction. J Clin Oncol. 2014;32:2983-2990. [PMID: 25071104 DOI: 10.1200/jco.2014.55.9070] [Cited by in Crossref: 129] [Cited by in F6Publishing: 70] [Article Influence: 18.4] [Reference Citation Analysis]
342 Schuhmacher CP, Fink U, Becker K, Busch R, Dittler H, Mueller J, Siewert JR. Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxirubicin, and cisplatinum: Closing results after 5 years of follow-up. Cancer 2001;91:918-27. [DOI: 10.1002/1097-0142(20010301)91:5<918::aid-cncr1081>3.0.co;2-w] [Cited by in Crossref: 64] [Article Influence: 3.0] [Reference Citation Analysis]
343 Varghese TK Jr, Hofstetter WL, Rizk NP, Low DE, Darling GE, Watson TJ, Mitchell JD, Krasna MJ. The society of thoracic surgeons guidelines on the diagnosis and staging of patients with esophageal cancer. Ann Thorac Surg. 2013;96:346-356. [PMID: 23752201 DOI: 10.1016/j.athoracsur.2013.02.069] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 5.4] [Reference Citation Analysis]
344 Taniere P, Borghi-scoazec G, Saurin J, Lombard-bohas C, Boulez J, Berger F, Hainaut P, Scoazec J. Cytokeratin Expression in Adenocarcinomas of the Esophagogastric Junction: A Comparative Study of Adenocarcinomas of the Distal Esophagus and of the Proximal Stomach. The American Journal of Surgical Pathology 2002;26:1213-21. [DOI: 10.1097/00000478-200209000-00012] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.3] [Reference Citation Analysis]
345 Buas MF, Vaughan TL. Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Semin Radiat Oncol. 2013;23:3-9. [PMID: 23207041 DOI: 10.1016/j.semradonc.2012.09.008] [Cited by in Crossref: 137] [Cited by in F6Publishing: 126] [Article Influence: 15.2] [Reference Citation Analysis]
346 Bornschein J, Selgrad M, Wex T, Kuester D, Malfertheiner P. Serological assessment of gastric mucosal atrophy in gastric cancer. BMC Gastroenterol. 2012;12:10. [PMID: 22289789 DOI: 10.1186/1471-230x-12-10] [Cited by in Crossref: 47] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
347 de Graaf GW, Ayantunde AA, Parsons SL, Duffy JP, Welch NT. The role of staging laparoscopy in oesophagogastric cancers. Eur J Surg Oncol. 2007;33:988-992. [PMID: 17344017 DOI: 10.1016/j.ejso.2007.01.007] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 3.3] [Reference Citation Analysis]
348 Matsuda T, Kurokawa Y, Yoshikawa T, Kishi K, Misawa K, Ohi M, Mine S, Hiki N, Takeuchi H. Clinicopathological Characteristics and Prognostic Factors of Patients with Siewert Type II Esophagogastric Junction Carcinoma: A Retrospective Multicenter Study. World J Surg 2016;40:1672-9. [PMID: 26928855 DOI: 10.1007/s00268-016-3451-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
349 Djärv T, Derogar M, Lagergren P. Influence of co-morbidity on long-term quality of life after oesophagectomy for cancer. Br J Surg 2014;101:495-501. [PMID: 24474187 DOI: 10.1002/bjs.9417] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
350 Orditura M, Galizia G, Di Martino N, Ancona E, Castoro C, Pacelli R, Morgillo F, Rossetti S, Gambardella V, Farella A. Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma-a pilot study. Curr Oncol. 2014;21:125-133. [PMID: 24940093 DOI: 10.3747/co.21.1570] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
351 Blakely AM, Miner TJ. Surgical considerations in the treatment of gastric cancer. Gastroenterol Clin North Am. 2013;42:337-357. [PMID: 23639644 DOI: 10.1016/j.gtc.2013.01.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
352 Piazuelo MB, Epplein M, Correa P. Gastric cancer: an infectious disease. Infect Dis Clin North Am. 2010;24:853-869, vii. [PMID: 20937454 DOI: 10.1016/j.idc.2010.07.010] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 4.5] [Reference Citation Analysis]
353 Deans C, Wigmore S, Paterson-brown S, Black J, Ross J, Fearon KCH. Serum parathyroid hormone-related peptide is associated with systemic inflammation and adverse prognosis in gastroesophageal carcinoma. Cancer 2005;103:1810-8. [DOI: 10.1002/cncr.20972] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
354 Zhao Y, Zhang J, Yang D, Tang Z, Wang Q. Feasibility of laparoscopic total gastrectomy for advanced Siewert type Ⅱ and type Ⅲ esophagogastric junction carcinoma: A propensity score-matched case-control study. Asian Journal of Surgery 2019;42:805-13. [DOI: 10.1016/j.asjsur.2018.12.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
355 Javeri H, Arora R, Correa AM, Hofstetter WL, Lee JH, Liao Z, McAleer MF, Maru D, Bhutani MS, Swisher SG, Izzo JG, Ajani JA. Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus. Cancer 2008;113:1302-8. [PMID: 18623381 DOI: 10.1002/cncr.23688] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
356 American Joint Committee On Cancer. Stomach. AJCC Cancer Staging Handbook. New York: Springer; 2010. pp. 145-52. [DOI: 10.1007/978-0-387-88443-1_11] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
357 Rahden BHV, Stein HJ, Siewert JR. Surgical management of esophagogastric junction tumors. World J Gastroenterol 2006; 12(41): 6608-6613 [PMID: 17075972 DOI: 10.3748/wjg.v12.i41.6608] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 37] [Article Influence: 2.8] [Reference Citation Analysis]
358 Wu XN, Liu CQ, Tian JY, Guo MF, Xu MQ. Prognostic significance of the number of lymph nodes examined in node-negative Siewert type II esophagogastric junction adenocarcinoma. Int J Surg. 2017;41:6-11. [PMID: 28323156 DOI: 10.1016/j.ijsu.2017.03.028] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
359 Tougeron D, Richer JP, Silvain C. Management of esophageal adenocarcinoma. J Visc Surg. 2011;148:e161-e170. [PMID: 21715236 DOI: 10.1016/j.jviscsurg.2011.05.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
360 Jomrich G, Kollmann D, Wilfing L, Radosavljevic S, Ramazanova D, Ristl R, Grose RP, Ilhan-Mutlu A, Preusser M, Fassnacht C, Tsai YC, Guenova E, Schoppmann SF. Programmed death ligand 2 expression plays a limited role in adenocarcinomas of the gastroesophageal junction after preoperative chemotherapy. Eur Surg 2021;53:287-93. [PMID: 34868284 DOI: 10.1007/s10353-021-00700-4] [Reference Citation Analysis]
361 von Rahden BH, Langner C, Brücher BL, Stein HJ, Sarbia M. No association of primary adenocarcinomas of the small bowel with Epstein-Barr virus infection. Mol Carcinog 2006;45:349-52. [PMID: 16493667 DOI: 10.1002/mc.20163] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
362 Al-Haddad S, El-Zimaity H, Hafezi-Bakhtiari S, Rajendra S, Streutker CJ, Vajpeyi R, Wang B. Infection and esophageal cancer. Ann N Y Acad Sci. 2014;1325:187-196. [PMID: 25266025 DOI: 10.1111/nyas.12530] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
363 Griffiths EA, Pritchard SA, Valentine HR, Whitchelo N, Bishop PW, Ebert MP, Price PM, Welch IM, West CM. Hypoxia-inducible factor-1alpha expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas. Br J Cancer 2007;96:95-103. [PMID: 17179985 DOI: 10.1038/sj.bjc.6603524] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 4.5] [Reference Citation Analysis]
364 Zhang GT, Song YC, Zhang XD. Hand-assisted laparoscopic total gastrectomy with regional lymph node dissection for advanced gastric cancer. Surg Laparosc Endosc Percutan Tech. 2014;24:e78-e84. [PMID: 24710226 DOI: 10.1097/sle.0b013e31828fa6fd] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
365 Chen Y, Tang W, Liu C, Lin J, Wang Y, Zhang S, Chen G, Zheng X. miRNA-146a rs2910164 C>G polymorphism increased the risk of esophagogastric junction adenocarcinoma: a case-control study involving 2,740 participants. Cancer Manag Res 2018;10:1657-64. [PMID: 29983589 DOI: 10.2147/CMAR.S165921] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
366 Reeh M, Mina S, Bockhorn M, Kutup A, Nentwich MF, Marx A, Sauter G, Rösch T, Izbicki JR, Bogoevski D. Staging and outcome depending on surgical treatment in adenocarcinomas of the oesophagogastric junction. Br J Surg. 2012;99:1406-1414. [PMID: 22961520 DOI: 10.1002/bjs.8884] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
367 Roedl JB, Harisinghani MG, Colen RR, Fischman AJ, Blake MA, Mathisen DJ, Mueller PR. Assessment of Treatment Response and Recurrence in Esophageal Carcinoma Based on Tumor Length and Standardized Uptake Value on Positron Emission Tomography–Computed Tomography. The Annals of Thoracic Surgery 2008;86:1131-8. [DOI: 10.1016/j.athoracsur.2008.05.019] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
368 Reynolds JV, Ravi N, Hollywood D, Kennedy MJ, Rowley S, Ryan A, Hughes N, Carey M, Byrne P. Neoadjuvant chemoradiation may increase the risk of respiratory complications and sepsis after transthoracic esophagectomy. The Journal of Thoracic and Cardiovascular Surgery 2006;132:549-55. [DOI: 10.1016/j.jtcvs.2006.05.015] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 5.0] [Reference Citation Analysis]
369 Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8:797-805. [PMID: 17693134 DOI: 10.2967/jnumed.110.085803] [Cited by in Crossref: 124] [Cited by in F6Publishing: 111] [Article Influence: 8.3] [Reference Citation Analysis]
370 Liu K, Yang K, Zhang W, Chen X, Zhang B, Chen Z, Chen J, Zhao Y, Zhou Z, Chen L, Hu J. Changes of Esophagogastric Junctional Adenocarcinoma and Gastroesophageal Reflux Disease Among Surgical Patients During 1988-2012: A Single-institution, High-volume Experience in China. Ann Surg. 2016;263:88-95. [PMID: 25647058 DOI: 10.1097/sla.0000000000001148] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 8.0] [Reference Citation Analysis]
371 Wang X, Kang GH, Campan M, Weisenberger DJ, Long TI, Cozen W, Bernstein L, Wu AH, Siegmund KD, Shibata D, Laird PW. Epigenetic subgroups of esophageal and gastric adenocarcinoma with differential GATA5 DNA methylation associated with clinical and lifestyle factors. PLoS One 2011;6:e25985. [PMID: 22028801 DOI: 10.1371/journal.pone.0025985] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
372 Langer R, Feith M, Siewert JR, Wester HJ, Hoefler H. Expression and clinical significance of glucose regulated proteins GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the esophagus. BMC Cancer 2008;8:70. [PMID: 18331622 DOI: 10.1186/1471-2407-8-70] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 4.2] [Reference Citation Analysis]
373 Chen B, Zeng Z, Xu L, Wu X, Yu J, Xue L, Hao Y, Wang Y, Sung JJ, Chen M, Hu P. IL23R +2199A/C polymorphism is associated with decreased risk of certain subtypes of gastric cancer in Chinese: a case-control study. Cancer Epidemiol. 2011;35:165-169. [PMID: 20863779 DOI: 10.1016/j.canep.2010.08.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
374 Healy LA, Ryan AM, Gopinath B, Rowley S, Byrne PJ, Reynolds JV. Impact of obesity on outcomes in the management of localized adenocarcinoma of the esophagus and esophagogastric junction. J Thorac Cardiovasc Surg. 2007;134:1284-1291. [PMID: 17976464 DOI: 10.1016/j.jtcvs.2007.06.037] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 3.7] [Reference Citation Analysis]
375 Ovrebo KK, Lie SA, Laerum OD, Svanes K, Viste A. Long-term survival from adenocarcinoma of the esophagus after transthoracic and transhiatal esophagectomy. World J Surg Oncol 2012;10:130. [PMID: 22747995 DOI: 10.1186/1477-7819-10-130] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
376 Chang X, Guo X, Li X, Han X, Li X, Liu X, Ren J. Potential Value of Radiomics in the Identification of Stage T3 and T4a Esophagogastric Junction Adenocarcinoma Based on Contrast-Enhanced CT Images. Front Oncol 2021;11:627947. [PMID: 33747947 DOI: 10.3389/fonc.2021.627947] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
377 Lehmann K, Schneider PM. Differences in the Molecular Biology of Adenocarcinoma of the Esophagus, Gastric Cardia, and Upper Gastric Third. In: Schneider PM, editor. Adenocarcinoma of the Esophagogastric Junction. Berlin: Springer Berlin Heidelberg; 2010. pp. 65-72. [DOI: 10.1007/978-3-540-70579-6_5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
378 Takeuchi H, Kitagawa Y. Adenocarcinoma of the esophagogastric junction: territory of the esophagus or stomach, or an independent region? Ann Surg Oncol 2013;20:705-6. [PMID: 23224904 DOI: 10.1245/s10434-012-2781-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
379 Platz TA, Nurkin SJ, Fong MK, Groman A, Flaherty L, Malhotra U, Levea CM, Yendamuri S, Warren GW, Nava HR. Neoadjuvant chemoradiotherapy for esophageal/gastroesophageal carcinoma. J Gastrointest Oncol. 2013;4:137-143. [PMID: 23730509 DOI: 10.3978/j.issn.2078-6891.2013.007] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
380 Roedl JB, Blake MA, Holalkere NS, Mueller PR, Colen RR, Harisinghani MG. Lymph node staging in esophageal adenocarcinoma with PET-CT based on a visual analysis and based on metabolic parameters. Abdom Imaging. 2009;34:610-617. [PMID: 18830663 DOI: 10.1007/s00261-008-9447-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
381 Li Y, Li J, Li J. Two updates on oesophagogastric junction adenocarcinoma from the fifth WHO classification: Alteration of definition and emphasis on HER2 test. Histol Histopathol 2021;36:339-46. [PMID: 33377175 DOI: 10.14670/HH-18-296] [Reference Citation Analysis]
382 Ebihara Y, Kurashima Y, Murakami S, Shichinohe T, Hirano S. Minimally invasive abdominal and left thoracic approach for Siewert type II adenocarcinoma of the oesophagogastric junction: Novel technique for simultaneous combined use of laparoscopy and thoracoscopy. J Minim Access Surg 2020;16:285-8. [PMID: 30178772 DOI: 10.4103/jmas.JMAS_228_17] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
383 Ito H, Inoue H, Odaka N, Satodate H, Suzuki M, Mukai S, Takehara Y, Omoto T, Kudo SE. Comparison of Clinicopathological Characteristics in the Patients with Cardiac Cancer with or without Esophagogastric Junctional Invasion: A Single-Center Retrospective Cohort Study. Int J Surg Oncol 2013;2013:189459. [PMID: 23365732 DOI: 10.1155/2013/189459] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
384 D'journo XB, Avaro JP, Michelet P, Trousse D, Tasei AM, Dahan L, Doddoli C, Guidicelli R, Fuentes P, Seitz JF, Thomas P. Extracapsular Lymph Node Involvement Is a Negative Prognostic Factor After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Cancer. Journal of Thoracic Oncology 2009;4:534-9. [DOI: 10.1097/jto.0b013e31819c862d] [Cited by in Crossref: 22] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
385 Guo YL, Zhu TN, Guo W, Dong ZM, Zhou Z, Cui YJ, Zhao RJ. Aberrant CpG Island Shore Region Methylation of CAV1 Is Associated with Tumor Progression and Poor Prognosis in Gastric Cardia Adenocarcinoma. Arch Med Res 2016;47:460-70. [PMID: 27986126 DOI: 10.1016/j.arcmed.2016.10.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
386 Hara Y, Zheng Z, Evans SC, Malatjalian D, Riddell DC, Guernsey DL, Wang LD, Riabowol K, Casson AG. ING1 and p53 tumor suppressor gene alterations in adenocarcinomas of the esophagogastric junction. Cancer Lett. 2003;192:109-116. [PMID: 12637159 DOI: 10.1016/s0304-3835(02)00635-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
387 Sanders G, Borie F, Husson E, Blanc PM, Mauro GD, Claus C, Millat B. Minimally invasive transhiatal esophagectomy: lessons learned. Surg Endosc 2007;21:1190-3. [DOI: 10.1007/s00464-007-9312-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
388 Oda I, Abe S, Kusano C, Suzuki H, Nonaka S, Yoshinaga S, Taniguchi H, Shimoda T, Gotoda T. Correlation between endoscopic macroscopic type and invasion depth for early esophagogastric junction adenocarcinomas. Gastric Cancer 2011;14:22-7. [PMID: 21274736 DOI: 10.1007/s10120-011-0001-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
389 Sanz Álvarez L, Turienzo Santos E, Rodicio Miravalles JL, Moreno Gijón M, Amoza Pais S, Sanz Navarro S, Rizzo Ramos A. Evidence in follow-up and prognosis of esophagogastric junction cancer. Cir Esp (Engl Ed) 2019;97:465-9. [PMID: 31060735 DOI: 10.1016/j.ciresp.2019.03.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
390 Sarbia M, Geddert H, Klump B, Kiel S, Iskender E, Gabbert HE. Hypermethylation of tumor suppressor genes (p16INK4A, p14ARF and APC) in adenocarcinomas of the upper gastrointestinal tract. Int J Cancer. 2004;111:224-228. [PMID: 15197775 DOI: 10.1002/ijc.20212] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 2.8] [Reference Citation Analysis]
391 Javeri H, Xiao L, Rohren E, Komaki R, Hofstetter W, Lee JH, Maru D, Bhutani MS, Swisher SG, Wang X, Ajani JA. Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation. Cancer. 2009;115:624-630. [PMID: 19130466 DOI: 10.1002/cncr.24056] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
392 Sjödahl K, Lagergren J. Epidemiological aspects of gastric adenocarcinoma: are predictive diagnostics and targeted preventive measures possible? EPMA J 2010;1:461-71. [PMID: 23199088 DOI: 10.1007/s13167-010-0043-0] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
393 Jennings NA, Griffin SM, Lamb PJ, Preston S, Richardson D, Karat D, Hayes N. Prospective study of bone scintigraphy as a staging investigation for oesophageal carcinoma. Br J Surg 2008;95:840-4. [PMID: 18551472 DOI: 10.1002/bjs.6175] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
394 Ayantunde AA, Ng MY, Pal S, Welch NT, Parsons SL. Analysis of blood transfusion predictors in patients undergoing elective oesophagectomy for cancer. BMC Surg 2008;8:3. [PMID: 18221510 DOI: 10.1186/1471-2482-8-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
395 Maeda H, Okabayashi T, Nishimori I, Sugimoto T, Namikawa T, Dabanaka K, Tsujii S, Onishi S, Kobayashi M, Hanazaki K. Clinicopathologic features of adenocarcinoma at the gastric cardia: is it different from distal cancer of the stomach? J Am Coll Surg. 2008;206:306-310. [PMID: 18222384 DOI: 10.1016/j.jamcollsurg.2007.06.306] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.3] [Reference Citation Analysis]
396 Takeuchi Y, Ebihara Y, Nakanishi Y, Asano T, Noji T, Kurashima Y, Murakami S, Nakamura T, Tsuchikawa T, Okamura K, Shichinohe T, Hirano S. A minimally invasive abdominal and left thoracic approach as a palliative treatment for adenocarcinoma of the esophagogastric junction with severe stenosis: A case report. Asian J Endosc Surg 2020;13:215-8. [PMID: 31240864 DOI: 10.1111/ases.12718] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
397 Gertler R, Richter J, Stecher L, Nitsche U, Feith M. What to do after R1-resection of adenocarcinomas of the esophagogastric junction? J Surg Oncol 2016;114:428-33. [PMID: 27333949 DOI: 10.1002/jso.24329] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
398 Stein HJ, Feith M, Siewert JR. Malignant degeneration of Barrett's esophagus: clinical point of view. Recent Results Cancer Res 2000;155:42-53. [PMID: 10693237 DOI: 10.1007/978-3-642-59600-1_4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
399 Gao Y, Sun J, Chen Y, Zhang Y, Chen P, Zong L, Huang J, Han J, Chen X. Proximal gastrectomy with anti-reflux anastomosis for patients with adenocarcinoma of the esophagogastric junction: The simple and safe triangle-valve technique. Mol Clin Oncol 2020;13:62. [PMID: 32963781 DOI: 10.3892/mco.2020.2132] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
400 Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, Meisetschläger G, Busch R, Siewert JR, Schwaiger M, Fink U. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001;19:3058-65. [PMID: 11408502 DOI: 10.1200/JCO.2001.19.12.3058] [Cited by in Crossref: 521] [Cited by in F6Publishing: 151] [Article Influence: 24.8] [Reference Citation Analysis]
401 Wang L, Xia Y, Jiang T, Li F, Wang W, Zhang D, Xu H, Yang L, Xu Z. Short-Term Surgical Outcomes of Laparoscopic Proximal Gastrectomy With Double-Tract Reconstruction Versus Laparoscopic Total Gastrectomy for Adenocarcinoma of Esophagogastric Junction: A Matched-Cohort Study. J Surg Res 2020;246:292-9. [PMID: 31630013 DOI: 10.1016/j.jss.2019.09.022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
402 Moehler M, Galle PR, Gockel I, Junginger T, Schmidberger H. The multidisciplinary management of gastrointestinal cancer. Multimodal treatment of gastric cancer. Best Pract Res Clin Gastroenterol 2007;21:965-81. [PMID: 18070698 DOI: 10.1016/j.bpg.2007.10.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
403 Giganti F, Ambrosi A, Chiari D, Orsenigo E, Esposito A, Mazza E, Albarello L, Staudacher C, Del Maschio A, De Cobelli F. Apparent diffusion coefficient by diffusion-weighted magnetic resonance imaging as a sole biomarker for staging and prognosis of gastric cancer. Chin J Cancer Res 2017;29:118-26. [PMID: 28536490 DOI: 10.21147/j.issn.1000-9604.2017.02.04] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
404 Carneiro F, Chaves P. Pathologic Risk Factors of Adenocarcinoma of the Gastric Cardia and Gastroesophageal Junction. Surgical Oncology Clinics of North America 2006;15:697-714. [DOI: 10.1016/j.soc.2006.07.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
405 Grotenhuis BA, Wijnhoven BP, Poley JW, Hermans JJ, Biermann K, Spaander MC, Bruno MJ, Tilanus HW, van Lanschot JJ. Preoperative assessment of tumor location and station-specific lymph node status in patients with adenocarcinoma of the gastroesophageal junction. World J Surg 2013;37:147-55. [PMID: 23015224 DOI: 10.1007/s00268-012-1804-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
406 Däster S, Soysal SD, Koechlin L, Stoll L, Peterli R, von Flüe M, Ackermann C. Perioperative outcomes of esophageal cancer surgery in a mid-volume institution in the era of centralization. Langenbecks Arch Surg 2016;401:787-95. [DOI: 10.1007/s00423-016-1477-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
407 Meier I, Merkel S, Papadopoulos T, Sauer R, Hohenberger W, Brunner TB. Adenocarcinoma of the esophagogastric junction: the pattern of metastatic lymph node dissemination as a rationale for elective lymphatic target volume definition. Int J Radiat Oncol Biol Phys. 2008;70:1408-1417. [PMID: 18374226 DOI: 10.1016/j.ijrobp.2007.08.053] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
408 Zhang W, Wang Q, Li T, Lv J, Liu H, Jia X, Liu B, Fan Y, Wang Y, Wang J, Wu L, Lang J. External beam radiation and high-dose-rate brachytherapy for elderly patients with gastroesophageal junction adenocarcinoma. J Contemp Brachytherapy 2017;9:330-7. [PMID: 28951752 DOI: 10.5114/jcb.2017.69334] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
409 Hanyu T, Kanda T, Matsuki A, Hasegawa G, Yajima K, Tsuchida M, Kosugi SI, Naito M, Hatakeyama K. Endobronchial metastasis from adenocarcinoma of gastric cardia 7 years after potentially curable resection. World J Gastrointest Surg 2010; 2(8): 270-274 [PMID: 21160887 DOI: 10.4240/wjgs.v2.i8.270] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
410 Mine S, Sano T, Hiki N, Yamada K, Kosuga T, Nunobe S, Shigaki H, Yamaguchi T. Thoracic lymph node involvement in adenocarcinoma of the esophagogastric junction and lower esophageal squamous cell carcinoma relative to the location of the proximal end of the tumor. Ann Surg Oncol. 2014;21:1596-1601. [PMID: 24531703 DOI: 10.1245/s10434-014-3548-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
411 Koëter M, Parry K, Verhoeven RHA, Luyer MDP, Ruurda JP, van Hillegersberg R, Lemmens VEPP, Nieuwenhuijzen GAP. Perioperative Treatment, Not Surgical Approach, Influences Overall Survival in Patients with Gastroesophageal Junction Tumors: A Nationwide, Population-Based Study in The Netherlands. Ann Surg Oncol 2016;23:1632-8. [DOI: 10.1245/s10434-015-5061-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
412 Kurokawa Y, Takeuchi H, Doki Y, Mine S, Terashima M, Yasuda T, Yoshida K, Daiko H, Sakuramoto S, Yoshikawa T, Kunisaki C, Seto Y, Tamura S, Shimokawa T, Sano T, Kitagawa Y. Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors: A Prospective Nationwide Multicenter Study.Ann Surg. 2021;274:120-127. [PMID: 31404008 DOI: 10.1097/SLA.0000000000003499] [Cited by in Crossref: 29] [Cited by in F6Publishing: 11] [Article Influence: 29.0] [Reference Citation Analysis]
413 Orditura M, Galizia G, Lieto E, De Vita F, Ciardiello F. Treatment of esophagogastric junction carcinoma: An unsolved debate. World J Gastroenterol 2015; 21(15): 4427-4431 [PMID: 25914451 DOI: 10.3748/wjg.v21.i15.4427] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
414 Forshaw M, Gossage J, Chrystal K, Cheong K, Harper P, Mason R. Symptomatic Responses to Neoadjuvant Chemotherapy for Carcinoma of the Oesophagus and Oesophagogastric Junction: Are They Worth Measuring? Clinical Oncology 2006;18:345-50. [DOI: 10.1016/j.clon.2006.02.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
415 Xiong J, Wang Y, Kang W, Ma F, Liu H, Ma S, Li Y, Jin P, Hu H, Tian Y. Prognostic Importance of the Preoperative Naples Prognostic Score for Patients With Adenocarcinoma of the Esophagogastric Junction. Front Oncol 2020;10:595793. [PMID: 33392090 DOI: 10.3389/fonc.2020.595793] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
416 Bornschein J, Selgrad M, Warnecke M, Kuester D, Wex T, Malfertheiner P. H. pylori infection is a key risk factor for proximal gastric cancer. Dig Dis Sci. 2010;55:3124-3131. [PMID: 20668939 DOI: 10.1007/s10620-010-1351-x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 3.9] [Reference Citation Analysis]
417 American Joint Committee on Cancer. Stomach. AJCC Cancer Staging Manual. New York: Springer; 2010. pp. 117-26. [DOI: 10.1007/978-0-387-88441-7_11] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
418 Charalampakis N, Tsakatikas S, Schizas D, Kykalos S, Tolia M, Fioretzaki R, Papageorgiou G, Katsaros I, Abdelhakeem AAF, Sewastjanow-Silva M, Rogers JE, Ajani JA. Trimodality treatment in gastric and gastroesophageal junction cancers: Current approach and future perspectives. World J Gastrointest Oncol 2022; 14(1): 181-202 [DOI: 10.4251/wjgo.v14.i1.181] [Reference Citation Analysis]
419 Klevebro F, Alexandersson von Döbeln G, Wang N, Johnsen G, Jacobsen AB, Friesland S, Hatlevoll I, Glenjen NI, Lind P, Tsai JA, Lundell L, Nilsson M. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol 2016;27:660-7. [PMID: 26782957 DOI: 10.1093/annonc/mdw010] [Cited by in Crossref: 167] [Cited by in F6Publishing: 154] [Article Influence: 27.8] [Reference Citation Analysis]
420 Burian M, Stein HJ, Sendler A, Piert M, Nährig J, Feith M, Siewert JR. Sentinel node detection in Barrett's and cardia cancer. Ann Surg Oncol 2004;11:255S-8S. [PMID: 15023763 DOI: 10.1007/BF02523640] [Cited by in Crossref: 2] [Cited by in F6Publishing: 20] [Article Influence: 0.1] [Reference Citation Analysis]
421 Lerut T, Decker G, Coosemans W, De Leyn P, Decaluwé H, Nafteux P, Van Raemdonck D. Quality indicators of surgery for adenocarcinoma of the esophagus and gastroesophageal junction. Recent Results Cancer Res. 2010;182:127-142. [PMID: 20676877 DOI: 10.1007/978-3-540-70579-6_11] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
422 Wilson D, Hiller L, Geh JI. Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol (R Coll Radiol). 2005;17:81-90. [PMID: 15830569 DOI: 10.1016/j.clon.2004.10.006] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 2.9] [Reference Citation Analysis]
423 Cense HA, van Eijck CH, Tilanus HW. New insights in the lymphatic spread of oesophageal cancer and its implications for the extent of surgical resection. Best Pract Res Clin Gastroenterol. 2006;20:893-906. [PMID: 16997168 DOI: 10.1016/j.bpg.2006.03.010] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 2.9] [Reference Citation Analysis]
424 Chen G, Xu M, Chen J, Hong L, Lin W, Zhao S, Zhang G, Dan G, Liu S. Clinicopathological Features and Increased Expression of Toll-Like Receptor 4 of Gastric Cardia Cancer in a High-Risk Chinese Population. J Immunol Res 2018;2018:7132868. [PMID: 29670922 DOI: 10.1155/2018/7132868] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
425 Brown AM, Giugliano DN, Berger AC, Pucci MJ, Palazzo F. Surgical approaches to adenocarcinoma of the gastroesophageal junction: the Siewert II conundrum. Langenbecks Arch Surg. 2017;402:1153-1158. [PMID: 28803334 DOI: 10.1007/s00423-017-1610-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
426 Pepek JM, Chino JP, Willett CG, Palta M, Blazer Iii DG, Tyler DS, Uronis HE, Czito BG. Preoperative chemoradiotherapy for locally advanced gastric cancer. Radiat Oncol 2013;8:6. [PMID: 23286735 DOI: 10.1186/1748-717X-8-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
427 Deans DAC, Wigmore SJ, de Beaux AC, Paterson-brown S, Garden OJ, Fearon KCH. Clinical prognostic scoring system to aid decision-making in gastro-oesophageal cancer. British Journal of Surgery 2007;94:1501-8. [DOI: 10.1002/bjs.5849] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 3.0] [Reference Citation Analysis]
428 Lambrecht M, Haustermans K. Clinical evidence on PET-CT for radiation therapy planning in gastro-intestinal tumors. Radiotherapy and Oncology 2010;96:339-46. [DOI: 10.1016/j.radonc.2010.07.019] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
429 Guo W, Dong Z, Bai Y, Guo Y, Shen S, Kuang G, Xu J. Associations between polymorphisms of HOTAIR and risk of gastric cardia adenocarcinoma in a population of north China. Tumour Biol. 2015;36:2845-2854. [PMID: 25476857 DOI: 10.1007/s13277-014-2912-y] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 7.1] [Reference Citation Analysis]
430 Martin L, Lagergren P. Risk Factors for Weight Loss Among Patients Surviving 5 Years After Esophageal Cancer Surgery. Ann Surg Oncol 2015;22:610-6. [DOI: 10.1245/s10434-014-3973-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
431 Rice TW, Rusch VW, Ishwaran H, Blackstone EH; Worldwide Esophageal Cancer Collaboration. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. Cancer. 2010;116:3763-3773. [PMID: 20564099 DOI: 10.1002/cncr.25146] [Cited by in Crossref: 301] [Cited by in F6Publishing: 308] [Article Influence: 25.1] [Reference Citation Analysis]
432 Takada K, Yabuuchi Y, Yamamoto Y, Yoshida M, Kawata N, Takizawa K, Kishida Y, Ito S, Imai K, Hotta K, Ishiwatari H, Matsubayashi H, Kawabata T, Ono H. Predicting the depth of superficial adenocarcinoma of the esophagogastric junction. J Gastroenterol Hepatol 2021. [PMID: 34820917 DOI: 10.1111/jgh.15741] [Reference Citation Analysis]
433 Fédération nationale des centres de lutte contre le cancer. [Recommendations for clinical practice: 2004 Standards, Options and Recommendations for management of patients with adenocarcinomas of the stomach (excluding cardial and other histological forms of cancer) Federation nationale des centres de lutte contre le cancer]. Gastroenterol Clin Biol 2005;29:41-55. [PMID: 15738894 DOI: 10.1016/s0399-8320(05)80692-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
434 Tepper JE, O'neil B. Transition in Biology and Philosophy in the Treatment of Gastroesophageal Junction Adenocarcinoma. JCO 2009;27:836-7. [DOI: 10.1200/jco.2008.19.5982] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
435 Miyasaka M, Ebihara Y, Yamamura Y, Tanaka K, Nakanishi Y, Asano T, Noji T, Kurashima Y, Nakamura T, Murakami S, Tsuchikawa T, Okamura K, Shichinohe T, Hirano S. Simultaneous surgical treatment for esophagogastric junctional cancer and splenic artery aneurysm resection with spleen preservation using fluorescence imaging: a case report. Surg Case Rep 2019;5:44. [PMID: 30911865 DOI: 10.1186/s40792-019-0602-0] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
436 Karstens KF, Ghadban T, Sawez S, Konczalla L, Woestemeier A, Bachmann K, Uzunoglu FG, Tachezy M, Vettorazzi E, Izbicki JR, Reeh M. Comparison of the 8th UICC staging system for esophageal and gastric cancers in Siewert type II junctional adenocarcinomas. Eur J Surg Oncol 2020;46:638-43. [PMID: 31879051 DOI: 10.1016/j.ejso.2019.12.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
437 Huang Q, Zhong J, Yang T, Li J, Luo K, Zheng Y, Yang H, Fu J. Impacts of anastomotic complications on the health-related quality of life after esophagectomy: HRQL After Esophagectomy. J Surg Oncol 2015;111:365-70. [DOI: 10.1002/jso.23837] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
438 Lacueva J, Gallego J, Díaz-González JA. Updating controversies on the multidisciplinary management of gastric cancer. Clin Transl Oncol. 2010;12:677-685. [PMID: 20947482 DOI: 10.1007/s12094-010-0577-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
439 Wong CL, Law S. Extent of lymphadenectomy for Barrett's cancer. Transl Gastroenterol Hepatol 2019;4:36. [PMID: 31231703 DOI: 10.21037/tgh.2019.05.07] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
440 McKernan M, McMillan DC, Anderson JR, Angerson WJ, Stuart RC. The relationship between quality of life (EORTC QLQ-C30) and survival in patients with gastro-oesophageal cancer. Br J Cancer 2008;98:888-93. [PMID: 18268490 DOI: 10.1038/sj.bjc.6604248] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 4.3] [Reference Citation Analysis]
441 Tosolini C, Reim D, Schirren R, Feith M, Friess H, Novotny AR. Influence of the surgical technique on survival in the treatment of carcinomas of the true cardia (Siewert Type II) - Right thoracoabdominal vs. transhiatal-abdominal approach. Eur J Surg Oncol 2019;45:416-24. [PMID: 30396809 DOI: 10.1016/j.ejso.2018.09.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
442 Siewert JR, Lordick F, Ott K, Stein HJ, Weber WA, Becker K, Peschel C, Fink U, Schwaiger M. Induction Chemotherapy in Barrett Cancer: Influence on Surgical Risk and Outcome. Annals of Surgery 2007;246:624-31. [DOI: 10.1097/sla.0b013e318155a7d1] [Cited by in Crossref: 43] [Cited by in F6Publishing: 11] [Article Influence: 2.9] [Reference Citation Analysis]
443 Beddy P, Howard J, McMahon C, Knox M, de Blacam C, Ravi N, Reynolds JV, Keogan MT. Association of visceral adiposity with oesophageal and junctional adenocarcinomas. Br J Surg. 2010;97:1028-1034. [PMID: 20632268 DOI: 10.1002/bjs.7100] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 4.6] [Reference Citation Analysis]
444 Liakakos T. Challenges in the treatment of gastroesophageal junction cancer. World J Surg 2011;35:1409-10; author reply 1411. [PMID: 21301836 DOI: 10.1007/s00268-011-0977-y] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
445 Schlosser T, Hoffmeister A, Feisthammel J, Niebisch S, Thieme R, Gockel I. [Treatment recommendations for early esophageal cancer : Endoscopic and surgical options]. Chirurg 2021;92:1077-84. [PMID: 34622303 DOI: 10.1007/s00104-021-01513-7] [Reference Citation Analysis]
446 Suttie S, McAteer D, Sheehan M, Nicolson M, Schweiger L, Hammonds S, Smith T, Welch A, Park K. F-18-FDG and C-11-Choline Positron Emission Tomography in Human Esophago-Gastric Cancer: Prediction of Response to Therapy. World J Oncol 2010;1:66-7. [PMID: 29147183 DOI: 10.4021/wjon2010.04.201w] [Reference Citation Analysis]
447 Li Z, Zou X, Xie L, Chen H, Chen Y, Yeung SC, Zhang H. Personalizing risk stratification by addition of PAK1 expression to TNM staging: improving the accuracy of clinical decision for gastroesophageal junction adenocarcinoma. Int J Cancer 2015;136:1636-45. [PMID: 25159681 DOI: 10.1002/ijc.29167] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
448 Li M, Wang X, Wang L, Wu X, Wu W, Song X, Zhao S, Zhang F, Ma Q, Liang H, Xiang S, Wang Z, Gong W, Dong P, Liu Y. A three-step method for modular lymphadenectomy in gastric cancer surgery: The ability to retrieve sufficient lymph nodes and improve survival. The American Journal of Surgery 2018;215:91-6. [DOI: 10.1016/j.amjsurg.2017.01.042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
449 Griffiths EA, Pritchard SA, Mapstone NP, Welch IM. Emerging aspects of oesophageal and gastro-oesophageal junction cancer histopathology - an update for the surgical oncologist. World J Surg Oncol. 2006;4:82. [PMID: 17118194 DOI: 10.1186/1477-7819-4-82] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
450 Maruyama S, Kawaguchi Y, Akaike H, Shiraishi K, Saito R, Shimizu H, Furuya S, Hosomura N, Amemiya H, Kawaida H, Sudo M, Inoue S, Kono H, Ichikawa D. Prognostic Significance of Hiatal Hernia in Patients with Gastric Cancer Located within the Upper-Third of the Stomach. World J Surg 2020;44:863-8. [PMID: 31637509 DOI: 10.1007/s00268-019-05236-z] [Reference Citation Analysis]
451 Van Cutsem E, Dicato M, Geva R, Arber N, Bang Y, Benson A, Cervantes A, Diaz-Rubio E, Ducreux M, Glynne-Jones R. The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. Ann Oncol. 2011;22 Suppl 5:v1-v9. [PMID: 21633049 DOI: 10.1093/annonc/mdr284] [Cited by in Crossref: 80] [Cited by in F6Publishing: 74] [Article Influence: 7.3] [Reference Citation Analysis]
452 Yoo CH, Sohn BH, Han WK, Pae WK. Long-term results of proximal and total gastrectomy for adenocarcinoma of the upper third of the stomach. Cancer Res Treat 2004;36:50-5. [PMID: 20396565 DOI: 10.4143/crt.2004.36.1.50] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 2.6] [Reference Citation Analysis]
453 Chen Y, Jin M, Shao Y, Xu G. Prognostic Value of the Systemic Inflammation Response Index in Patients with Adenocarcinoma of the Oesophagogastric Junction: A Propensity Score-Matched Analysis. Dis Markers 2019;2019:4659048. [PMID: 31781301 DOI: 10.1155/2019/4659048] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
454 American Joint Committee on Cancer. Esophagus and Esophagogastric Junction. AJCC Cancer Staging Manual. New York: Springer; 2010. pp. 103-15. [DOI: 10.1007/978-0-387-88441-7_10] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
455 Wong R, Malthaner R. Esophageal cancer: A systematic review. Current Problems in Cancer 2000;24:293-373. [DOI: 10.1016/s0147-0272(00)80002-1] [Cited by in Crossref: 35] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
456 Mine S, Sano T, Hiki N, Yamada K, Kosuga T, Nunobe S, Yamaguchi T. Proximal margin length with transhiatal gastrectomy for Siewert type II and III adenocarcinomas of the oesophagogastric junction. Br J Surg. 2013;100:1050-1054. [PMID: 23754647 DOI: 10.1002/bjs.9170] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
457 Moureau-Zabotto L, Teissier E, Cowen D, Azria D, Ellis S, Resbeut M. Impact of the Siewert Classification on the Outcome of Patients Treated by Preoperative Chemoradiotherapy for a Nonmetastatic Adenocarcinoma of the Oesophagogastric Junction. Gastroenterol Res Pract 2015;2015:404203. [PMID: 26448741 DOI: 10.1155/2015/404203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
458 Bornschein J, Quante M, Jansen M. The complexity of cancer origins at the gastro-oesophageal junction. Best Pract Res Clin Gastroenterol 2021;50-51:101729. [PMID: 33975686 DOI: 10.1016/j.bpg.2021.101729] [Reference Citation Analysis]
459 Viklund P, Lindblad M, Lu M, Ye W, Johansson J, Lagergren J. Risk factors for complications after esophageal cancer resection: a prospective population-based study in Sweden. Ann Surg. 2006;243:204-211. [PMID: 16432353 DOI: 10.1097/01.sla.0000197698.17794.eb] [Cited by in Crossref: 112] [Cited by in F6Publishing: 115] [Article Influence: 7.0] [Reference Citation Analysis]
460 de Jonge PJ, Steyerberg EW, Kuipers EJ, Honkoop P, Wolters LM, Kerkhof M, van Dekken H, Siersema PD. Risk factors for the development of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol. 2006;101:1421-1429. [PMID: 16863542 DOI: 10.1111/j.1572-0241.2006.00626.x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 69] [Article Influence: 4.6] [Reference Citation Analysis]
461 Siewert JR, Feith M, Stein HJ. Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification. J Surg Oncol. 2005;90:139-146; discussion 146. [PMID: 15895452 DOI: 10.1002/jso.20218] [Cited by in Crossref: 136] [Cited by in F6Publishing: 119] [Article Influence: 8.0] [Reference Citation Analysis]
462 Novotny AR, Reim D, Friess HM, Schuhmacher C. Secondary gastrectomy for stage IV gastroesophageal adenocarcinoma after induction-chemotherapy. Langenbecks Arch Surg 2014;399:773-81. [PMID: 24898674 DOI: 10.1007/s00423-014-1217-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
463 Patnana SV, Murthy SB, Xiao L, Rohren E, Hofstetter WL, Swisher SG, Liao Z, Lee JH, Bhutani MS, Macapinlac HA, Wang X, Ajani JA. Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography. Cancer 2010;116:4487-94. [PMID: 20629031 DOI: 10.1002/cncr.25431] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
464 Ott K, Weber WA, Fink U, Helmberger H, Becker K, Stein HJ, Müller J, Schwaiger M, Siewert JR. Fluorodeoxyglucose-positron emission tomography in adenocarcinomas of the distal esophagus and cardia. World J Surg 2003;27:1035-9. [PMID: 12917760 DOI: 10.1007/s00268-003-7058-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
465 Blakely AM, Miner TJ. Surgical considerations in the treatment of gastric cancer. Gastroenterol Clin North Am. 2013;42:337-357. [PMID: 23639644 DOI: 10.1016/j.gtc.2013.01.010.surgical] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
466 Palanivelu C, Prakash A, Parthasarathi R, Senthilkumar R, Senthilnathan PR, Rajapandian S. Laparoscopic esophagogastrectomy without thoracic or cervical access for adenocarcinoma of the gastroesophageal junction: an Indian experience from a tertiary center. Surg Endosc 2007;21:16-20. [PMID: 17031742 DOI: 10.1007/s00464-005-0418-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
467 Abbrederis K, Bassermann F, Schuhmacher C, Voelter V, Busch R, Roethling N, Sendler A, Siewert JR, Peschel C, Lordick F. Erythropoietin-alfa During Neoadjuvant Chemotherapy for Locally Advanced Esophagogastric Adenocarcinoma. The Annals of Thoracic Surgery 2006;82:293-7. [DOI: 10.1016/j.athoracsur.2006.01.097] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
468 Kröll D, Noser L, Erdem S, Storni F, Arnold D, Dislich B, Zlobec I, Candinas D, Seiler CA, Langer R. Application of the 8th edition of the AJCC yTNM staging system shows improved prognostication in a single center cohort of esophageal carcinomas. Surgical Oncology 2018;27:100-5. [DOI: 10.1016/j.suronc.2017.12.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
469 Gockel I, Mehdorn M. [Modern surgery of gastric cancer - innovations for more effectiveness and safety]. MMW Fortschr Med 2016;158:43-6. [PMID: 27439830 DOI: 10.1007/s15006-016-8514-4] [Reference Citation Analysis]
470 Patel VR, Hofstetter WL, Correa AM, Agarwal A, Rashid A, Bhutani MS, Lin SH, Ajani JA, Swisher SG, Maru DM. Signet Ring Cells in Esophageal Adenocarcinoma Predict Poor Response to Preoperative Chemoradiation. The Annals of Thoracic Surgery 2014;98:1064-71. [DOI: 10.1016/j.athoracsur.2014.04.099] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
471 Bringeland EA, Wasmuth HH, Mjønes P, Myklebust TÅ, Grønbech JE. A population-based study on incidence rates, Lauren distribution, stage distribution, treatment, and long-term outcomes for gastric adenocarcinoma in Central Norway 2001–2011. Acta Oncologica 2017;56:39-45. [DOI: 10.1080/0284186x.2016.1227086] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
472 Martin L, Lagergren P. Long-term weight change after oesophageal cancer surgery. Br J Surg 2009;96:1308-14. [PMID: 19847871 DOI: 10.1002/bjs.6723] [Cited by in Crossref: 83] [Cited by in F6Publishing: 80] [Article Influence: 6.4] [Reference Citation Analysis]
473 Rawicz-Pruszyński K, van Sandick JW, Mielko J, Ciseł B, Polkowski WP. Current challenges in gastric cancer surgery: European perspective. Surg Oncol 2018;27:650-6. [PMID: 30449488 DOI: 10.1016/j.suronc.2018.08.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
474 Kurokawa Y, Takeuchi H, Doki Y, Kitagawa Y. Response to the Comment on "Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors". Ann Surg 2021;274:e682-3. [PMID: 32511127 DOI: 10.1097/SLA.0000000000003814] [Reference Citation Analysis]
475 Smith JW, Moreira J, Abood G, Aranha GV, Nagda S, Wagner RH, Shoup M. The influence of 18flourodeoxyglucose positron emission tomography on the management of gastroesophageal junction carcinoma. The American Journal of Surgery 2009;197:308-12. [DOI: 10.1016/j.amjsurg.2008.10.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
476 Andreou A, Biebl M, Dadras M, Struecker B, Sauer IM, Thuss-Patience PC, Chopra S, Fikatas P, Bahra M, Seehofer D, Pratschke J, Schmidt SC. Anastomotic leak predicts diminished long-term survival after resection for gastric and esophageal cancer. Surgery 2016;160:191-203. [PMID: 27067160 DOI: 10.1016/j.surg.2016.02.020] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
477 Geng Q, Lao J, Zuo X, Chen S, Bei JX, Xu D. Identification of the distinct genomic features in gastroesophageal junction adenocarcinoma and its Siewert subtypes. J Pathol 2020;252:263-73. [PMID: 32715475 DOI: 10.1002/path.5516] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
478 Djärv T, Blazeby JM, Lagergren P. Predictors of postoperative quality of life after esophagectomy for cancer. J Clin Oncol. 2009;27:1963-1968. [PMID: 19289614 DOI: 10.1200/jco.2008.20.5864] [Cited by in Crossref: 79] [Cited by in F6Publishing: 23] [Article Influence: 6.1] [Reference Citation Analysis]
479 Sarbia M, Bitzer M, Siegel D, Ross D, Schulz WA, Zotz RB, Kiel S, Geddert H, Kandemir Y, Walter A, Willers R, Gabbert HE. Association betweenNAD(P)H: Quinone oxidoreductase 1 (NQ01) inactivating C609T polymorphism and adenocarcinoma of the upper gastrointestinal tract. Int J Cancer 2003;107:381-6. [DOI: 10.1002/ijc.11430] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 2.3] [Reference Citation Analysis]
480 Cellini F, Morganti AG, Di Matteo FM, Mattiucci GC, Valentini V. Clinical management of gastroesophageal junction tumors: past and recent evidences for the role of radiotherapy in the multidisciplinary approach. Radiat Oncol 2014;9:45. [PMID: 24499595 DOI: 10.1186/1748-717X-9-45] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
481 Casson AG. Role of molecular biology in the follow-up of patients who have Barrett's esophagus. Chest Surgery Clinics of North America 2002;12:93-111. [DOI: 10.1016/s1052-3359(03)00068-1] [Cited by in Crossref: 13] [Article Influence: 0.7] [Reference Citation Analysis]
482 Oono Y, Kuwata T, Takashima K, Yoda Y, Ikematsu H, Shitara K, Kinoshita T, Yano T. Clinicopathological features and endoscopic findings of HER2-positive gastric cancer. Surg Endosc. 2018;32:3964-3971. [PMID: 29500656 DOI: 10.1007/s00464-018-6138-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
483 Tamandl D, Gore RM, Fueger B, Kinsperger P, Hejna M, Paireder M, Haug A, Schoppmann SF, Ba-Ssalamah A. Change in volume parameters induced by neoadjuvant chemotherapy provide accurate prediction of overall survival after resection in patients with oesophageal cancer. Eur Radiol 2016;26:311-21. [PMID: 26040648 DOI: 10.1007/s00330-015-3860-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
484 Wang N, Dong XJ, Zhou RM, Guo W, Zhang XJ, Li Y. An investigation on the polymorphisms of two DNA repair genes and susceptibility to ESCC and GCA of high-incidence region in northern China. Mol Biol Rep. 2009;36:357-364. [PMID: 18046624 DOI: 10.1007/s11033-007-9187-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
485 Jensen LS, Pilegaard HK, Puho E, Pahle E, Melsen NC. Outcome after Transthoracic Resection of Carcinoma of the Oesophagus and Oesophago-Gastric Junction: Impact of a Dedicated Surgical Team Unit. Scand J Surg 2005;94:191-6. [DOI: 10.1177/145749690509400303] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
486 Lutz MP, Zalcberg JR, Ducreux M, Adenis A, Allum W, Aust D, Carneiro F, Grabsch HI, Laurent-Puig P, Lordick F, Möhler M, Mönig S, Obermannova R, Piessen G, Riddell A, Röcken C, Roviello F, Schneider PM, Seewald S, Smyth E, van Cutsem E, Verheij M, Wagner AD, Otto F. The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma. Eur J Cancer 2019;112:1-8. [PMID: 30878666 DOI: 10.1016/j.ejca.2019.01.106] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
487 Dellaportas D, Gossage JA, Davies AR. Management and Reconstruction of a Gastroesophageal Junction Adenocarcinoma Patient Three Years after Pancreaticoduodenectomy: A Surgical Puzzle. Case Rep Surg 2016;2016:5650382. [PMID: 27635275 DOI: 10.1155/2016/5650382] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
488 Ito H, Inoue H, Odaka N, Satodate H, Suzuki M, Mukai S, Takehara Y, Kida H, Kudo SE. Clinicopathological characteristics and optimal management for esophagogastric junctional cancer; a single center retrospective cohort study. J Exp Clin Cancer Res 2013;32:2. [PMID: 23289488 DOI: 10.1186/1756-9966-32-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
489 Darnton SJ, Hardie LJ, Muc RS, Wild CP, Casson AG. Tissue inhibitor of metalloproteinase-3 (TIMP-3) gene is methylated in the development of esophageal adenocarcinoma: loss of expression correlates with poor prognosis. Int J Cancer. 2005;115:351-358. [PMID: 15688381 DOI: 10.1002/ijc.20830] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 2.5] [Reference Citation Analysis]
490 Wang Q, Li T, Liu H, Jia X, Liu B, Wan X, Lang J. The safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy. Radiat Oncol 2014;9:99. [PMID: 24774780 DOI: 10.1186/1748-717X-9-99] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
491 Li Y, Sun DL, Duan YN, Zhang XJ, Wang N, Zhou RM, Chen ZF, Wang SJ. Association of functional polymorphisms in MMPs genes with gastric cardia adenocarcinoma and esophageal squamous cell carcinoma in high incidence region of North China. Mol Biol Rep. 2010;37:197-205. [PMID: 19562509 DOI: 10.1007/s11033-009-9593-4] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 3.5] [Reference Citation Analysis]
492 Liu XB, Gao ZY, Zhang QH, Pandey S, Gao B, Yang F, Tong Q, Li SB. Preoperative Neutrophil Lymphocyte Ratio Can Be Used as a Predictor of Prognosis in Patients With Adenocarcinoma of the Esophagogastric Junction: A Systematic Review and Meta Analysis. Front Oncol 2020;10:178. [PMID: 32154173 DOI: 10.3389/fonc.2020.00178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
493 Zhao J, Zhao J, Du F, Zhang Y, Shen G, Zhu H, Ji F, Ma F, Dong L, Kan J, Zheng F, Chen H, Wang Z, Xu B. Cardia and Non-Cardia Gastric Cancer Have Similar Stage-for-Stage Prognoses After R0 Resection: a Large-Scale, Multicenter Study in China. J Gastrointest Surg 2016;20:700-7. [PMID: 26831062 DOI: 10.1007/s11605-016-3089-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
494 Allum WH, Bonavina L, Cassivi SD, Cuesta MA, Dong ZM, Felix VN, Figueredo E, Gatenby PA, Haverkamp L, Ibraev MA, Krasna MJ, Lambert R, Langer R, Lewis MP, Nason KS, Parry K, Preston SR, Ruurda JP, Schaheen LW, Tatum RP, Turkin IN, van der Horst S, van der Peet DL, van der Sluis PC, van Hillegersberg R, Wormald JC, Wu PC, Zonderhuis BM. Surgical treatments for esophageal cancers. Ann N Y Acad Sci. 2014;1325:242-268. [PMID: 25266029 DOI: 10.1111/nyas.12533] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
495 Gopalakrishnan G, Kalayarasan R, Gnanasekaran S, Pottakkat B. The technique of fourth jejunal artery-based jejunal conduit for oesophagojejunostomy after thoracolaparoscopic oesophagogastrectomy for locally advanced Siewert type II tumour. J Minim Access Surg 2021;17:236-40. [PMID: 32964877 DOI: 10.4103/jmas.JMAS_99_20] [Reference Citation Analysis]
496 Mine S, Sano T, Hiki N, Yamada K, Nunobe S, Yamaguchi T. Lymphadenectomy around the left renal vein in Siewert type II adenocarcinoma of the oesophagogastric junction. Br J Surg. 2013;100:261-266. [PMID: 23180514 DOI: 10.1002/bjs.8967] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
497 Wang Y, Zhang FX, Chang ZH, Liu X, Deng SX, Zhao HX. EUS versus CT for preoperative TN staging of adenocarcinoma of the esophagogastric junction. Shijie Huaren Xiaohua Zazhi 2013; 21(20): 1977-1981 [DOI: 10.11569/wcjd.v21.i20.1977] [Reference Citation Analysis]
498 Becker L, Huang Q, Mashimo H. Lgr5, an intestinal stem cell marker, is abnormally expressed in Barrett’s esophagus and esophageal adenocarcinoma. Dis Esophagus. 2010;23:168-174. [PMID: 19549212 DOI: 10.1111/j.1442-2050.2009.00979.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 59] [Article Influence: 4.2] [Reference Citation Analysis]
499 Griffiths EA, Pritchard SA, McGrath SM, Valentine HR, Price PM, Welch IM, West CM. Hypoxia-associated markers in gastric carcinogenesis and HIF-2alpha in gastric and gastro-oesophageal cancer prognosis. Br J Cancer. 2008;98:965-973. [PMID: 18283323 DOI: 10.1038/sj.bjc.6604210] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
500 DE Jonge PJ, Wolters LM, Steyerberg EW, VAN Dekken H, Kusters JG, Kuipers EJ, Siersema PD. Environmental risk factors in the development of adenocarcinoma of the oesophagus or gastric cardia: a cross-sectional study in a Dutch cohort. Aliment Pharmacol Ther. 2007;26:31-39. [PMID: 17555419 DOI: 10.1111/j.1365-2036.2007.03344.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
501 Micev M, Cosic-micev M. Pathology and pathobiology of the oesophageal carcinoma. Acta chir iugo 2010;57:15-26. [DOI: 10.2298/aci1002015m] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
502 Lorenzen S, Blank S, Lordick F, Siewert JR, Ott K. Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients. Ann Surg Oncol. 2012;19:2119-2127. [PMID: 22395980 DOI: 10.1245/s10434-012-2254-1] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
503 Grimm M, Lazariotou M, Kircher S, Stuermer L, Reiber C, Höfelmayr A, Gattenlöhner S, Otto C, Germer CT, von Rahden BH. MMP-1 is a (pre-)invasive factor in Barrett-associated esophageal adenocarcinomas and is associated with positive lymph node status. J Transl Med 2010;8:99. [PMID: 20946664 DOI: 10.1186/1479-5876-8-99] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
504 Power D, Reynolds J. Localized adenocarcinoma of the esophagogastric junction – Is there a standard of care? Cancer Treatment Reviews 2010;36:400-9. [DOI: 10.1016/j.ctrv.2010.01.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
505 Stein HJ, Brücher BL, Sendler A, Siewert JR. Esophageal cancer: patient evaluation and pre-treatment staging. Surg Oncol. 2001;10:103-111. [PMID: 11750229 DOI: 10.1016/s0960-7404(01)00023-8] [Cited by in Crossref: 52] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
506 Zhu T, Wang Z, Wang G, Hu Z, Ding H, Li R, Sun J. Long non-coding RNA ZFAS1 promotes the expression of EPAS1 in gastric cardia adenocarcinoma. J Adv Res 2021;28:7-15. [PMID: 33364040 DOI: 10.1016/j.jare.2020.06.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
507 Arkadopoulos N, Marinis A, Dafnios N, Theodosopoulos T, Smyrniotis V. A novel technique for gaining extra length of the abdominal esophagus. Am J Surg 2009;198:e10-2. [PMID: 19345335 DOI: 10.1016/j.amjsurg.2008.11.042] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
508 Stein HJ, Feith M, Bruecher BL, Naehrig J, Sarbia M, Siewert JR. Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. Ann Surg. 2005;242:566-573; discussion 573-575. [PMID: 16192817 DOI: 10.1016/s0739-5930(08)70389-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
509 Lin D, Khan U, Goetze TO, Reizine N, Goodman KA, Shah MA, Catenacci DV, Al-Batran SE, Posey JA. Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management? Am Soc Clin Oncol Educ Book 2019;39:e88-95. [PMID: 31099690 DOI: 10.1200/EDBK_236827] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
510 Wesolowski R, Lee C, Kim R. Is there a role for second-line chemotherapy in advanced gastric cancer? Lancet Oncol. 2009;903-912. [PMID: 19717092 DOI: 10.1016/s1470-2045(09)70136-6] [Cited by in Crossref: 81] [Cited by in F6Publishing: 42] [Article Influence: 6.2] [Reference Citation Analysis]
511 Langer R, Ott K, Feith M, Lordick F, Siewert JR, Becker K. Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas. Mod Pathol. 2009;22:1555-1563. [PMID: 19801967 DOI: 10.1038/modpathol.2009.123] [Cited by in Crossref: 70] [Cited by in F6Publishing: 75] [Article Influence: 5.4] [Reference Citation Analysis]
512 Liu Y, He S, Zhang Y, Dou L, Liu X, Yu X, Lu N, Xue L, Wang G. Comparing long-term outcomes between endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR) for type II esophagogastric junction neoplasm. Ann Transl Med 2021;9:322. [PMID: 33708949 DOI: 10.21037/atm-20-4265] [Reference Citation Analysis]
513 Martin JT, Mahan A, Zwischenberger JB, McGrath PC, Tzeng CW. Should gastric cardia cancers be treated with esophagectomy or total gastrectomy? A comprehensive analysis of 4,996 NSQIP/SEER patients. J Am Coll Surg 2015;220:510-20. [PMID: 25667138 DOI: 10.1016/j.jamcollsurg.2014.12.024] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 4.1] [Reference Citation Analysis]
514 Zhu M, Cao B, Li X, Li P, Wen Z, Ji J, Min L, Zhang S. Risk factors and a predictive nomogram for lymph node metastasis of superficial esophagogastric junction cancer. J Gastroenterol Hepatol 2020;35:1524-31. [PMID: 32023349 DOI: 10.1111/jgh.15004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
515 Galán M, Farran L, Aliste L, Hormigo G, Aranda H, Bettonica C, Boladeras AM, Botargues JM, Calvo M, Creus G, De Lama ME, Gornals JB, Mast R, Miró M, Paúles MJ, Robles J, Virgili N, Borràs JM. Multidisciplinary cancer care may impact on the postoperative mortality and survival of patients with oesophageal and oesophagogastric junction cancer: a retrospective cohort study. Clin Transl Oncol 2015;17:247-56. [DOI: 10.1007/s12094-014-1221-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
516 Yamada M, Kushima R, Oda I, Mojtahed K, Nonaka S, Suzuki H, Yoshinaga S, Matsubara A, Taniguchi H, Sekine S, Saito Y, Shimoda T. Different histological status of gastritis in superficial adenocarcinoma of the esophagogastric junction. Jpn J Clin Oncol 2014;44:65-71. [PMID: 24220802 DOI: 10.1093/jjco/hyt167] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
517 Healy LA, Ryan AM, Moore J, Rowley S, Ravi N, Byrne PJ, Reynolds JV. Health-related quality of life assessment at presentation may predict complications and early relapse in patients with localized cancer of the esophagus: Quality of life is associated with outcomes after esophagectomy. Diseases of the Esophagus 2008;21:522-8. [DOI: 10.1111/j.1442-2050.2008.00814.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
518 Voelter V, Schuhmacher C, Busch R, Peschel C, Rüdiger Siewert J, Lordick F. Incidence of anemia in patients receiving neoadjuvant chemotherapy for locally advanced esophagogastric cancer. The Annals of Thoracic Surgery 2004;78:1037-41. [DOI: 10.1016/j.athoracsur.2004.01.049] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
519 Kim KT, Jeong O, Jung MR, Ryu SY, Park YK. Outcomes of Abdominal Total Gastrectomy for Type II and III Gastroesophageal Junction Tumors: Single Center's Experience in Korea. J Gastric Cancer 2012;12:36-42. [PMID: 22500262 DOI: 10.5230/jgc.2012.12.1.36] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
520 Zhang G, Zhang X, Xue H. Open Versus Hand-assisted Laparoscopic Total Gastric Resection With D2 Lymph Node Dissection for Adenocarcinoma: A Case-Control Study. Surgical Laparoscopy, Endoscopy & Percutaneous Techniques 2017;27:42-50. [DOI: 10.1097/sle.0000000000000363] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
521 Sun W, Powell M, O'Dwyer PJ, Catalano P, Ansari RH, Benson AB 3rd. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 2010;28:2947-51. [PMID: 20458043 DOI: 10.1200/JCO.2009.27.7988] [Cited by in Crossref: 141] [Cited by in F6Publishing: 84] [Article Influence: 11.8] [Reference Citation Analysis]
522 Dresner S, Lamb P, Bennett M, Hayes N, Griffin S. The pattern of metastatic lymph node dissemination from adenocarcinoma of the esophagogastric junction. Surgery 2001;129:103-9. [DOI: 10.1067/msy.2001.110024] [Cited by in Crossref: 117] [Cited by in F6Publishing: 108] [Article Influence: 5.6] [Reference Citation Analysis]
523 Barbour AP, Rizk NP, Gonen M, Tang L, Bains MS, Rusch VW, Coit DG, Brennan MF. Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome. Ann Surg. 2007;246:1-8. [PMID: 17592282 DOI: 10.1097/01.sla.0000255563.65157.d2] [Cited by in Crossref: 151] [Cited by in F6Publishing: 136] [Article Influence: 10.1] [Reference Citation Analysis]
524 Vos EL, Carr RA, Hsu M, Nakauchi M, Nobel T, Russo A, Barbetta A, Tan KS, Tang L, Ilson D, Ku GY, Wu AJ, Janjigian YY, Yoon SS, Bains MS, Jones DR, Coit D, Molena D, Strong VE. Prognosis after neoadjuvant chemoradiation or chemotherapy for locally advanced gastro-oesophageal junctional adenocarcinoma. Br J Surg 2021;108:1332-40. [PMID: 34476473 DOI: 10.1093/bjs/znab228] [Reference Citation Analysis]
525 Kunisaki C, Akiyama H, Nomura M, Matsuda G, Otsuka Y, Ono H, Shimada H. Surgical outcomes for early gastric cancer in the upper third of the stomach. J Am Coll Surg. 2005;200:15-19. [PMID: 15631915 DOI: 10.1016/j.jamcollsurg.2004.09.015] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 1.7] [Reference Citation Analysis]
526 Shen JG, Cheong JH, Hyung WJ, Kim J, Choi SH, Noh SH. Influence of a microscopic positive proximal margin in the treatment of gastric adenocarcinoma of the cardia. World J Gastroenterol 2006; 12(24): 3883-3886 [PMID: 16804975 DOI: 10.3748/wjg.v12.i24.3883] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
527 Wang Y, Guo W, He Y, Chen Z, Wen D, Zhang X, Wang N, Li Y, Ge H, Zhang J. Association of MTHFR C677T and SHMT1 C1420T with susceptibility to ESCC and GCA in a high incident region of Northern China. Cancer Causes Control 2007;18:143-52. [DOI: 10.1007/s10552-006-0097-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
528 Achiam MP, Jensen LB, Larsson H, Jensen LS, Larsen AC, Holm J, Svendsen LB. Comparative Investigation of Postoperative Complications in Patients With Gastroesophageal Junction Cancer Treated With Preoperative Chemotherapy or Surgery Alone. Scand J Surg 2016;105:22-8. [DOI: 10.1177/1457496915577021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
529 Koyanagi K, Kato F, Kanamori J, Daiko H, Ozawa S, Tachimori Y. Clinical significance of esophageal invasion length for the prediction of mediastinal lymph node metastasis in Siewert type II adenocarcinoma: A retrospective single-institution study. Ann Gastroenterol Surg 2018;2:187-96. [PMID: 29863189 DOI: 10.1002/ags3.12069] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
530 Kauppila JH, Wahlin K, Lagergren J. Gastrectomy compared to oesophagectomy for Siewert II and III gastro-oesophageal junctional cancer in relation to resection margins, lymphadenectomy and survival. Sci Rep 2017;7:17783. [PMID: 29259274 DOI: 10.1038/s41598-017-18005-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
531 Wang LD, Zheng S, Zheng ZY, Casson AG. Primary adenocarcinomas of lower esophagus, esophagogastric junction and gastric cardia: in special reference to China. World J Gastroenterol 2003; 9(6): 1156-1164 [PMID: 12800215 DOI: 10.3748/wjg.v9.i6.1156] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 38] [Article Influence: 1.9] [Reference Citation Analysis]
532 Amini N, Spolverato G, Kim Y, Squires MH, Poultsides GA, Fields R, Schmidt C, Weber SM, Votanopoulos K, Maithel SK, Pawlik TM. Clinicopathological features and prognosis of gastric cardia adenocarcinoma: a multi-institutional US study. J Surg Oncol 2015;111:285-92. [PMID: 25308915 DOI: 10.1002/jso.23799] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
533 De Cobelli F, Giganti F, Orsenigo E, Cellina M, Esposito A, Agostini G, Albarello L, Mazza E, Ambrosi A, Socci C, Staudacher C, Del Maschio A. Apparent diffusion coefficient modifications in assessing gastro-oesophageal cancer response to neoadjuvant treatment: Comparison with tumour regression grade at histology. Eur Radiol. 2013;23:2165-2174. [PMID: 23588582 DOI: 10.1007/s00330-013-2807-0] [Cited by in Crossref: 65] [Cited by in F6Publishing: 68] [Article Influence: 7.2] [Reference Citation Analysis]
534 Hellstadius Y, Lagergren P, Lagergren J, Johar A, Hultman CM, Wikman A. Aspects of emotional functioning following oesophageal cancer surgery in a population-based cohort study.Psychooncology. 2015;24:47-53. [PMID: 24895142 DOI: 10.1002/pon.3583] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
535 Lv CB, Huang CM, Zheng CH, Li P, Xie JW, Wang JB, Lin JX, Lu J, Chen QY, Cao LL, Lin M, Tu RH. Should Splenic Hilar Lymph Nodes be Dissected for Siewert Type II and III Esophagogastric Junction Carcinoma Based on Tumor Diameter?: A Retrospective Database Analysis. Medicine (Baltimore) 2016;95:e3473. [PMID: 27227913 DOI: 10.1097/MD.0000000000003473] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
536 Zhang CH, Zhan WH, He YL, Chen CQ, Huang MJ, Cai SR. Spleen preservation in radical surgery for gastric cardia cancer. Ann Surg Oncol. 2007;14:1312-1319. [PMID: 17265118 DOI: 10.1245/s10434-006-9190-x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 2.5] [Reference Citation Analysis]
537 Paireder M, Jomrich G, Asari R, Kristo I, Gleiss A, Preusser M, Schoppmann SF. External validation of the NUn score for predicting anastomotic leakage after oesophageal resection. Sci Rep 2017;7:9725. [PMID: 28852063 DOI: 10.1038/s41598-017-10084-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
538 Kakeji Y, Yamamoto M, Ito S, Sugiyama M, Egashira A, Saeki H, Morita M, Sakaguchi Y, Toh Y, Maehara Y. Lymph node metastasis from cancer of the esophagogastric junction, and determination of the appropriate nodal dissection. Surg Today. 2012;42:351-358. [PMID: 22245924 DOI: 10.1007/s00595-011-0114-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
539 Chen K, Deng X, Yang Z, Yu D, Zhang X, Li W, Xie D, He Z, Cheng D. Sites of distant metastases and the cancer-specific survival of metastatic Siewert type II esophagogastric junction adenocarcinoma: a population-based study. Expert Rev Gastroenterol Hepatol 2020;14:491-7. [PMID: 32324423 DOI: 10.1080/17474124.2020.1760839] [Reference Citation Analysis]
540 Huang Q, Shi J, Feng A, Fan X, Zhang L, Mashimo H, Cohen D, Lauwers G. Gastric cardiac carcinomas involving the esophagus are more adequately staged as gastric cancers by the 7th edition of the American Joint Commission on Cancer Staging System. Mod Pathol. 2011;24:138-146. [PMID: 20852593 DOI: 10.1038/modpathol.2010.183] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
541 Pedrazzani C, de Manzoni G, Marrelli D, Giacopuzzi S, Corso G, Bernini M, Roviello F. Nodal Staging in Adenocarcinoma of the Gastro-Esophageal Junction. Proposal of a Specific Staging System. Ann Surg Oncol 2007;14:299-305. [DOI: 10.1245/s10434-006-9094-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
542 Deans C, Rose-Zerilli M, Wigmore S, Ross J, Howell M, Jackson A, Grimble R, Fearon K. Host cytokine genotype is related to adverse prognosis and systemic inflammation in gastro-oesophageal cancer. Ann Surg Oncol 2007;14:329-39. [PMID: 17103073 DOI: 10.1245/s10434-006-9122-9] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 2.8] [Reference Citation Analysis]
543 Deans C, Yeo MS, Soe MY, Shabbir A, Ti TK, So JB. Cancer of the gastric cardia is rising in incidence in an Asian population and is associated with adverse outcome. World J Surg. 2011;35:617-624. [PMID: 21203759 DOI: 10.1007/s00268-010-0935-0] [Cited by in Crossref: 82] [Cited by in F6Publishing: 71] [Article Influence: 7.5] [Reference Citation Analysis]
544 Reynolds JV, Muldoon C, Hollywood D, Ravi N, Rowley S, O'Byrne K, Kennedy J, Murphy TJ. Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg 2007;245:707-16. [PMID: 17457163 DOI: 10.1097/01.sla.0000254367.15810.38] [Cited by in Crossref: 118] [Cited by in F6Publishing: 107] [Article Influence: 7.9] [Reference Citation Analysis]
545 Van De Voorde L, Larue RT, Pijls M, Buijsen J, Troost EG, Berbée M, Sosef M, van Elmpt W, Schraepen M, Vanneste B, Oellers M, Lambin P. A qualitative synthesis of the evidence behind elective lymph node irradiation in oesophageal cancer. Radiotherapy and Oncology 2014;113:166-74. [DOI: 10.1016/j.radonc.2014.11.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
546 Hashimoto T, Kurokawa Y, Mori M, Doki Y. Surgical Treatment of Gastroesophageal Junction Cancer. J Gastric Cancer 2018;18:209-17. [PMID: 30275998 DOI: 10.5230/jgc.2018.18.e28] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
547 Yang ZF, Wu DQ, Wang JJ, Feng XY, Zheng JB, Hu WX, Li Y. Surgical approach for Siewert type II adenocarcinoma of the esophagogastric junction: transthoracic or transabdominal? -a single-center retrospective study. Ann Transl Med 2018;6:450. [PMID: 30603638 DOI: 10.21037/atm.2018.10.66] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
548 Nakata T, Kobayashi A, Miwa S, Soeda J, Uehara T, Miyagawa S. Clinical and pathological features of primary carcinoma of the cystic duct. J Hepatobiliary Pancreat Surg 2009;16:75-82. [PMID: 19096752 DOI: 10.1007/s00534-008-0008-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
549 Huang Q, Fan X, Agoston AT, Feng A, Yu H, Lauwers G, Zhang L, Odze RD. Comparison of gastro-oesophageal junction carcinomas in Chinese versus American patients. Histopathology. 2011;59:188-197. [PMID: 21884197 DOI: 10.1111/j.1365-2559.2011.03924.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
550 Jovanović I, Alempijević T, Milosavljević T, Popović D, Bjelović M, Micev M, Pesko P. [Clinicopathological characteristics of Barrett's carcinoma, cardia carcinoma type II and distal gastric carcinoma: influence of observed parameters on the five-year postoperative survival of patients]. Srp Arh Celok Lek 2009;137:249-54. [PMID: 19594065 DOI: 10.2298/sarh0906249j] [Reference Citation Analysis]
551 Weitz J, D’angelica M, Gonen M, Klimstra D, Coit DG, Brennan MF, Karpeh MS. Interaction of Splenectomy and Perioperative Blood Transfusions on Prognosis of Patients With Proximal Gastric and Gastroesophageal Junction Cancer. JCO 2003;21:4597-603. [DOI: 10.1200/jco.2003.12.136] [Cited by in Crossref: 36] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
552 Cuesta MA, van der Wielen N, Weijs TJ, Bleys RL, Gisbertz SS, van Duijvendijk P, van Hillegersberg R, Ruurda JP, van Berge Henegouwen MI, Straatman J, Osugi H, van der Peet DL. Surgical anatomy of the supracarinal esophagus based on a minimally invasive approach: vascular and nervous anatomy and technical steps to resection and lymphadenectomy. Surg Endosc 2017;31:1863-70. [PMID: 27553798 DOI: 10.1007/s00464-016-5186-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
553 Aurello P, D'angelo F, Nigri G, Bellagamba R, Cicchini C, Ruzzetti R, Ramacciato G. Comparison between Site N-Category and Number N-Category for Nodal Staging in Carcinoma of the Gastroesophageal Junction: Our Experience and Literature Review. The American Surgeon 2006;72:118-23. [DOI: 10.1177/000313480607200204] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
554 Archid R, Bazerbachi F, Thomas MC, Königsrainer A, Wichmann D. Endoscopic negative pressure therapy for upper gastrointestinal leaks: description of a fashioned device allowing simultaneous enteral feeding. VideoGIE 2021;6:58-61. [PMID: 33884328 DOI: 10.1016/j.vgie.2020.10.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
555 Openshaw MR, Richards CJ, Guttery DS, Shaw JA, Thomas AL. The genetics of gastroesophageal adenocarcinoma and the use of circulating cell free DNA for disease detection and monitoring. Expert Review of Molecular Diagnostics 2017;17:459-70. [DOI: 10.1080/14737159.2017.1308824] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
556 Reynolds JV, Murphy TJ, Ravi N. Multimodality Therapy for Adenocarcinoma of the Esophagus, Gastric Cardia, and Upper Gastric Third. In: Schneider PM, editor. Adenocarcinoma of the Esophagogastric Junction. Berlin: Springer Berlin Heidelberg; 2010. pp. 155-66. [DOI: 10.1007/978-3-540-70579-6_13] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
557 Yuan Y, Chen L, Ren S, Wang Z, Chen Y, Jin A, Li S, Fang X, Wang T, Bian Y, Yang Q, Bai C, Hao Q, Lu J. Diagnostic performance in T staging for patients with esophagogastric junction cancer using high-resolution MRI: a comparison with conventional MRI at 3 tesla. Cancer Imaging 2019;19:83. [PMID: 31801587 DOI: 10.1186/s40644-019-0269-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
558 Pattison S, Mann GB, Crosthwaite G, Lade S, Mitchell C, Leong T, Busuttil RA, Boussioutas A. Predictors of outcome after surgery for gastric cancer in a Western cohort. ANZ J Surg. 2016;86:469-474. [PMID: 25388659 DOI: 10.1111/ans.12915] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
559 Carboni F, Lorusso R, Santoro R, Lepiane P, Mancini P, Sperduti I, Santoro E. Adenocarcinoma of the esophagogastric junction: the role of abdominal-transhiatal resection. Ann Surg Oncol 2009;16:304-10. [PMID: 19050964 DOI: 10.1245/s10434-008-0247-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
560 Balakrishnan M, George R, Sharma A, Graham DY, Malaty HM. An Investigation into the Recent Increase in Gastric Cancer in the USA. Dig Dis Sci 2018;63:1613-9. [PMID: 29546646 DOI: 10.1007/s10620-018-5012-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
561 Fukuda S, Watanabe K, Yoshida T, Takahashi S, Fujimori S, Horikawa Y, Komatsu T, Shirane K, Shimodaira Y, Matsuhashi T, Iijima K. Low risk of esophageal adenocarcinoma among patients with ultrashort-segment Barrett's esophagus in Japan. Dig Endosc 2021. [PMID: 34437742 DOI: 10.1111/den.14118] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
562 Hejna M, Birner P, Preusser M, Thallinger CM, Worel N, Asari R, Dolak W, Schmid R, Schoppmann SF, Raderer M. Lack of correlation between blood group and HER-2 status in adenocarcinomas of the upper gastrointestinal tract. Mol Clin Oncol 2013;1:1079-83. [PMID: 24649296 DOI: 10.3892/mco.2013.181] [Reference Citation Analysis]
563 Ptok H, Gastinger I, Meyer F, Ilsemann A, Lippert H, Bruns C. [Hospital volume effects in surgical treatment of gastric cancer : Results of a prospective multicenter observational study]. Chirurg 2017;88:328-38. [PMID: 27678401 DOI: 10.1007/s00104-016-0292-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
564 Hasegawa S, Yoshikawa T, Aoyama T, Hayashi T, Yamada T, Tsuchida K, Cho H, Oshima T, Yukawa N, Rino Y. Esophagus or stomach? The seventh TNM classification for Siewert type II/III junctional adenocarcinoma. Ann Surg Oncol. 2013;20:773-779. [PMID: 23224137 DOI: 10.1245/s10434-012-2780-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
565 Jeremiasen M, Walther B, Djerf P, Staël von Holstein C, Zilling T, Hermansson M, Falkenback D, Johansson J. Thoracoabdominal gastrectomy and distal 2/3 esophageal resection with wide lymph node dissection for type II and III adenocarcinoma at the gastro-esophageal junction. Am J Surg 2019;218:329-34. [PMID: 30635210 DOI: 10.1016/j.amjsurg.2018.11.049] [Reference Citation Analysis]
566 Lordick F, Ott K, Sendler A. [Gastric cancer and adenocarcinoma of the esophagogastric junction: principles of neoadjuvant therapy]. Chirurg 2011;82:968-73. [PMID: 22002702 DOI: 10.1007/s00104-011-2127-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
567 Liu CT, Xu YW, Guo H, Hong CQ, Huang XY, Luo YH, Yang SH, Chu LY, Li EM, Peng YH. Serum Insulin-Like Growth Factor Binding Protein 7 as a Potential Biomarker in the Diagnosis and Prognosis of Esophagogastric Junction Adenocarcinoma. Gut Liver 2020;14:727-34. [PMID: 31822054 DOI: 10.5009/gnl19135] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
568 Amenabar A, Hoppo T, Jobe BA. Surgical management of gastroesophageal junction tumors. Semin Radiat Oncol. 2013;23:16-23. [PMID: 23207043 DOI: 10.1016/j.semradonc.2012.09.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
569 Kakar S, Burgart LJ. Adenocarcinoma of the Esophagus and Gastric Cardia: Two Diseases or One?: . Pathology Case Reviews 2002;7:43-7. [DOI: 10.1097/00132583-200201000-00007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
570 Lamb PJ, Griffin SM, Burt AD, Lloyd J, Karat D, Hayes N. Sentinel node biopsy to evaluate the metastatic dissemination of oesophageal adenocarcinoma. British Journal of Surgery 2005;92:60-7. [DOI: 10.1002/bjs.4693] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 3.4] [Reference Citation Analysis]
571 Chen J, Xia YJ, Liu TY, Lai YH, Yu JS, Zhang TH, Ooi S, He YL. Development and validation of a survival nomogram for patients with Siewert type II/III adenocarcinoma of the esophagogastric junction based on real-world data. BMC Cancer 2021;21:532. [PMID: 33971833 DOI: 10.1186/s12885-021-08249-x] [Reference Citation Analysis]
572 Casson AG, Williams L, Guernsey DL. Epidemiology and molecular biology of Barrett esophagus. Semin Thorac Cardiovasc Surg. 2005;17:284-291. [PMID: 16428034 DOI: 10.1053/j.semtcvs.2005.09.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
573 Viklund P, Lindblad M, Lagergren J. Influence of surgery-related factors on quality of life after esophageal or cardia cancer resection. World J Surg. 2005;29:841-848. [PMID: 15951920 DOI: 10.1007/s00268-005-7887-9] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 3.6] [Reference Citation Analysis]
574 Ding BC, Xu AM, Ye ZQ, Han WX, Wei ZJ, Chen ZM, Yuan X, Liu H. Value of transabdominal ultrasoud in preoperative assessment of adenocarcinoma of the esophagogastric junction. Shijie Huaren Xiaohua Zazhi 2016; 24(24): 3612-3617 [DOI: 10.11569/wcjd.v24.i24.3612] [Reference Citation Analysis]
575 Cai MZ, Lv CB, Cai LS, Chen QX. Priority of lymph node dissection for advanced esophagogastric junction adenocarcinoma with the tumor center located below the esophagogastric junction. Medicine (Baltimore) 2019;98:e18451. [PMID: 31861019 DOI: 10.1097/MD.0000000000018451] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
576 Guo W, Lv P, Liu S, Xu F, Guo Y, Shen S, Liang J, Kuang G, Dong Z. Aberrant methylation-mediated downregulation of long noncoding RNA C5orf66-AS1 promotes the development of gastric cardia adenocarcinoma. Mol Carcinog 2018;57:854-65. [PMID: 29566283 DOI: 10.1002/mc.22806] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
577 Wakatsuki K, Takayama T, Ueno M, Matsumoto S, Enomoto K, Tanaka T, Nakajima Y. Characteristics of Gastric Cancer with Esophageal Invasion and Aspects of Surgical Treatment. World J Surg 2009;33:1446-53. [DOI: 10.1007/s00268-009-0053-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
578 Rüdiger Siewert J, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg. 2000;232:353-361. [PMID: 10973385 DOI: 10.1097/00000658-200009000-00007] [Cited by in Crossref: 474] [Cited by in F6Publishing: 432] [Article Influence: 21.5] [Reference Citation Analysis]
579 Brenner B, Hoshen MB, Purim O, David MB, Ashkenazi K, Marshak G, Kundel Y, Brenner R, Morgenstern S, Halpern M, Rosenfeld N, Chajut A, Niv Y, Kushnir M. MicroRNAs as a potential prognostic factor in gastric cancer. World J Gastroenterol 2011; 17(35): 3976-3985 [PMID: 22046085 DOI: 10.3748/wjg.v17.i35.3976] [Cited by in CrossRef: 67] [Cited by in F6Publishing: 62] [Article Influence: 6.1] [Reference Citation Analysis]
580 McCall MD, Graham PJ, Bathe OF. Quality of life: A critical outcome for all surgical treatments of gastric cancer. World J Gastroenterol 2016; 22(3): 1101-1113 [PMID: 26811650 DOI: 10.3748/wjg.v22.i3.1101] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
581 Zacherl J, Sendler A, Stein HJ, Ott K, Feith M, Jakesz R, Siewert JR, Fink U. Current status of neoadjuvant therapy for adenocarcinoma of the distal esophagus. World J Surg. 2003;27:1067-1074. [PMID: 12934159 DOI: 10.1007/s00268-003-7063-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 0.9] [Reference Citation Analysis]
582 Di Leo A, Zanoni A. Siewert III adenocarcinoma: treatment update. Updates Surg. 2017;69:319-325. [PMID: 28303519 DOI: 10.1007/s13304-017-0429-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
583 Sakai T, Ichikawa H, Hanyu T, Usui K, Kano Y, Muneoka Y, Ishikawa T, Shimada Y, Sakata J, Wakai T. Accuracy of the endoscopic evaluation of esophageal involvement in esophagogastric junction cancer. Ann Med Surg (Lond) 2021;68:102590. [PMID: 34401117 DOI: 10.1016/j.amsu.2021.102590] [Reference Citation Analysis]
584 Pye JK, Crumplin MK, Charles J, Kerwat R, Foster ME, Biffin A; Hospital clinicians in Wales. One-year survey of carcinoma of the oesophagus and stomach in Wales. Br J Surg 2001;88:278-85. [PMID: 11167881 DOI: 10.1046/j.1365-2168.2001.01655.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 2.3] [Reference Citation Analysis]
585 Kim HJ, Chung H, Shin SK, Kim H, Park JC, Lee SK, Hyung WJ, Lee YC, Noh SH. Comparison of long-term clinical outcomes between endoscopic and surgical resection for early-stage adenocarcinoma of the esophagogastric junction. Surg Endosc 2018;32:3540-7. [DOI: 10.1007/s00464-018-6076-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
586 Lagergren P, Fayers P, Conroy T, Stein HJ, Sezer O, Hardwick R, Hammerlid E, Bottomley A, Van Cutsem E, Blazeby JM. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago–gastric junction and the stomach. European Journal of Cancer 2007;43:2066-73. [DOI: 10.1016/j.ejca.2007.07.005] [Cited by in Crossref: 89] [Cited by in F6Publishing: 85] [Article Influence: 5.9] [Reference Citation Analysis]
587 Estrella JS, Hofstetter WL, Correa AM, Swisher SG, Ajani JA, Lee JH, Bhutani MS, Abraham SC, Rashid A, Maru DM. Duplicated muscularis mucosae invasion has similar risk of lymph node metastasis and recurrence-free survival as intramucosal esophageal adenocarcinoma. Am J Surg Pathol. 2011;35:1045-1053. [PMID: 21602659 DOI: 10.1097/pas.0b013e318219ccef] [Cited by in Crossref: 31] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
588 Kinoshita T, Gotohda N, Kato Y, Takahashi S, Konishi M, Okazumi S, Katoh R, Kinoshita T. Laparoscopic transhiatal resection for Siewert type II adenocarcinoma of the esophagogastric junction: operative technique and initial results. Surg Laparosc Endosc Percutan Tech. 2012;22:e199-e203. [PMID: 22874699 DOI: 10.1097/sle.0b013e31825a72e2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
589 Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8:797-805. [PMID: 17693134 DOI: 10.1016/s1470-2045(07)70244-9] [Cited by in Crossref: 566] [Cited by in F6Publishing: 202] [Article Influence: 37.7] [Reference Citation Analysis]
590 Weise F, Vieth M, Reinhold D, Haybaeck J, Goni E, Lippert H, Ridwelski K, Lingohr P, Schildberg C, Vassos N, Kruschewski M, Krasniuk I, Grimminger PP, Waidmann O, Peitz U, Veits L, Kreuser N, Lang H, Bruns C, Moehler M, Lordick F, Gockel I, Schumacher J, Malfertheiner P, Venerito M. Gastric cancer in autoimmune gastritis: A case-control study from the German centers of the staR project on gastric cancer research. United European Gastroenterol J 2020;8:175-84. [PMID: 32213076 DOI: 10.1177/2050640619891580] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
591 Mir MR, Lashkari M, Ghalehtaki R, Mir A, Latif AH. Transhiatal versus Left Transthoracic Esophagectomy for Gastroesophageal Junction Cancer; The Impact of Surgical Approach on Postoperative Complications. Middle East J Dig Dis 2019;11:104-9. [PMID: 31380007 DOI: 10.15171/mejdd.2018.135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
592 Anandavadivelan P, Wikman A, Johar A, Lagergren P. Profiles of patient and tumour characteristics in relation to health-related quality of life after oesophageal cancer surgery. PLoS One 2018;13:e0196187. [PMID: 29708994 DOI: 10.1371/journal.pone.0196187] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
593 Giganti F, Orsenigo E, Arcidiacono PG, Nicoletti R, Albarello L, Ambrosi A, Salerno A, Esposito A, Petrone MC, Chiari D. Preoperative locoregional staging of gastric cancer: is there a place for magnetic resonance imaging? Prospective comparison with EUS and multidetector computed tomography. Gastric Cancer. 2016;19:216-225. [PMID: 25614468 DOI: 10.1007/s10120-015-0468-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
594 Li S, Li B, Wang J, Zhang D, Liu Z, Zhang Z, Zhang W, Wang Y, Bai D, Guan J. Identification of Sensitivity Predictors of Neoadjuvant Chemotherapy for the Treatment of Adenocarcinoma of Gastroesophageal Junction. Oncol Res. 2017;25:93-97. [PMID: 28081737 DOI: 10.3727/096504016x14719078133564] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
595 Yin J, Wang X, Wei J, Wang L, Shi Y, Zheng L, Tang W, Ding G, Liu C, Liu R, Chen S, Xu Z, Gu H. Interleukin 12B rs3212227 T > G polymorphism was associated with an increased risk of gastric cardiac adenocarcinoma in a Chinese population. Dis Esophagus 2015;28:291-8. [PMID: 24529168 DOI: 10.1111/dote.12189] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
596 Wainberg ZA, Lin LS, DiCarlo B, Dao KM, Patel R, Park DJ, Wang HJ, Elashoff R, Ryba N, Hecht JR. Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. Br J Cancer 2011;105:760-5. [PMID: 21811258 DOI: 10.1038/bjc.2011.280] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 5.0] [Reference Citation Analysis]
597 von Döbeln GA, Wagenius G, Holtved E, Jacobsen AB, Nilsson M, Yu J, Baeksgaard L. Definitive chemoradiotherapy plus cetuximab for cancer in the oesophagus or gastro-oesophageal junction. Cancer Treat Res Commun 2020;24:100187. [PMID: 32619832 DOI: 10.1016/j.ctarc.2020.100187] [Reference Citation Analysis]
598 Konieczny A, Meyer P, Schnider A, Komminoth P, Schmid M, Lombriser N, Weishaupt D. Accuracy of multidetector-row CT for restaging after neoadjuvant treatment in patients with oesophageal cancer. Eur Radiol. 2013;23:2492-2502. [PMID: 23645329 DOI: 10.1007/s00330-013-2844-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
599 Fuse N, Kuboki Y, Kuwata T, Nishina T, Kadowaki S, Shinozaki E, Machida N, Yuki S, Ooki A, Kajiura S, Kimura T, Yamanaka T, Shitara K, Nagatsuma AK, Yoshino T, Ochiai A, Ohtsu A. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients. Gastric Cancer. 2016;19:183-191. [PMID: 25682441 DOI: 10.1007/s10120-015-0471-6] [Cited by in Crossref: 62] [Cited by in F6Publishing: 64] [Article Influence: 8.9] [Reference Citation Analysis]
600 Stein H, Feith M, Siewert J. Cancer of the esophagogastric junction. Surgical Oncology 2000;9:35-41. [DOI: 10.1016/s0960-7404(00)00021-9] [Cited by in Crossref: 99] [Cited by in F6Publishing: 37] [Article Influence: 4.5] [Reference Citation Analysis]
601 Suzuki A, Xiao L, Taketa T, Blum MA, Matamoros A Jr, Chien PL, Mansfield PF, Fournier KF, Weston B, Lee JH, Bhutani MS, Estrella JS, Delclos ME, Krishnan S, Das P, Ajani JA. Localized gastric cancer treated with chemoradation without surgery: UTMD Anderson Cancer Center experience. Oncology 2012;82:347-51. [PMID: 22677933 DOI: 10.1159/000338318] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
602 Siewert JR, Stein HJ, Feith M. Adenocarcinoma of the esophago-gastric junction. Scand J Surg. 2006;95:260-269. [PMID: 17249275 DOI: 10.1177/145749690609500409] [Cited by in Crossref: 74] [Cited by in F6Publishing: 67] [Article Influence: 4.9] [Reference Citation Analysis]
603 Wijnhoven BP, Tran KT, Esterman A, Watson DI, Tilanus HW. An evaluation of prognostic factors and tumor staging of resected carcinoma of the esophagus. Ann Surg. 2007;245:717-725. [PMID: 17457164 DOI: 10.1097/01.sla.0000251703.35919.02] [Cited by in Crossref: 131] [Cited by in F6Publishing: 131] [Article Influence: 8.7] [Reference Citation Analysis]
604 Hatta W, Tong D, Lee YY, Ichihara S, Uedo N, Gotoda T. Different time trend and management of esophagogastric junction adenocarcinoma in three Asian countries. Dig Endosc 2017;29 Suppl 2:18-25. [PMID: 28425657 DOI: 10.1111/den.12808] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
605 Kim JJ. Epidemiology of Gastroesophageal Junction Adenocarcinoma in Korea. J Gastric Cancer 2018;18:328-38. [PMID: 30607296 DOI: 10.5230/jgc.2018.18.e38] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
606 Evans SC, Gillis A, Geldenhuys L, Vaninetti NM, Malatjalian DA, Porter GA, Guernsey DL, Casson AG. Microsatellite instability in esophageal adenocarcinoma. Cancer Lett. 2004;212:241-251. [PMID: 15279904 DOI: 10.1016/j.canlet.2004.03.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
607 Takeuchi Y, Ebihara Y, Nakanishi Y, Asano T, Noji T, Kurashima Y, Murakami S, Nakamura T, Tsuchikawa T, Okamura K, Shichinohe T, Hirano S. Minimally invasive abdominal and left thoracic approach for esophagogastric junction adenocarcinoma with esophageal diverticulum: A case report. Asian J Endosc Surg 2019;12:167-70. [PMID: 29888543 DOI: 10.1111/ases.12604] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
608 Liang C, Chen H, Yang Z, Han C, Ren C. Risk factors and prognosis of bone metastases in newly diagnosed gastric cancer. Future Oncol 2020;16:733-48. [PMID: 32285687 DOI: 10.2217/fon-2019-0728] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
609 D'Journo XB, Ouattara M, Loundou A, Trousse D, Dahan L, Nathalie T, Doddoli C, Seitz JF, Thomas PA. Prognostic impact of weight loss in 1-year survivors after transthoracic esophagectomy for cancer. Dis Esophagus 2012;25:527-34. [PMID: 22121887 DOI: 10.1111/j.1442-2050.2011.01282.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
610 Martin-Richard M, Custodio A, García-Girón C, Grávalos C, Gomez C, Jimenez-Fonseca P, Manzano JL, Pericay C, Rivera F, Carrato A. Seom guidelines for the treatment of gastric cancer 2015. Clin Transl Oncol 2015;17:996-1004. [PMID: 26691658 DOI: 10.1007/s12094-015-1456-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
611 Lagarde SM, ten Kate FJ, de Boer DJ, Busch OR, Obertop H, van Lanschot JJ. Extracapsular lymph node involvement in node-positive patients with adenocarcinoma of the distal esophagus or gastroesophageal junction. Am J Surg Pathol 2006;30:171-6. [PMID: 16434890 DOI: 10.1097/01.pas.0000189182.92815.12] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 3.5] [Reference Citation Analysis]
612 Dorth JA, Pura JA, Palta M, Willett CG, Uronis HE, D'Amico TA, Czito BG. Patterns of recurrence after trimodality therapy for esophageal cancer. Cancer 2014;120:2099-105. [PMID: 24711267 DOI: 10.1002/cncr.28703] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
613 Martin L, Jia C, Rouvelas I, Lagergren P. Risk factors for malnutrition after oesophageal and cardia cancer surgery. British Journal of Surgery 2008;95:1362-8. [DOI: 10.1002/bjs.6374] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 3.0] [Reference Citation Analysis]
614 Gee DW, Rattner DW. Management of gastroesophageal tumors. Oncologist. 2007;12:175-185. [PMID: 17296813 DOI: 10.1634/theoncologist.12-2-175] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
615 Leers JM, DeMeester SR, Chan N, Ayazi S, Oezcelik A, Abate E, Banki F, Lipham JC, Hagen JA, DeMeester TR. Clinical characteristics, biologic behavior, and survival after esophagectomy are similar for adenocarcinoma of the gastroesophageal junction and the distal esophagus. J Thorac Cardiovasc Surg. 2009;138:594-602; discussion 601-602. [PMID: 19698841 DOI: 10.1016/j.jtcvs.2009.05.039] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 4.6] [Reference Citation Analysis]
616 Casson AG, Darnton SJ, Subramanian S, Hiller L. What is the optimal distal resection margin for esophageal carcinoma? Ann Thorac Surg. 2000;69:205-209. [PMID: 10654514 DOI: 10.1016/s0003-4975(99)01262-x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
617 Feith M, Stein HJ, Siewert JR. Adenocarcinoma of the esophagogastric junction: surgical therapy based on 1602 consecutive resected patients. Surg Oncol Clin N Am. 2006;15:751-764. [PMID: 17030271 DOI: 10.1016/j.soc.2006.07.015] [Cited by in Crossref: 83] [Cited by in F6Publishing: 69] [Article Influence: 5.2] [Reference Citation Analysis]
618 Aichler M, Motschmann M, Jütting U, Luber B, Becker K, Ott K, Lordick F, Langer R, Feith M, Siewert JR, Walch A. Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy. Oncotarget 2014;5:6620-32. [PMID: 25216514 DOI: 10.18632/oncotarget.2268] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
619 Derogar M, Orsini N, Sadr-Azodi O, Lagergren P. Influence of major postoperative complications on health-related quality of life among long-term survivors of esophageal cancer surgery. J Clin Oncol. 2012;30:1615-1619. [PMID: 22473157 DOI: 10.1200/jco.2011.40.3568] [Cited by in Crossref: 110] [Cited by in F6Publishing: 51] [Article Influence: 11.0] [Reference Citation Analysis]
620 von Rahden BH, Stein HJ, Feith M, Becker K, Siewert JR. Lymphatic Vessel Invasion As a Prognostic Factor in Patients With Primary Resected Adenocarcinomas of the Esophagogastric Junction. JCO 2005;23:874-9. [DOI: 10.1200/jco.2005.12.151] [Cited by in Crossref: 72] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
621 Crosby TD, Brewster AE, Borley A, Perschky L, Kehagioglou P, Court J, Maughan TS. Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer. 2004;90:70-75. [PMID: 14710209 DOI: 10.1038/sj.bjc.6601461] [Cited by in Crossref: 76] [Cited by in F6Publishing: 76] [Article Influence: 4.2] [Reference Citation Analysis]
622 Hu C, Zhu HT, Xu ZY, Yu JF, Du YA, Huang L, Yu PF, Wang LJ, Cheng XD. Novel abdominal approach for dissection of advanced type II/III adenocarcinoma of the esophagogastric junction: a new surgical option. J Int Med Res 2019;47:398-410. [PMID: 30296865 DOI: 10.1177/0300060518802923] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
623 Roedl JB, Colen RR, Holalkere NS, Fischman AJ, Choi NC, Blake MA. Adenocarcinomas of the esophagus: Response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET–CT. Radiotherapy and Oncology 2008;89:278-86. [DOI: 10.1016/j.radonc.2008.06.014] [Cited by in Crossref: 91] [Cited by in F6Publishing: 95] [Article Influence: 6.5] [Reference Citation Analysis]
624 Schurr PG, Yekebas EF, Kaifi JT, Lasch S, Strate T, Kutup A, Cataldegirmen G, Bubenheim M, Pantel K, Izbicki JR. Lymphatic spread and microinvolvement in adenocarcinoma of the esophago-gastric junction. J Surg Oncol 2006;94:307-15. [PMID: 16917878 DOI: 10.1002/jso.20582] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
625 Zhao J, Du F, Zhang Y, Kan J, Dong L, Shen G, Zheng F, Chen H, Zhao J, Ji F, Luo Y, Ma F, Wang Z, Xu B. Impact on long-term survival of the number of lymph nodes resected in patients with pT1N0 gastric cancer after R0 resection: A multicenter study in China. Medicine (Baltimore) 2016;95:e4420. [PMID: 27495062 DOI: 10.1097/MD.0000000000004420] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
626 Chen X, He F, Chen M, Zhao F. Incidence of lymph node metastasis at each station in Siewert types Ⅱ/Ⅲ adenocarcinoma of the esophagogastric junction: A systematic review and meta-analysis. Surgical Oncology 2020;35:62-70. [DOI: 10.1016/j.suronc.2020.08.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
627 Lutz MP, Zalcberg JR, Ducreux M, Ajani JA, Allum W, Aust D, Bang YJ, Cascinu S, Hölscher A, Jankowski J. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer. 2012;48:2941-2953. [PMID: 22921186 DOI: 10.1016/j.ejca.2012.07.029] [Cited by in Crossref: 84] [Cited by in F6Publishing: 86] [Article Influence: 8.4] [Reference Citation Analysis]
628 Russell MC, Mansfield PF. Surgical approaches to gastric cancer. J Surg Oncol. 2013;107:250-258. [PMID: 22674546 DOI: 10.1002/jso.23180] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
629 Alessandrini L, Manchi M, De Re V, Dolcetti R, Canzonieri V. Proposed Molecular and miRNA Classification of Gastric Cancer. Int J Mol Sci 2018;19:E1683. [PMID: 29882766 DOI: 10.3390/ijms19061683] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
630 Lorenzen S, von Gall C, Stange A, Haag GM, Weitz J, Haberkorn U, Lordick F, Weichert W, Abel U, Debus J. Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial. BMC Cancer. 2011;11:266. [PMID: 21702914 DOI: 10.1186/1471-2407-11-266] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
631 Baldus SE. Histopathologic classification of adenocarcinoma of the esophagogastric junction. Recent Results Cancer Res 2010;182:29-38. [PMID: 20676869 DOI: 10.1007/978-3-540-70579-6_3] [Reference Citation Analysis]
632 Lee IS, Ahn JY, Yook JH, Kim BS. Mediastinal lymph node dissection and distal esophagectomy is not essential in early esophagogastric junction adenocarcinoma. World J Surg Oncol 2017;15:28. [PMID: 28100248 DOI: 10.1186/s12957-016-1088-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
633 Balandraud P, Moutardier V, Giovannini M, Giovannini M, Lelong B, Guiramand J, Magnin V, Houvenaeghel G, Delpero J. Locally advanced adenocarcinomas of the gastric cardia: results of pre-operative chemoradiotherapy. Gastroentérologie Clinique et Biologique 2004;28:651-7. [DOI: 10.1016/s0399-8320(04)95043-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
634 Xu J, Cao J, Wang L, Wang Z, Wang Y, Wu Y, Lv W, Hu J. Prognostic performance of three lymph node staging schemes for patients with Siewert type II adenocarcinoma of esophagogastric junction. Sci Rep. 2017;7:10123. [PMID: 28860457 DOI: 10.1038/s41598-017-09625-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
635 Triboulet J, Fabre S, Castel B, Toursel H. Adénocarcinome du bas œsophage et du cardia: prise en charge chirurgicale. Cancer/Radiothérapie 2001;5:90s-7s. [DOI: 10.1016/s1278-3218(01)80013-5] [Cited by in Crossref: 5] [Article Influence: 0.2] [Reference Citation Analysis]
636 Brell JM, Krishnamurthi SS, Javle M, Saltzman J, Wollner I, Pelley R, Dowlati A, Kantharaj BN, Schluchter MD, Rath L. A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma. Cancer Chemother Pharmacol. 2009;63:851-857. [PMID: 18670776 DOI: 10.1007/s00280-008-0807-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
637 Fitzgerald RC, Farthing MJ. The pathogenesis of Barrett's esophagus. Gastrointest Endosc Clin N Am 2003;13:233-55. [PMID: 12916657 DOI: 10.1016/s1052-5157(03)00007-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
638 Zhou J, Wang H, Niu Z, Chen D, Wang D, Lv L, Li Y, Zhang J, Cao S, Shen Y, Zhou Y. Comparisons of Clinical Outcomes and Prognoses in Patients With Gastroesophageal Junction Adenocarcinoma, by Transthoracic and Transabdominal Hiatal Approaches: A Teaching Hospital Retrospective Cohort Study. Medicine (Baltimore) 2015;94:e2277. [PMID: 26683954 DOI: 10.1097/MD.0000000000002277] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
639 Zhou Z, Xie X, Hao N, Diao D, Song Y, Xia P, Dang C, Zhang H. Different lymph node staging systems for patients with adenocarcinoma of esophagogastric junction. Curr Med Res Opin 2018;34:963-70. [PMID: 29338535 DOI: 10.1080/03007995.2018.1429390] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
640 Huang Q. Carcinoma of the gastroesophageal junction in Chinese patients. World J Gastroenterol 2012; 18(48): 7134-7140 [PMID: 23326117 DOI: 10.3748/wjg.v18.i48.7134] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
641 Potrc S, Ivanecz A, Krebs B, Marolt U, Iljevec B, Jagric T. Outcomes of the Surgical Treatment for Adenocarcinoma of the Cardia - Single Institution Experience. Radiol Oncol 2018;52:65-74. [PMID: 29520207 DOI: 10.1515/raon-2017-0039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
642 Pyo JH, Lee H, Min YW, Min BH, Lee JH, Kim KM, Yoo H, Ahn S, Kim JJ. Indication for endoscopic treatment based on the risk of lymph node metastasis in patients with Siewert type II/III early gastric cancer. Gastric Cancer 2018;21:672-9. [PMID: 29243195 DOI: 10.1007/s10120-017-0789-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
643 Jeromen A, Oblak I, Anderluh F, Velenik V, Vidmar MS, Ratoša I. Results of postoperative radiochemotherapy of the patients with resectable gastroesophageal junction adenocarcinoma in Slovenia. Radiol Oncol 2012;46:337-45. [PMID: 23412351 DOI: 10.2478/v10019-012-0049-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
644 Yang L, Zhu YL, Wang B, Yuan YL, Guo L, Zhang HF, Xue XH, Lv N. Clinicopathological and prognostic analysis of 319 cases of advanced esophageal gastric adenocarcinoma. Shijie Huaren Xiaohua Zazhi 2012; 20(9): 784-789 [DOI: 10.11569/wcjd.v20.i9.784] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
645 Lehwald-Tywuschik N, Steinfurth F, Kröpil F, Krieg A, Sarikaya H, Knoefel WT, Krüger M, Benhidjeb T, Beshay M, Schulte Am Esch J. Dorsal Track Control (DTC): A Modified Surgical Technique for Atraumatic Handling of the Distal Esophagus in Esophagojejunostomy. J Gastric Cancer 2019;19:473-83. [PMID: 31897349 DOI: 10.5230/jgc.2019.19.e35] [Reference Citation Analysis]
646 Guo W, Dong Z, He M, Guo Y, Guo J, Chen Z, Yang Z, Kuang G. Aberrant methylation of thrombospondin-1 and its association with reduced expression in gastric cardia adenocarcinoma. J Biomed Biotechnol 2010;2010:721485. [PMID: 20300551 DOI: 10.1155/2010/721485] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
647 Zhang Y, Liu D, Zeng, Chen C. Lymph Node Ratio Is an Independent Prognostic Factor for Patients with Siewert Type II Adenocarcinoma of Esophagogastric Junction: Results from a 10-Year Follow-up Study. J Gastrointest Cancer 2021;52:983-92. [PMID: 32954465 DOI: 10.1007/s12029-020-00468-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
648 Wang J, Zhang H, Zhou X, Wang T, Zhang J, Zhu W, Zhu H, Cheng W. Five serum-based miRNAs were identified as potential diagnostic biomarkers in gastric cardia adenocarcinoma. Cancer Biomark. 2018;23:193-203. [PMID: 30198863 DOI: 10.3233/cbm-181258] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 5.7] [Reference Citation Analysis]
649 Barbour AP, Lagergren P, Hughes R, Alderson D, Barham CP, Blazeby JM. Health-related quality of life among patients with adenocarcinoma of the gastro-oesophageal junction treated by gastrectomy or oesophagectomy. British Journal of Surgery 2008;95:80-4. [DOI: 10.1002/bjs.5912] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 2.9] [Reference Citation Analysis]
650 Driessen A, Van Raemdonck D, De Leyn P, Filez L, Peeters M, Winnepenninckx V, Penninckx F, Lerut T, Ectors N; H.P. Belgian Contact Group. Are carcinomas of the cardia oesophageal or gastric adenocarcinomas? Eur J Cancer 2003;39:2487-94. [PMID: 14602134 DOI: 10.1016/s0959-8049(03)00664-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
651 Thomaschewski M, Hummel R, Petrova E, Knief J, Wellner UF, Keck T, Bausch D. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours. World J Gastroenterol 2018; 24(13): 1429-1439 [PMID: 29632424 DOI: 10.3748/wjg.v24.i13.1429] [Reference Citation Analysis]
652 Nobel T, Molena D. Surgical principles for optimal treatment of esophagogastric junction adenocarcinoma. Ann Gastroenterol Surg 2019;3:390-5. [PMID: 31346578 DOI: 10.1002/ags3.12268] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
653 Blais E, Vendrely V, Sargos P, Créhange G, Huguet F, Maingon P, Simon JM, Bourdais R, Ozsahin M, Bourhis J, Clément-Colmou K, Belghith B, Proudhom Briois MA, Gilliot O, Dujols JP, Peyras A, Dupin C, Riet FG, Canova CH, Huertas A, Troussier I. [Chemoradiation for oesophageal cancer: A critical review of the literature]. Cancer Radiother 2019;23:62-72. [PMID: 30639379 DOI: 10.1016/j.canrad.2018.05.003] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
654 Matsuda T, Takeuchi H, Tsuwano S, Nakamura R, Takahashi T, Wada N, Kawakubo H, Saikawa Y, Omori T, Kitagawa Y. Optimal surgical management for esophagogastric junction carcinoma. Gen Thorac Cardiovasc Surg 2014;62:560-6. [PMID: 24570201 DOI: 10.1007/s11748-014-0381-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
655 Rouvelas I, Jia C, Viklund P, Lindblad M, Lagergren J. Surgeon volume and postoperative mortality after oesophagectomy for cancer. European Journal of Surgical Oncology (EJSO) 2007;33:162-8. [DOI: 10.1016/j.ejso.2006.10.029] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
656 von Rahden BHA, Stein HJ, Siewert JR. Barrett’s esophagus and Barrett’s carcinoma. Curr Oncol Rep 2003;5:203-9. [DOI: 10.1007/s11912-003-0111-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
657 Uedo N, Yoshio T, Yoshinaga S, Takeuchi M, Hatta W, Yano T, Tanuma T, Goto O, Takahashi A, Tong D, Lee YY, Nakayama Y, Ichihara S, Gotoda T. Endoscopic gastric mucosal atrophy distinguishes the characteristics of superficial esophagogastric junction adenocarcinoma. Digestive Endoscopy 2017;29:26-36. [DOI: 10.1111/den.12849] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
658 Forman D. Counting cancers at the junction – a problem of routine statistics: . European Journal of Gastroenterology & Hepatology 2002;14:99-101. [DOI: 10.1097/00042737-200202000-00001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
659 Davies AR, Sandhu H, Pillai A, Sinha P, Mattsson F, Forshaw MJ, Gossage JA, Lagergren J, Allum WH, Mason RC. Surgical resection strategy and the influence of radicality on outcomes in oesophageal cancer. Br J Surg. 2014;101:511-517. [PMID: 24615656 DOI: 10.1002/bjs.9456] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 4.5] [Reference Citation Analysis]
660 Zeng Y, Jin RU. Molecular Pathogenesis, Targeted Therapies, and Future Perspectives for Gastric Cancer. Semin Cancer Biol 2021:S1044-579X(21)00297-2. [PMID: 34933124 DOI: 10.1016/j.semcancer.2021.12.004] [Reference Citation Analysis]
661 Richter F, Baratay A, Röder C, Egberts JH, Kalthoff H, Becker T, Sebens S. Comparative Analysis of Blood and Bone Marrow for the Detection of Circulating and Disseminated Tumor Cells and Their Prognostic and Predictive Value in Esophageal Cancer Patients. J Clin Med 2020;9:E2674. [PMID: 32824841 DOI: 10.3390/jcm9082674] [Reference Citation Analysis]
662 Cotton RG, Langer R, Leong T, Martinek J, Sewram V, Smithers M, Swanson PE, Qiao Y, Udagawa H, Ueno M, Wang M, Wei W, White RE. Coping with esophageal cancer approaches worldwide: Coping with esophageal cancer. Ann N Y Acad Sci 2014;1325:138-58. [DOI: 10.1111/nyas.12522] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
663 Brücher BL, Kitajima M, Siewert JR. Undervalued criteria in the evaluation of multimodal trials for upper GI cancers. Cancer Invest 2014;32:497-506. [PMID: 25250506 DOI: 10.3109/07357907.2014.958497] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
664 Yura M, Takeuchi H, Fukuda K, Nakamura R, Suda K, Wada N, Kawakubo H, Kitagawa Y. High-risk group of upper and middle mediastinal lymph node metastasis in patients with esophagogastric junction carcinoma. Ann Gastroenterol Surg 2018;2:419-27. [PMID: 30460345 DOI: 10.1002/ags3.12215] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
665 Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, Wieder H, Fink U, Schwaiger M, Siewert JR. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2006;24:4692-4698. [PMID: 16966684 DOI: 10.1200/jco.2006.06.7801] [Cited by in Crossref: 339] [Cited by in F6Publishing: 121] [Article Influence: 21.2] [Reference Citation Analysis]
666 Charalampakis N, Nogueras González GM, Elimova E, Wadhwa R, Shiozaki H, Shimodaira Y, Blum MA, Rogers JE, Harada K, Matamoros A Jr, Sagebiel T, Das P, Minsky BD, Lee JH, Weston B, Bhutani MS, Estrella JS, Badgwell BD, Ajani JA. The Proportion of Signet Ring Cell Component in Patients with Localized Gastric Adenocarcinoma Correlates with the Degree of Response to Pre-Operative Chemoradiation. Oncology 2016;90:239-47. [PMID: 27046280 DOI: 10.1159/000443506] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
667 Gabrielson S, Sanchez-crespo A, Klevebro F, Axelsson R, Albert Tsai J, Johansson O, Nilsson M. 18F FDG-PET/CT evaluation of histological response after neoadjuvant treatment in patients with cancer of the esophagus or gastroesophageal junction. Acta Radiol 2019;60:578-85. [DOI: 10.1177/0284185118791204] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
668 Paireder M, Asari R, Kristo I, Rieder E, Tamandl D, Ba-Ssalamah A, Schoppmann SF. Impact of sarcopenia on outcome in patients with esophageal resection following neoadjuvant chemotherapy for esophageal cancer. Eur J Surg Oncol 2017;43:478-84. [PMID: 28024944 DOI: 10.1016/j.ejso.2016.11.015] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 10.5] [Reference Citation Analysis]
669 Campbell NP, Villaflor VM. Neoadjuvant treatment of esophageal cancer. World J Gastroenterol 2010; 16(30): 3793-3803 [PMID: 20698042 DOI: 10.3748/wjg.v16.i30.3793] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
670 de Manzoni G, Pedrazzani C, Verlato G, Roviello F, Pasini F, Pugliese R, Cordiano C. Comparison of old and new TNM systems for nodal staging in adenocarcinoma of the gastro-oesophageal junction. British Journal of Surgery 2004;91:296-303. [DOI: 10.1002/bjs.4431] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 2.1] [Reference Citation Analysis]
671 Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. Lancet. 2017;390:2383-2396. [PMID: 28648400 DOI: 10.1016/s0140-6736(17)31462-9] [Cited by in Crossref: 323] [Cited by in F6Publishing: 207] [Article Influence: 64.6] [Reference Citation Analysis]
672 Zhang W, Chen X, Liu K, Yang K, Chen X, Zhao Y, Zhao Y, Chen J, Chen L, Hu J. Comparison of survival outcomes between transthoracic and transabdominal surgical approaches in patients with Siewert-II/III esophagogastric junction adenocarcinoma: a single-institution retrospective cohort study. Chin J Cancer Res 2016;28:413-22. [PMID: 27647969 DOI: 10.21147/j.issn.1000-9604.2016.04.04] [Reference Citation Analysis]
673 Mukherjee S, Aston D, Minett M, Brewster A, Crosby T. The Significance of Cardiac Doses Received During Chemoradiation of Oesophageal and Gastro–oesophageal Junctional Cancers. Clinical Oncology 2003;15:115-20. [DOI: 10.1053/clon.2003.0218] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
674 Haverkamp L, Seesing MF, Ruurda JP, Boone J, V Hillegersberg R. Worldwide trends in surgical techniques in the treatment of esophageal and gastroesophageal junction cancer. Dis Esophagus. 2017;30:1-7. [PMID: 27001442 DOI: 10.1111/dote.12480] [Cited by in Crossref: 22] [Cited by in F6Publishing: 45] [Article Influence: 4.4] [Reference Citation Analysis]
675 Zingg U, Montani M, Frey D, Dirnhofer S, Esterman A, Went P, Oertli D. Tumour-infiltrating lymphocytes and survival in patients with adenocarcinoma of the oesophagus. European Journal of Surgical Oncology (EJSO) 2010;36:670-7. [DOI: 10.1016/j.ejso.2010.05.012] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 3.4] [Reference Citation Analysis]
676 Chen XD, He FQ, Liao MS, Chen M. Laparoscopic versus open transhiatal approach for adenocarcinoma of the esophagogastric junction: A systematic review and meta-analysis. Eur J Surg Oncol 2021;47:778-88. [PMID: 33268214 DOI: 10.1016/j.ejso.2020.10.022] [Reference Citation Analysis]
677 Wittekind C. The development of the TNM classification of gastric cancer. Pathol Int. 2015;65:399-403. [PMID: 26036980 DOI: 10.1111/pin.12306] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
678 Kulig P, Sierzega M, Pach R, Kolodziejczyk P, Kulig J; Polish Gastric Cancer Study Group. Differences in prognosis of Siewert II and III oesophagogastric junction cancers are determined by the baseline tumour staging but not its anatomical location. Eur J Surg Oncol. 2016;42:1215-1221. [PMID: 27241921 DOI: 10.1016/j.ejso.2016.04.061] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
679 Cavazzola LT, Rosa AR, Schirmer CC, Gurski RR, Telles JP, Mielke F, Meurer L, Edelweiss MI, Kruel CD. Immunohistochemical evaluation for P53 and VEGF (Vascular Endothelial Growth Factor) is not prognostic for long term survival in end stage esophageal adenocarcinoma. Rev Col Bras Cir. 2009;36:24-34. [PMID: 20076865 DOI: 10.1590/S0100-69912009000100007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
680 Peters CJ, Hardwick RH, Vowler SL, Fitzgerald RC; Oesophageal Cancer Clinical and Molecular Stratification Study Group. Generation and validation of a revised classification for oesophageal and junctional adenocarcinoma. Br J Surg 2009;96:724-33. [PMID: 19526624 DOI: 10.1002/bjs.6584] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
681 Bystricky B, Okines AF, Cunningham D. Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs 2011;71:541-55. [PMID: 21443280 DOI: 10.2165/11585460-000000000-00000] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
682 McLoughlin JM. Adenocarcinoma of the stomach: a review. Proc (Bayl Univ Med Cent) 2004;17:391-9. [PMID: 16200126 DOI: 10.1080/08998280.2004.11928001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]